<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://onlinelibrarystatic.wiley.com/xslt/wol-journal-rss.xsl"
            type="text/xsl"?><rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"><channel rdf:about="http://onlinelibrary.wiley.com/rss/journal/10.1002/(ISSN)1097-4652" xmlns="http://purl.org/rss/1.0/"><title>Journal of Cellular Physiology</title><description> Wiley Online Library : Journal of Cellular Physiology</description><link>http://dx.doi.org/10.1002%2F%28ISSN%291097-4652</link><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc</dc:publisher><dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">en</dc:language><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Copyright © 2012 Wiley Periodicals Inc.</dc:rights><prism:issn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">0021-9541</prism:issn><prism:eIssn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1097-4652</prism:eIssn><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-05-01T00:00:00-05:00</dc:date><prism:coverDisplayDate xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">May 2012</prism:coverDisplayDate><prism:volume xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">227</prism:volume><prism:number xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">5</prism:number><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1787</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">2286</prism:endingPage><image rdf:resource="http://onlinelibrary.wiley.com/store/10.1002/jcp.v227.5/asset/cover.gif?v=1&amp;s=d728b83d72840e58cf49ce39106db8a02b135d55"/><items><rdf:Seq><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24071"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24070"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24069"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24068"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24064"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24065"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24066"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24067"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24062"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24063"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24061"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24058"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24056"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24057"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24054"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24055"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24053"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24052"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24050"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24051"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24049"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24048"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24042"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24043"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24044"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24045"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24046"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24047"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24041"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24039"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24040"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24034"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24033"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24035"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24038"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24036"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24037"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24032"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24019"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24026"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24031"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24027"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24030"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24028"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24029"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23028"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23067"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24022"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24023"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24024"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24021"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24018"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24020"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24017"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22999"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24016"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24012"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24014"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24015"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24013"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24008"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24009"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24003"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24001"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24002"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24004"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24005"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24006"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23065"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.24000"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23061"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23062"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23063"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23058"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23059"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23052"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23053"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23051"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23045"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23046"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23047"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23044"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23054"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23040"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23042"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23041"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23043"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23033"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23039"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23006"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23037"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23038"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23032"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23034"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23035"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23029"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23030"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23021"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23022"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23023"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23024"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23027"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23025"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23026"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23019"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23020"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23017"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23018"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23015"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23016"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23009"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23010"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23011"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23012"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23013"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23014"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23007"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23005"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23008"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23000"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23001"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22992"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22994"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22995"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22996"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22997"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22987"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22988"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22989"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22990"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22991"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22980"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22981"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22982"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22984"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22977"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22978"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22979"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22970"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22971"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22972"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22973"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22974"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22975"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22976"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22967"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22969"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22968"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22731"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23960"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23961"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.23962"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22952"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22903"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22905"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22904"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22906"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22907"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22910"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22912"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22913"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22914"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22915"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22916"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22917"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22918"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22919"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22920"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22921"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22922"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22923"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22924"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22925"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22926"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22928"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22930"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22927"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22929"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22931"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22932"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22933"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22934"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22937"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22935"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22936"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22938"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22941"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22944"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22940"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22942"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22943"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22946"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22947"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22949"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22950"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22951"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22954"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22956"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22957"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22958"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22962"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22963"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22964"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22965"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22966"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fjcp.22945"/></rdf:Seq></items></channel><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24071" xmlns="http://purl.org/rss/1.0/"><title>Oxidases and reactive oxygen species during hematopoiesis: A focus on megakaryocytes</title><link>http://dx.doi.org/10.1002%2Fjcp.24071</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Oxidases and reactive oxygen species during hematopoiesis: A focus on megakaryocytes</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alexia Eliades</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shinobu Matsuura</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Katya Ravid</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-13T10:04:18.553673-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24071</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24071</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24071</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Reactive oxygen species (ROS), generated as a result of various reactions, control an array of cellular processes. The role of ROS during megakaryocyte (MK) development has been a subject of interest and research. The bone marrow niche is the major site of MK differentiation and maturation. In this environment, a gradient of oxygen tension, from normoxia to hypoxia results in different levels of ROS, impacting cellular physiology. This article provides an overview of major sources of ROS, their implication in different signaling pathways, and their effect on cellular physiology, with a focus on megakaryopoiesis. The importance of ROS-generating oxidases in MK biology and pathology, including myelofibrosis, is also described. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Reactive oxygen species (ROS), generated as a result of various reactions, control an array of cellular processes. The role of ROS during megakaryocyte (MK) development has been a subject of interest and research. The bone marrow niche is the major site of MK differentiation and maturation. In this environment, a gradient of oxygen tension, from normoxia to hypoxia results in different levels of ROS, impacting cellular physiology. This article provides an overview of major sources of ROS, their implication in different signaling pathways, and their effect on cellular physiology, with a focus on megakaryopoiesis. The importance of ROS-generating oxidases in MK biology and pathology, including myelofibrosis, is also described. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24070" xmlns="http://purl.org/rss/1.0/"><title>Glycoxydation promotes vascular damage via MAPK-ERK/JNK pathways</title><link>http://dx.doi.org/10.1002%2Fjcp.24070</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Glycoxydation promotes vascular damage via MAPK-ERK/JNK pathways</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Filomena de Nigris</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Monica Rienzo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marcella Sessa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Teresa Infante</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elena Cesario</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Louis J. Ignarro</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mohammed Al-Omran</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Antonio Giordano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wulf Palinski</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Claudio Napoli</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-13T10:04:16.732592-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24070</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24070</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24070</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Oxidation and glycation enhance foam cell formation via MAPK/JNK in euglycemic and diabetic subjects. Here, we investigated the effects of glycated and oxidized LDL (glc-oxLDL) on MAPK-ERK and JNK signaling pathways using human coronary smooth muscle cells. Glc-oxLDL induced a broad cascade of MAPK/JNK-dependent signaling transduction pathways and the AP-1 complex. In glc-oxLDL treated coronary arterioles, tumor necrosis factor (TNF) α increased JNK phosphorylation, whereas protein kinase inhibitor dimethylaminopurine (DMAP) prevented the TNF-induced increase in JNK phosphorylation. The role of MKK4 and JNK were then investigated in vivo, by using apolipoprotein E knockout (ApoE<sup>-/-</sup>) mice. Peritoneal macrophages, isolated from spontaneously hyperlipidemic but euglycemic mice showed increases in both proteins and phosphorylated proteins. Compared to streptozotocin-treated diabetic C57BL6 and non-diabetic C57BL6 Wt mice, in streptozotocin-diabetic ApoE<sup>-/-</sup> mice, the increment of foam cell formation corresponded to an increment of phosphorylation of JNK1, JNK2 and MMK4. Thus, we provide a first line of evidence that MAPK-ERK/JNK pathways are involved in vascular damage induced by glycoxidation. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Oxidation and glycation enhance foam cell formation via MAPK/JNK in euglycemic and diabetic subjects. Here, we investigated the effects of glycated and oxidized LDL (glc-oxLDL) on MAPK-ERK and JNK signaling pathways using human coronary smooth muscle cells. Glc-oxLDL induced a broad cascade of MAPK/JNK-dependent signaling transduction pathways and the AP-1 complex. In glc-oxLDL treated coronary arterioles, tumor necrosis factor (TNF) α increased JNK phosphorylation, whereas protein kinase inhibitor dimethylaminopurine (DMAP) prevented the TNF-induced increase in JNK phosphorylation. The role of MKK4 and JNK were then investigated in vivo, by using apolipoprotein E knockout (ApoE-/-) mice. Peritoneal macrophages, isolated from spontaneously hyperlipidemic but euglycemic mice showed increases in both proteins and phosphorylated proteins. Compared to streptozotocin-treated diabetic C57BL6 and non-diabetic C57BL6 Wt mice, in streptozotocin-diabetic ApoE-/- mice, the increment of foam cell formation corresponded to an increment of phosphorylation of JNK1, JNK2 and MMK4. Thus, we provide a first line of evidence that MAPK-ERK/JNK pathways are involved in vascular damage induced by glycoxidation. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24069" xmlns="http://purl.org/rss/1.0/"><title>Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference</title><link>http://dx.doi.org/10.1002%2Fjcp.24069</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jie Chen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiaoyan Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jie Zhang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yueran Zhao</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-13T10:04:16.054414-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24069</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24069</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24069</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>High mobility group box l (HMGB1), a nuclear and extracellular protein, is implicated in the development and progression of some types of cancers. However, no information is available to date regarding the function of HMGB1 in ovarian cancer. In this study, we performed cDNA microarray analysis and identified HMGB1 as a gene dramatically elevated in the highly invasive subclone S1 compared with the low invasive subclone S21 derived from the same cell line SKOV3. Then lentivirus vector with HMGB1 shRNA was constructed and infected the highly invasive cell line S1, A1 and HO8910PM. Real-time RT-PCR, Western Blot and IHC results confirmed the down-regulation of HMGB1 expression by its shRNA was about 80%∼90% at both the mRNA and protein levels. Knockdown of HMGB1significantly suppressed ovarian cancer cell proliferation and induced cell cycle arrest at the G1/G0 phase, which was accompanied by decreased expressions of cyclin D1 and PCNA. Furthermore, Knockdown of HMGB1 induced ovarian cancer cell apoptosis, which was mediated by increased expression of Bax and decreased expression of Bcl-2. Finally, Knockdown of HMGB1 significantly inhibited ovarian cancer cell invasion and metastasis, which was regulated by decreased expressions of MMP2 and MMP9. Serum HMGB1 levels in patients with epithelial ovarian cancer were significantly higher than that in patients with benign ovarian tumor and healthy controls. These results indicate that HMGB1 is a newly identified gene associated with ovarian cancer growth and metastasis. HMGB1 may serve as a new therapeutic target for the treatment of ovarian cancer in the future. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>High mobility group box l (HMGB1), a nuclear and extracellular protein, is implicated in the development and progression of some types of cancers. However, no information is available to date regarding the function of HMGB1 in ovarian cancer. In this study, we performed cDNA microarray analysis and identified HMGB1 as a gene dramatically elevated in the highly invasive subclone S1 compared with the low invasive subclone S21 derived from the same cell line SKOV3. Then lentivirus vector with HMGB1 shRNA was constructed and infected the highly invasive cell line S1, A1 and HO8910PM. Real-time RT-PCR, Western Blot and IHC results confirmed the down-regulation of HMGB1 expression by its shRNA was about 80%∼90% at both the mRNA and protein levels. Knockdown of HMGB1significantly suppressed ovarian cancer cell proliferation and induced cell cycle arrest at the G1/G0 phase, which was accompanied by decreased expressions of cyclin D1 and PCNA. Furthermore, Knockdown of HMGB1 induced ovarian cancer cell apoptosis, which was mediated by increased expression of Bax and decreased expression of Bcl-2. Finally, Knockdown of HMGB1 significantly inhibited ovarian cancer cell invasion and metastasis, which was regulated by decreased expressions of MMP2 and MMP9. Serum HMGB1 levels in patients with epithelial ovarian cancer were significantly higher than that in patients with benign ovarian tumor and healthy controls. These results indicate that HMGB1 is a newly identified gene associated with ovarian cancer growth and metastasis. HMGB1 may serve as a new therapeutic target for the treatment of ovarian cancer in the future. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24068" xmlns="http://purl.org/rss/1.0/"><title>Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells</title><link>http://dx.doi.org/10.1002%2Fjcp.24068</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Monica Lupu-Meiri</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elizabeth Geras-Raaka</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ruth Lupu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hagit Shapira</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Judith Sandbank</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Liora Segal</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marvin C. Gershengorn</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yoram Oron</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-13T10:04:14.252085-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24068</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24068</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24068</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>High levels of plasminogen activator inhibitor-1 (PAI-1), which is produced by stromal, endothelial and cancer cells and has multiple complex effects on cancers, correlate with poor cancer prognosis. To more definitively study the role of endogenously produced PAI-1 in human pancreatic adenocarcinoma (PAC) PANC-1 cell line biology, we used anti-PAI-1 shRNA to create stable PAI-1 deficient cells (PD-PANC-1s). PD-PANC-1s exhibited a heterogeneous morphology. While the majority of cells exhibited a cuboidal shape similar to the parental PANC-1 or the vector-infected control cells, numerous large cells with long filopodia and a neuronal-like appearance were observed. Although both Vector-control cells and PD-PANC-1s expressed mRNAs that are characteristic of mesenchymal, neural and epithelial phenotypes, epithelial marker RNAs were up-regulated (e.g. E-cadherin, 32-fold) whereas mesenchymal marker RNAs were down-regulated (e.g. Thy1, 9-fold) in PD-PANC-1s, suggesting mesenchymal-to-epithelial transition. Neural markers exhibited both up- and down-regulation. Immunocytochemistry indicated that epithelial-like PD-PANC-1s expressed E-cadherin and β-catenin in significantly more cells, while neural-like cells exhibited robust expression of organized β-3-tubulin. PAI-1 and E-cadherin were rarely co-expressed in the same cells. Indeed, examination of PAI-1 and E-cadherin mRNAs expression in additional cell lines yielded clear inverse correlation. Indeed, infection of Colo357 PAC cells (that exhibit high expression of E-cadherin) with PAI-1-expressing adenovirus led to a marked decrease in E-cadherin expression and to enhanced migration of cells from clusters. Our results suggest that endogenous PAI-1 suppresses expression of E-cadherin and differentiation in PAC cells in vitro, supporting its negative impact on tumor prognosis. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>High levels of plasminogen activator inhibitor-1 (PAI-1), which is produced by stromal, endothelial and cancer cells and has multiple complex effects on cancers, correlate with poor cancer prognosis. To more definitively study the role of endogenously produced PAI-1 in human pancreatic adenocarcinoma (PAC) PANC-1 cell line biology, we used anti-PAI-1 shRNA to create stable PAI-1 deficient cells (PD-PANC-1s). PD-PANC-1s exhibited a heterogeneous morphology. While the majority of cells exhibited a cuboidal shape similar to the parental PANC-1 or the vector-infected control cells, numerous large cells with long filopodia and a neuronal-like appearance were observed. Although both Vector-control cells and PD-PANC-1s expressed mRNAs that are characteristic of mesenchymal, neural and epithelial phenotypes, epithelial marker RNAs were up-regulated (e.g. E-cadherin, 32-fold) whereas mesenchymal marker RNAs were down-regulated (e.g. Thy1, 9-fold) in PD-PANC-1s, suggesting mesenchymal-to-epithelial transition. Neural markers exhibited both up- and down-regulation. Immunocytochemistry indicated that epithelial-like PD-PANC-1s expressed E-cadherin and β-catenin in significantly more cells, while neural-like cells exhibited robust expression of organized β-3-tubulin. PAI-1 and E-cadherin were rarely co-expressed in the same cells. Indeed, examination of PAI-1 and E-cadherin mRNAs expression in additional cell lines yielded clear inverse correlation. Indeed, infection of Colo357 PAC cells (that exhibit high expression of E-cadherin) with PAI-1-expressing adenovirus led to a marked decrease in E-cadherin expression and to enhanced migration of cells from clusters. Our results suggest that endogenous PAI-1 suppresses expression of E-cadherin and differentiation in PAC cells in vitro, supporting its negative impact on tumor prognosis. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24064" xmlns="http://purl.org/rss/1.0/"><title>Myeloid Elf-1-like factor stimulates adipogenic differentiation through the induction of peroxisome proliferator-activated receptor γ expression in bone marrow</title><link>http://dx.doi.org/10.1002%2Fjcp.24064</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Myeloid Elf-1-like factor stimulates adipogenic differentiation through the induction of peroxisome proliferator-activated receptor γ expression in bone marrow</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kyunghwa Baek</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Je-Yoel Cho</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hyo Rin Hwang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Arang Kwon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hye-Lim Lee</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hyun-Jung Park</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Abdul S Qadir</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hyun-Mo Ryoo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kyung Mi Woo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeong-Hwa Baek</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-03T13:54:01.219455-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24064</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24064</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24064</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Myeloid Elf-1 like factor (MEF) is one of the Ets transcription factors known to regulate cell proliferation and differentiation. A previous report has shown that osteoblast-specific MEF transgenic mice (<em>Col1a1-MEF-TG</em> mice) have low bone mass but high bone marrow adiposity. In the present study, we explored a previously unappreciated mechanism whereby MEF promotes adipogenesis in bone marrow. An adipogenic colony forming unit assay showed that bone marrow cells derived from <em>Col1a1-MEF-TG</em> mice had a higher adipogenic differentiation potential compared to those from wild-type. The levels of adipogenic marker genes expression in 3T3L1 cells were higher when co-cultured with <em>Col1a1-MEF- TG</em> bone marrow cells than with wild-type cells. MC3T3-E1 preosteoblasts transfected with MEF secreted higher levels of 15-deoxy-delta (12, 14)-prostaglandin J<sub>2</sub>, a potent endogenous ligand of peroxisome proliferator-activated receptor <em>γ</em> (<em>PPARγ</em>), under adipogenic conditions. MEF overexpression increased the adipogenic marker genes expression including <em>PPARγ and</em> lipid droplet accumulation in MC3T3-E1 preosteoblasts and 3T3L1 preadipocytes. Endogenous MEF expression levels increased as adipocyte differentiation proceeded. Knockdown of MEF by siRNA suppressed expression levels of adipogenic marker genes including <em>PPARγ.</em> MEF directly bound to the MEF binding element on the mouse PPARγ promoter, transactivating promoter activity. Immunohistochemical staining of tibia sections demonstrated that bone lining cells and bone marrow cells express higher levels of PPARγ protein in <em>Col1a1-MEF-TG</em> mice than in wild-type mice. These results suggest that MEF transactivates PPARγ expression, which, in turn, enhances adipogenic differentiation. Furthermore, MEF overexpressing osteoblasts secrete higher levels of adipogenic factors, creating a marrow microenvironment that favors adipogenesis. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Myeloid Elf-1 like factor (MEF) is one of the Ets transcription factors known to regulate cell proliferation and differentiation. A previous report has shown that osteoblast-specific MEF transgenic mice (Col1a1-MEF-TG mice) have low bone mass but high bone marrow adiposity. In the present study, we explored a previously unappreciated mechanism whereby MEF promotes adipogenesis in bone marrow. An adipogenic colony forming unit assay showed that bone marrow cells derived from Col1a1-MEF-TG mice had a higher adipogenic differentiation potential compared to those from wild-type. The levels of adipogenic marker genes expression in 3T3L1 cells were higher when co-cultured with Col1a1-MEF- TG bone marrow cells than with wild-type cells. MC3T3-E1 preosteoblasts transfected with MEF secreted higher levels of 15-deoxy-delta (12, 14)-prostaglandin J2, a potent endogenous ligand of peroxisome proliferator-activated receptor γ (PPARγ), under adipogenic conditions. MEF overexpression increased the adipogenic marker genes expression including PPARγ and lipid droplet accumulation in MC3T3-E1 preosteoblasts and 3T3L1 preadipocytes. Endogenous MEF expression levels increased as adipocyte differentiation proceeded. Knockdown of MEF by siRNA suppressed expression levels of adipogenic marker genes including PPARγ. MEF directly bound to the MEF binding element on the mouse PPARγ promoter, transactivating promoter activity. Immunohistochemical staining of tibia sections demonstrated that bone lining cells and bone marrow cells express higher levels of PPARγ protein in Col1a1-MEF-TG mice than in wild-type mice. These results suggest that MEF transactivates PPARγ expression, which, in turn, enhances adipogenic differentiation. Furthermore, MEF overexpressing osteoblasts secrete higher levels of adipogenic factors, creating a marrow microenvironment that favors adipogenesis. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24065" xmlns="http://purl.org/rss/1.0/"><title>PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics</title><link>http://dx.doi.org/10.1002%2Fjcp.24065</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kiran Mahajan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nupam P. Mahajan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-03T13:53:58.945985-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24065</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24065</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24065</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>AKT/PKB serine threonine kinase, a critical signaling molecule promoting cell growth and survival pathways, is frequently dysregulated in many cancers. Although phosphatidylinositol-3-OH kinase (PI3K), a lipid kinase, is well characterized as a major regulator of AKT activation in response to a variety of ligands, recent studies highlight a diverse group of tyrosine (Ack1/TNK2, Src, PTK6) and serine/threonine (TBK1, IKBKE, DNAPKcs) kinases that activate AKT directly to promote its pro-proliferative signaling functions. While some of these alternate AKT activating kinases respond to growth factors, others respond to inflammatory and genotoxic stimuli. A common theme emerging from these studies is that aberrant or hyperactivation of these alternate kinases is often associated with malignancy. Consequently, evaluating the use of small molecular inhibitors against these alternate AKT activating kinases at earlier stages of cancer therapy may overcome the pressing problem of drug resistance surfacing especially in patients treated with PI3K inhibitors. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>AKT/PKB serine threonine kinase, a critical signaling molecule promoting cell growth and survival pathways, is frequently dysregulated in many cancers. Although phosphatidylinositol-3-OH kinase (PI3K), a lipid kinase, is well characterized as a major regulator of AKT activation in response to a variety of ligands, recent studies highlight a diverse group of tyrosine (Ack1/TNK2, Src, PTK6) and serine/threonine (TBK1, IKBKE, DNAPKcs) kinases that activate AKT directly to promote its pro-proliferative signaling functions. While some of these alternate AKT activating kinases respond to growth factors, others respond to inflammatory and genotoxic stimuli. A common theme emerging from these studies is that aberrant or hyperactivation of these alternate kinases is often associated with malignancy. Consequently, evaluating the use of small molecular inhibitors against these alternate AKT activating kinases at earlier stages of cancer therapy may overcome the pressing problem of drug resistance surfacing especially in patients treated with PI3K inhibitors. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24066" xmlns="http://purl.org/rss/1.0/"><title>CIZ/NMP4 is expressed in B16 melanoma and forms a positive feedback loop with RANKL to promote migration of the melanoma cells</title><link>http://dx.doi.org/10.1002%2Fjcp.24066</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">CIZ/NMP4 is expressed in B16 melanoma and forms a positive feedback loop with RANKL to promote migration of the melanoma cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tomomi Sakuma</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tetsuya Nakamoto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hiroaki Hemmi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sohei Kitazawa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Riko Kitazawa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takuya Notomi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tadayosi Hayata</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yoichi Ezura</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Teruo Amagasa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Masaki Noda</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-03T13:53:57.58803-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24066</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24066</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24066</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Rapid Communication</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Tumor metastasis to bone is a serious pathological situation that causes severe pain, and deterioration in locomoter function. However, the mechanisms underlying tumor metastasis is still incompletely understood. CIZ/NMP4 is a nucleocytoplasmic shuttling protein and its roles in tumor cells have not been known. We, therefore, hypothesized the role of CIZ/NMP4 in B16 melanoma cells that metastasize to bone. CIZ/NMP4 is expressed in B16 cells. The CIZ/NMP4 expression levels are correlated to the metastatic activity in divergent types of melanoma cells. Overexpression of CIZ/NMP4increased B16 cell migration in Trans-well assay. Conversely, siRNA-based knockdown of CIZ/NMP4 suppressed migratory activity of these cells. As RANKL promotes metastasis of tumor cells in bone, we tested its effect on CIZ in melanoma cells. RANKL treatment enhanced CIZ/NMP4 expression. This increase of CIZ by RANKL promoted migration. Conversely, we identified CIZ/NMP4 binding site in the promoter of RANKL. Furthermore, luciferase assay indicated that CIZ/NMP4 overexpression enhanced RANKL promoter activities, revealing a positive feedback loop of CIZ/NMP4and RANKL in melanoma. These observations indicate that CIZ/NMP4 is critical regulator of metastasis of melanoma cerlls. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Tumor metastasis to bone is a serious pathological situation that causes severe pain, and deterioration in locomoter function. However, the mechanisms underlying tumor metastasis is still incompletely understood. CIZ/NMP4 is a nucleocytoplasmic shuttling protein and its roles in tumor cells have not been known. We, therefore, hypothesized the role of CIZ/NMP4 in B16 melanoma cells that metastasize to bone. CIZ/NMP4 is expressed in B16 cells. The CIZ/NMP4 expression levels are correlated to the metastatic activity in divergent types of melanoma cells. Overexpression of CIZ/NMP4increased B16 cell migration in Trans-well assay. Conversely, siRNA-based knockdown of CIZ/NMP4 suppressed migratory activity of these cells. As RANKL promotes metastasis of tumor cells in bone, we tested its effect on CIZ in melanoma cells. RANKL treatment enhanced CIZ/NMP4 expression. This increase of CIZ by RANKL promoted migration. Conversely, we identified CIZ/NMP4 binding site in the promoter of RANKL. Furthermore, luciferase assay indicated that CIZ/NMP4 overexpression enhanced RANKL promoter activities, revealing a positive feedback loop of CIZ/NMP4and RANKL in melanoma. These observations indicate that CIZ/NMP4 is critical regulator of metastasis of melanoma cerlls. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24067" xmlns="http://purl.org/rss/1.0/"><title>Gadd45a and Gadd45b modulate innate immune functions of granulocytes and macrophages by differential regulation of p38 and JNK signaling</title><link>http://dx.doi.org/10.1002%2Fjcp.24067</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Gadd45a and Gadd45b modulate innate immune functions of granulocytes and macrophages by differential regulation of p38 and JNK signaling</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dominic M. Salerno</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jennifer S. Tront</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Barbara Hoffman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dan A. Liebermann</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-03T13:53:55.643993-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24067</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24067</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24067</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Gadd45 proteins function as stress sensors in response to various physiological and environmental stressors, interacting with other cellular proteins implicated in cellular stress responses, including p38 and JNK. This study shows that mice lacking either Gadd45a or Gadd45b are defective in the recruitment of granulocytes and macrophages to the intra-peritoneal cavity following intra-peritoneal administration of the bacterial cell-wall PAMP lipopolysaccharide (LPS). Bone marrow (BM) derived granulocytes and macrophages lacking either Gadd45a or Gadd45b are shown to be impaired in their chemotactic response to LPS, as well as other inflammatory stimuli such as fMLP and IL-8. Evidence was obtained also implicating Gadd45a and Gadd45b in other myeloid innate immune functions, including ROS production, phagocytosis, and adhesion. Gadd45a and Gadd45b activation of p38 kinase was implicated in the response of granulocytes to LPS mediated chemotaxis, whereas Gadd45a and Gadd45b curtailment of JNK activation was linked to chemotaxis of macrophages in response to LPS. Collectively, these data highlight a novel role for both Gadd45a and Gadd45b in myeloid innate immune functions by differential modulation of p38 and JNK signaling in granulocytes compared to macrophages. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Gadd45 proteins function as stress sensors in response to various physiological and environmental stressors, interacting with other cellular proteins implicated in cellular stress responses, including p38 and JNK. This study shows that mice lacking either Gadd45a or Gadd45b are defective in the recruitment of granulocytes and macrophages to the intra-peritoneal cavity following intra-peritoneal administration of the bacterial cell-wall PAMP lipopolysaccharide (LPS). Bone marrow (BM) derived granulocytes and macrophages lacking either Gadd45a or Gadd45b are shown to be impaired in their chemotactic response to LPS, as well as other inflammatory stimuli such as fMLP and IL-8. Evidence was obtained also implicating Gadd45a and Gadd45b in other myeloid innate immune functions, including ROS production, phagocytosis, and adhesion. Gadd45a and Gadd45b activation of p38 kinase was implicated in the response of granulocytes to LPS mediated chemotaxis, whereas Gadd45a and Gadd45b curtailment of JNK activation was linked to chemotaxis of macrophages in response to LPS. Collectively, these data highlight a novel role for both Gadd45a and Gadd45b in myeloid innate immune functions by differential modulation of p38 and JNK signaling in granulocytes compared to macrophages. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24062" xmlns="http://purl.org/rss/1.0/"><title>Src modulates contractile vascular smooth muscle function via regulation of focal adhesions</title><link>http://dx.doi.org/10.1002%2Fjcp.24062</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Src modulates contractile vascular smooth muscle function via regulation of focal adhesions</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jianghong Min</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maya Reznichenko</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ransom H. Poythress</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cynthia M. Gallant</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susanne Vetterkind</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yunping Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kathleen G. Morgan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-27T09:55:16.427407-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24062</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24062</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24062</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Src is a known regulator of focal adhesion turnover in migrating cells; but, in contrast, Src is generally assumed to play little role in differentiated, contractile vascular smooth muscle (dVSM). The goal of the present study was to determine if Src-family kinases regulate focal adhesion proteins and how this might affect contractility of non-proliferative vascular smooth muscle. We demonstrate here, through the use of phosphotyrosine screening, deconvolution microscopy imaging, and differential centrifugation, that the activity of Src family kinases in aorta is regulated by the alpha agonist and vasoconstrictor phenylephrine, and leads to focal adhesion protein phosphorylation and remodeling in dVSM. Furthermore, Src inhibition via morpholino knockdown of Src or by the small molecule inhibitor PP2 prevents phenylephrine-induced adhesion protein phosphorylation, markedly slows the tissue's ability to contract and decreases steady state contractile force amplitude. Significant vasoconstrictor-induced and Src-dependent phosphorylation of Cas pY-165, FAK pY-925, paxillin pY-118, and Erk1/2 were observed. However, increases in FAK 397 phosphorylation were not seen, demonstrating differences between cells in tissue versus migrating, proliferating cells. We show here that Src, in a cause-and effect manner, regulates focal adhesion protein function and consequently, modulates contractility during the action of a vasoconstrictor. These data point to the possibility that vascular focal adhesion proteins may be useful drug discovery targets for novel therapeutic approaches to cardiovascular disease. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Src is a known regulator of focal adhesion turnover in migrating cells; but, in contrast, Src is generally assumed to play little role in differentiated, contractile vascular smooth muscle (dVSM). The goal of the present study was to determine if Src-family kinases regulate focal adhesion proteins and how this might affect contractility of non-proliferative vascular smooth muscle. We demonstrate here, through the use of phosphotyrosine screening, deconvolution microscopy imaging, and differential centrifugation, that the activity of Src family kinases in aorta is regulated by the alpha agonist and vasoconstrictor phenylephrine, and leads to focal adhesion protein phosphorylation and remodeling in dVSM. Furthermore, Src inhibition via morpholino knockdown of Src or by the small molecule inhibitor PP2 prevents phenylephrine-induced adhesion protein phosphorylation, markedly slows the tissue's ability to contract and decreases steady state contractile force amplitude. Significant vasoconstrictor-induced and Src-dependent phosphorylation of Cas pY-165, FAK pY-925, paxillin pY-118, and Erk1/2 were observed. However, increases in FAK 397 phosphorylation were not seen, demonstrating differences between cells in tissue versus migrating, proliferating cells. We show here that Src, in a cause-and effect manner, regulates focal adhesion protein function and consequently, modulates contractility during the action of a vasoconstrictor. These data point to the possibility that vascular focal adhesion proteins may be useful drug discovery targets for novel therapeutic approaches to cardiovascular disease. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24063" xmlns="http://purl.org/rss/1.0/"><title>TGFß1 inhibits lymphatic endothelial cell differentiation from mouse embryonic stem cells</title><link>http://dx.doi.org/10.1002%2Fjcp.24063</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">TGFß1 inhibits lymphatic endothelial cell differentiation from mouse embryonic stem cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniel Vittet</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Galina Merdzhanova</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marie-Hélène Prandini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jean-Jacques Feige</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sabine Bailly</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-27T09:55:09.691083-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24063</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24063</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24063</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The lymphatic vasculature is essential for the maintenance of tissue fluid, immune surveillance and dissemination of metastasis. Recently, several models for lymphatic vascular research and markers specific for lymphatic endothelium have been characterized. Despite these significant achievements, our understanding of the early lymphatic development is still rather limited. The purpose of the study was to further define early lymphatic differentiation regulatory pathways. In the present study, we have developed conditions leading to lymphatic endothelial cell differentiation under both serum-rich and serum-free conditions, using the coculture system of Flk-1-positive vascular precursors derived from murine embryonic stem (ES) cells grown on an OP9 stromal cell layer. In this work, we also identified Transforming Growth Factor-ß1 (TGFß1) as a negative regulator of lymphvasculogenesis from ES-derived vascular progenitors. Finally, we could show that TGFß1 addition decreases COUP-TFII and Sox18 mRNA levels, which are two transcription factors known to be involved in early lymphatic endothelial differentiation. Taken together these findings support the concept that manipulating the TGFß signaling pathway may represent an interesting target to favor lymphatic endothelial cell expansion for cell replacement strategies. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The lymphatic vasculature is essential for the maintenance of tissue fluid, immune surveillance and dissemination of metastasis. Recently, several models for lymphatic vascular research and markers specific for lymphatic endothelium have been characterized. Despite these significant achievements, our understanding of the early lymphatic development is still rather limited. The purpose of the study was to further define early lymphatic differentiation regulatory pathways. In the present study, we have developed conditions leading to lymphatic endothelial cell differentiation under both serum-rich and serum-free conditions, using the coculture system of Flk-1-positive vascular precursors derived from murine embryonic stem (ES) cells grown on an OP9 stromal cell layer. In this work, we also identified Transforming Growth Factor-ß1 (TGFß1) as a negative regulator of lymphvasculogenesis from ES-derived vascular progenitors. Finally, we could show that TGFß1 addition decreases COUP-TFII and Sox18 mRNA levels, which are two transcription factors known to be involved in early lymphatic endothelial differentiation. Taken together these findings support the concept that manipulating the TGFß signaling pathway may represent an interesting target to favor lymphatic endothelial cell expansion for cell replacement strategies. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24061" xmlns="http://purl.org/rss/1.0/"><title>PAR-1-dependent and PAR-independent pro-inflammatory signalling in human lung fibroblasts exposed to thrombin</title><link>http://dx.doi.org/10.1002%2Fjcp.24061</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">PAR-1-dependent and PAR-independent pro-inflammatory signalling in human lung fibroblasts exposed to thrombin</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alejandro Ortiz-Stern</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiaoling Deng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Natalia Smoktunowicz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paul F. Mercer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rachel C. Chambers</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-25T12:36:42.390578-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24061</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24061</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24061</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Proteinase-activated receptors (PARs) are crucial in orchestrating cellular responses to coagulation proteinases, such as thrombin and FXa. Four PARs have been characterized and have been shown to be differentially expressed in mice and humans and between tissues. We have previously shown that in murine lung fibroblasts, PAR-1 is solely responsible for all cellular responses to thrombin and FXa. In contrast, we report here that in primary human lung fibroblasts, known PARs fail to account for all of the cellular responses to thrombin, in particular in the presence of high, but physiologically achievable concentrations of thrombin. We report that primary human lung fibroblasts secrete CCL2 in a PAR-1-dependent manner at low thrombin concentration (∼ 0.3 nM). At or above 10 nM thrombin, pharmacological antagonism (RWJ-58259) fails to block thrombin-induced CCL2 release; whereas PAR-1 cleavage-blocking monoclonal antibodies (ATAP2 and WEDE15) only partially inhibit thrombin-induced CCL2 secretion. In addition, activation of PAR-3, PAR-4 and transactivation of either PAR-2 or EGFR were ruled out as being responsible for thrombin-mediated CCL2 secretion at high yet standard concentrations of the proteinase. We further provide evidence that PAR-1-dependent and PAR-independent signaling involves the rapid phosphorylation of ERK which in turn is absolutely required for thrombin-induced CCL2 secretion at both low and standard concentration of the proteinase. Our findings suggest the existence of a PAR-independent signaling mechanism in human lung fibroblasts and have important implications for the design of therapeutic strategies aimed at blocking pro-inflammatory signaling responses associated with excessive thrombin generation. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Proteinase-activated receptors (PARs) are crucial in orchestrating cellular responses to coagulation proteinases, such as thrombin and FXa. Four PARs have been characterized and have been shown to be differentially expressed in mice and humans and between tissues. We have previously shown that in murine lung fibroblasts, PAR-1 is solely responsible for all cellular responses to thrombin and FXa. In contrast, we report here that in primary human lung fibroblasts, known PARs fail to account for all of the cellular responses to thrombin, in particular in the presence of high, but physiologically achievable concentrations of thrombin. We report that primary human lung fibroblasts secrete CCL2 in a PAR-1-dependent manner at low thrombin concentration (∼ 0.3 nM). At or above 10 nM thrombin, pharmacological antagonism (RWJ-58259) fails to block thrombin-induced CCL2 release; whereas PAR-1 cleavage-blocking monoclonal antibodies (ATAP2 and WEDE15) only partially inhibit thrombin-induced CCL2 secretion. In addition, activation of PAR-3, PAR-4 and transactivation of either PAR-2 or EGFR were ruled out as being responsible for thrombin-mediated CCL2 secretion at high yet standard concentrations of the proteinase. We further provide evidence that PAR-1-dependent and PAR-independent signaling involves the rapid phosphorylation of ERK which in turn is absolutely required for thrombin-induced CCL2 secretion at both low and standard concentration of the proteinase. Our findings suggest the existence of a PAR-independent signaling mechanism in human lung fibroblasts and have important implications for the design of therapeutic strategies aimed at blocking pro-inflammatory signaling responses associated with excessive thrombin generation. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24058" xmlns="http://purl.org/rss/1.0/"><title>In silico analysis of the two tandem somatomedin B domains of ENPP1 reveals hints on the homodimerization of the protein</title><link>http://dx.doi.org/10.1002%2Fjcp.24058</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">In silico analysis of the two tandem somatomedin B domains of ENPP1 reveals hints on the homodimerization of the protein</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Emanuele Bellacchio</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-19T08:38:59.097263-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24058</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24058</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24058</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The homodimerization of ENPP1 is mediated by the two somatomedin B (SMB) domains of the protein through a mechanism that is yet unknown at the atomistic level. The tandem arrangement of these domains without an intermediate spacer implies their possible packing into a functional assembly, which we explored by rigid docking. To exclude potential bias in the docking search we assessed the absence of flexible protein regions by evaluating the normalized B-factors calculated from the Cα atom displacements derived from Molecular Dynamics simulations. After filtering the docking results exploiting the criterion that residues located at the inter-domain interfaces are more conserved than non-interface residues, the resulting best model of the tandem SMB domains revealed the presence of two large conserved surface patches not engaged in the inter-domain contact. The largest patch is flat and contains all the invariant positively charged residues characterized by fully solvent-exposed side chains within the tandem SMB domains, suggesting as a possible role its interaction with the negative phospholipids on the cell surface. We envisage that an ENPP1 monomer bound to the cell membrane via the transmembrane segment can also interact with the cell surface through the largest conserved patch favouring a specific geometry of the tandem SMB module on the cell that optimally exposes the second conserved patch for the symmetric interaction with another membrane-bound ENPP1 monomer, finally promoting the homodimerization. Biological implications of this model and insights into the effects of the K173Q variant associated with insulin resistance and related abnormalities are presented. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The homodimerization of ENPP1 is mediated by the two somatomedin B (SMB) domains of the protein through a mechanism that is yet unknown at the atomistic level. The tandem arrangement of these domains without an intermediate spacer implies their possible packing into a functional assembly, which we explored by rigid docking. To exclude potential bias in the docking search we assessed the absence of flexible protein regions by evaluating the normalized B-factors calculated from the Cα atom displacements derived from Molecular Dynamics simulations. After filtering the docking results exploiting the criterion that residues located at the inter-domain interfaces are more conserved than non-interface residues, the resulting best model of the tandem SMB domains revealed the presence of two large conserved surface patches not engaged in the inter-domain contact. The largest patch is flat and contains all the invariant positively charged residues characterized by fully solvent-exposed side chains within the tandem SMB domains, suggesting as a possible role its interaction with the negative phospholipids on the cell surface. We envisage that an ENPP1 monomer bound to the cell membrane via the transmembrane segment can also interact with the cell surface through the largest conserved patch favouring a specific geometry of the tandem SMB module on the cell that optimally exposes the second conserved patch for the symmetric interaction with another membrane-bound ENPP1 monomer, finally promoting the homodimerization. Biological implications of this model and insights into the effects of the K173Q variant associated with insulin resistance and related abnormalities are presented. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24056" xmlns="http://purl.org/rss/1.0/"><title>Bone marrow stromal cells stimulate an angiogenic program that requires endothelial MT1-MMP</title><link>http://dx.doi.org/10.1002%2Fjcp.24056</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Bone marrow stromal cells stimulate an angiogenic program that requires endothelial MT1-MMP</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Suraj Kachgal</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bita Carrion</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Isaac A. Janson</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrew J. Putnam</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-19T08:38:57.122714-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24056</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24056</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24056</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Bone marrow-derived stromal/stem cells (BMSCs) have recently been characterized as mediators of tissue regeneration after injury.  In addition to preventing fibrosis at the wound site, BMSCs elicit an angiogenic response within the fibrin matrix.  The mechanistic interactions between BMSCs and invading endothelial cells (ECs) during this process are not fully understood.  Using a three-dimensional, fibrin-based angiogenesis model, we sought to investigate the proteolytic mechanisms by which BMSCs promote vessel morphogenesis.  We find that BMSC-mediated vessel formation depends on the proteolytic ability of membrane type 1-matrix metalloproteinase (MT1-MMP).  Knockdown of the protease results in a small network of vessels with enlarged lumens.  Contrastingly, vessel morphogenesis is unaffected by the knockdown of MMP-2 and MMP-9.  Furthermore, we find that BMSC-mediated vessel morphogenesis in vivo follows mechanisms similar to what we observe in vitro.  Subcutaneous, cellular fibrin implants in C.B-17/SCID mice form aberrant vasculature when MMPs are inhibited with a broad spectrum chemical inhibitor, and a very minimal amount of vessels when MT1-MMP proteolytic activity is interrupted in ECs.  Other studies have debated the necessity of MT1-MMP in the context of vessel invasion in fibrin, but this study clearly demonstrates its requirement in BMSC-mediated angiogenesis. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Bone marrow-derived stromal/stem cells (BMSCs) have recently been characterized as mediators of tissue regeneration after injury.  In addition to preventing fibrosis at the wound site, BMSCs elicit an angiogenic response within the fibrin matrix.  The mechanistic interactions between BMSCs and invading endothelial cells (ECs) during this process are not fully understood.  Using a three-dimensional, fibrin-based angiogenesis model, we sought to investigate the proteolytic mechanisms by which BMSCs promote vessel morphogenesis.  We find that BMSC-mediated vessel formation depends on the proteolytic ability of membrane type 1-matrix metalloproteinase (MT1-MMP).  Knockdown of the protease results in a small network of vessels with enlarged lumens.  Contrastingly, vessel morphogenesis is unaffected by the knockdown of MMP-2 and MMP-9.  Furthermore, we find that BMSC-mediated vessel morphogenesis in vivo follows mechanisms similar to what we observe in vitro.  Subcutaneous, cellular fibrin implants in C.B-17/SCID mice form aberrant vasculature when MMPs are inhibited with a broad spectrum chemical inhibitor, and a very minimal amount of vessels when MT1-MMP proteolytic activity is interrupted in ECs.  Other studies have debated the necessity of MT1-MMP in the context of vessel invasion in fibrin, but this study clearly demonstrates its requirement in BMSC-mediated angiogenesis. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24057" xmlns="http://purl.org/rss/1.0/"><title>Inactivation of Bcl-2 through IκB kinase (IKK)-dependent phosphorylation mediates apoptosis upon exposure to 4-hydroxynonenal (HNE)</title><link>http://dx.doi.org/10.1002%2Fjcp.24057</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Inactivation of Bcl-2 through IκB kinase (IKK)-dependent phosphorylation mediates apoptosis upon exposure to 4-hydroxynonenal (HNE)</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cagri Bodur</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ozgur Kutuk</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tugsan Tezil</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Huveyda Basaga</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-19T08:38:54.251358-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24057</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24057</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24057</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Apoptosis of macrophage foam cells loaded with modified/oxidized lipids is implicated in destabilization of advanced atherosclerotic plaques in humans. Concentration of HNE, main aldehydic product of plasma LDL peroxidation, elevates in atherosclerotic lesions as well as in cultured cells under oxidative stress. Although this reactive aldehyde has been shown to promote apoptosis with the involvement of p38 MAPK and JNK in various mammalian cell lines, roles of Bcl-2 family proteins remain to be deciphered. We demonstrated that HNE-induced apoptosis was accompanied by concurrent downregulations of antiapoptotic Bcl-xL and Mcl-1 as well as upregulation of proapoptotic Bak. Furthermore phoshorylation of Bcl-2 at Thr56, Ser70, and probably more phosphorylation sites located on N-terminal loop domain associated with HNE-induced apoptosis in both U937 and HeLa cells while ectopic expression of a phospho-defective Bcl-2 mutant significantly attenuated apoptosis. In parallel to this, HNE treatment caused release of proapoptotic Bax from Bcl-2. Pharmacological inhbition of IKK inhibited HNE-induced Bcl-2 phosphorylation. Similarly, silencing IKKα and -β both ended up with abrogation of Bcl-2 phosphorylation along with attenuation of apoptosis. Moreover, both IKKa and -β coimmunoprecipitated with Bcl-2 and <em>in vitro</em> kinase assay proved the ability of IKK to phosphorylate Bcl-2. In view of these findings and considering HNE inhibits DNA-binding activity of NF-κB through prevention of IκB phosphorylation/ubiquitination/proteolysis, IKK appears to directly interfere with Bcl-2 activity through phosphorylation in HNE-mediated apoptosis independent of NF-κB signaling. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Apoptosis of macrophage foam cells loaded with modified/oxidized lipids is implicated in destabilization of advanced atherosclerotic plaques in humans. Concentration of HNE, main aldehydic product of plasma LDL peroxidation, elevates in atherosclerotic lesions as well as in cultured cells under oxidative stress. Although this reactive aldehyde has been shown to promote apoptosis with the involvement of p38 MAPK and JNK in various mammalian cell lines, roles of Bcl-2 family proteins remain to be deciphered. We demonstrated that HNE-induced apoptosis was accompanied by concurrent downregulations of antiapoptotic Bcl-xL and Mcl-1 as well as upregulation of proapoptotic Bak. Furthermore phoshorylation of Bcl-2 at Thr56, Ser70, and probably more phosphorylation sites located on N-terminal loop domain associated with HNE-induced apoptosis in both U937 and HeLa cells while ectopic expression of a phospho-defective Bcl-2 mutant significantly attenuated apoptosis. In parallel to this, HNE treatment caused release of proapoptotic Bax from Bcl-2. Pharmacological inhbition of IKK inhibited HNE-induced Bcl-2 phosphorylation. Similarly, silencing IKKα and -β both ended up with abrogation of Bcl-2 phosphorylation along with attenuation of apoptosis. Moreover, both IKKa and -β coimmunoprecipitated with Bcl-2 and in vitro kinase assay proved the ability of IKK to phosphorylate Bcl-2. In view of these findings and considering HNE inhibits DNA-binding activity of NF-κB through prevention of IκB phosphorylation/ubiquitination/proteolysis, IKK appears to directly interfere with Bcl-2 activity through phosphorylation in HNE-mediated apoptosis independent of NF-κB signaling. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24054" xmlns="http://purl.org/rss/1.0/"><title>Metaboloepigenetics: Interrelationships between energy metabolism and epigenetic control of gene expression</title><link>http://dx.doi.org/10.1002%2Fjcp.24054</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Metaboloepigenetics: Interrelationships between energy metabolism and epigenetic control of gene expression</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dallas R. Donohoe</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Scott J. Bultman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-19T08:38:53.434688-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24054</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24054</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24054</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Diet and energy metabolism affect gene expression, which influences human health and disease. Here, we discuss the role of epigenetics as a mechanistic link between energy metabolism and control of gene expression. A number of key energy metabolites including SAM, acetyl-CoA, NAD<sup>+</sup>, and ATP serve as essential co-factors for many, perhaps most, epigenetic enzymes that regulate DNA methylation, posttranslational histone modifications, and nucleosome position. The relative abundance of these energy metabolites allows a cell to sense its energetic state. And as co-factors, energy metabolites act as rheostats to modulate the activity of epigenetic enzymes and upregulate/downregulate transcription as appropriate to maintain homeostasis. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Diet and energy metabolism affect gene expression, which influences human health and disease. Here, we discuss the role of epigenetics as a mechanistic link between energy metabolism and control of gene expression. A number of key energy metabolites including SAM, acetyl-CoA, NAD+, and ATP serve as essential co-factors for many, perhaps most, epigenetic enzymes that regulate DNA methylation, posttranslational histone modifications, and nucleosome position. The relative abundance of these energy metabolites allows a cell to sense its energetic state. And as co-factors, energy metabolites act as rheostats to modulate the activity of epigenetic enzymes and upregulate/downregulate transcription as appropriate to maintain homeostasis. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24055" xmlns="http://purl.org/rss/1.0/"><title>Report of the 2011 annual meeting of the Italian society for virology</title><link>http://dx.doi.org/10.1002%2Fjcp.24055</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Report of the 2011 annual meeting of the Italian society for virology</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cristiano Salata</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Arianna Calistri</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cristina Parolin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giorgio Palù</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-19T08:38:52.024232-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24055</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24055</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24055</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Meeting Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24053" xmlns="http://purl.org/rss/1.0/"><title>Phenylephrine protects cardiomyocytes from starvation- induced apoptosis by increasing Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity</title><link>http://dx.doi.org/10.1002%2Fjcp.24053</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Phenylephrine protects cardiomyocytes from starvation- induced apoptosis by increasing Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ling-Ling Yao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yong-Gang Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiu-Jie Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yu Zhou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Na Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jun Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yi-Chun Zhu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-17T10:19:19.188747-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24053</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24053</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24053</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is known to be a “housekeeping” protein, studies in non-cardiomyocytic cells have shown that GAPDH plays pro-apoptotic role by translocating from cytoplasm to the nucleus or to the mitochondria. However, the cardiovascular roles of GAPDH are unknown. We observed that phenylephrine (PE) (100 µM) protected against serum and glucose starvation -induced apoptosis in neonatal rat cardiac myocytes as assessed by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and mitochondrial membrane potential depolarization. GAPDH glycolysis activity was positively correlated with the antiapoptotic action of PE. GAPDH activity inhibition blunted PE-induced protection of the mitochondrial membrane potential and cardiomyocytes. PE-induced Bcl-2 protein increase, Bax mitochondrial decrease and inhibition of cytochrome C release and Caspase 3 activation, as well as ROS production were blunted by GAPDH activity inhibition. Moreover, GAPDH overexpression provided protection against starvation-induced cardiomyocyte apoptosis in vitro and ischemia-induced cardiac infarction in vivo. Inhibition of Akt prevented PE-induced GAPDH activity increase and cardiomyocytes protection. In conclusion, the present study provides the first direct evidence of an antiapoptotic role of GAPDH in PE-induced cardiomyocytes protection; GAPDH activity elevation mainly affects the mitochondria-induced apoptosis. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is known to be a “housekeeping” protein, studies in non-cardiomyocytic cells have shown that GAPDH plays pro-apoptotic role by translocating from cytoplasm to the nucleus or to the mitochondria. However, the cardiovascular roles of GAPDH are unknown. We observed that phenylephrine (PE) (100 µM) protected against serum and glucose starvation -induced apoptosis in neonatal rat cardiac myocytes as assessed by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and mitochondrial membrane potential depolarization. GAPDH glycolysis activity was positively correlated with the antiapoptotic action of PE. GAPDH activity inhibition blunted PE-induced protection of the mitochondrial membrane potential and cardiomyocytes. PE-induced Bcl-2 protein increase, Bax mitochondrial decrease and inhibition of cytochrome C release and Caspase 3 activation, as well as ROS production were blunted by GAPDH activity inhibition. Moreover, GAPDH overexpression provided protection against starvation-induced cardiomyocyte apoptosis in vitro and ischemia-induced cardiac infarction in vivo. Inhibition of Akt prevented PE-induced GAPDH activity increase and cardiomyocytes protection. In conclusion, the present study provides the first direct evidence of an antiapoptotic role of GAPDH in PE-induced cardiomyocytes protection; GAPDH activity elevation mainly affects the mitochondria-induced apoptosis. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24052" xmlns="http://purl.org/rss/1.0/"><title>Biogenesis, functions and fate of plant microRNAs</title><link>http://dx.doi.org/10.1002%2Fjcp.24052</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Biogenesis, functions and fate of plant microRNAs</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Afsar Raza Naqvi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maryam Sarwat</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shirin Hasan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nirupam Roy Choudhury</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-17T10:19:17.753533-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24052</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24052</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24052</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>MicroRNAs (miRNAs), a recently discovered class of small RNAs, are endogenously transcribed non-coding RNAs that are known to control diverse developmental processes and defense responses. They regulate these pathways by fine-tuning the levels of transcripts to which they bind and cause their cleavage or translation repression. Several studies on the processing of miRNA precursors have shed light on the essential structural features for precise release of miRNA duplexes. The identification of a protein that degrade single stranded small RNA has provided us with some understanding of how miRNA flux is maintained in plants. This review focuses on the genome organization, biogenesis, miRNA activity and the fate of miRNAs. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>MicroRNAs (miRNAs), a recently discovered class of small RNAs, are endogenously transcribed non-coding RNAs that are known to control diverse developmental processes and defense responses. They regulate these pathways by fine-tuning the levels of transcripts to which they bind and cause their cleavage or translation repression. Several studies on the processing of miRNA precursors have shed light on the essential structural features for precise release of miRNA duplexes. The identification of a protein that degrade single stranded small RNA has provided us with some understanding of how miRNA flux is maintained in plants. This review focuses on the genome organization, biogenesis, miRNA activity and the fate of miRNAs. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24050" xmlns="http://purl.org/rss/1.0/"><title>Involvements of the ABC protein ABCF2 and α-actinin-4 in regulation of cell volume and anion channels in human epithelial cells</title><link>http://dx.doi.org/10.1002%2Fjcp.24050</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Involvements of the ABC protein ABCF2 and α-actinin-4 in regulation of cell volume and anion channels in human epithelial cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yuhko Ando-Akatsuka</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takahiro Shimizu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tomohiro Numata</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yasunobu Okada</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-17T10:19:16.668669-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24050</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24050</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24050</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>After osmotic swelling, cell volume is regulated by a process called regulatory volume decrease (RVD). Although actin cytoskeletons are known to play a regulatory role in RVD, it is not clear how actin-binding proteins are involved in the RVD process. In the present study, an involvement of an actin-binding protein, α-actinin-4 (ACTN4), in RVD was examined in human epithelial HEK293T cells. Overexpression of ACTN4 significantly facilitated RVD, whereas siRNA-mediated downregulation of endogenous ACTN4 suppressed RVD. When the cells were subjected to hypotonic stress, the content of ACTN4 increased in a 100,000 × g pellet, which was sensitive to cytochalasin D pretreatment. Protein overlay assays revealed that ABCF2, a cytosolic member of the ABC transporter superfamily, is a binding partner of ACTN4. The ACTN4-ABCF2 interaction was markedly enhanced by hypotonic stimulation and required the NH<sub>2</sub>-terminal region of ABCF2. Overexpression of ABCF2 suppressed RVD, whereas downregulation of ABCF2 facilitated RVD. We then tested whether ABCF2 has a suppressive effect on the activity of volume-sensitive outwardly rectifying anion channel (VSOR), which is known to mediate Cl<sup>−</sup> efflux involved in RVD, because another ABC transporter member, CFTR, was shown to suppress VSOR activity. Whole-cell VSOR currents were largely reduced by overexpression of ABCF2 and markedly enhanced by siRNA-mediated depletion of ABCF2. Thus, the present study indicates that ACTN4 acts as an enhancer of RVD, whereas ABCF2 acts as a suppressor of VSOR and RVD, and suggests that a swelling-induced interaction between ACTN4 and ABCF2 prevents ABCF2 from suppressing VSOR activity in the human epithelial cells. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>After osmotic swelling, cell volume is regulated by a process called regulatory volume decrease (RVD). Although actin cytoskeletons are known to play a regulatory role in RVD, it is not clear how actin-binding proteins are involved in the RVD process. In the present study, an involvement of an actin-binding protein, α-actinin-4 (ACTN4), in RVD was examined in human epithelial HEK293T cells. Overexpression of ACTN4 significantly facilitated RVD, whereas siRNA-mediated downregulation of endogenous ACTN4 suppressed RVD. When the cells were subjected to hypotonic stress, the content of ACTN4 increased in a 100,000 × g pellet, which was sensitive to cytochalasin D pretreatment. Protein overlay assays revealed that ABCF2, a cytosolic member of the ABC transporter superfamily, is a binding partner of ACTN4. The ACTN4-ABCF2 interaction was markedly enhanced by hypotonic stimulation and required the NH2-terminal region of ABCF2. Overexpression of ABCF2 suppressed RVD, whereas downregulation of ABCF2 facilitated RVD. We then tested whether ABCF2 has a suppressive effect on the activity of volume-sensitive outwardly rectifying anion channel (VSOR), which is known to mediate Cl− efflux involved in RVD, because another ABC transporter member, CFTR, was shown to suppress VSOR activity. Whole-cell VSOR currents were largely reduced by overexpression of ABCF2 and markedly enhanced by siRNA-mediated depletion of ABCF2. Thus, the present study indicates that ACTN4 acts as an enhancer of RVD, whereas ABCF2 acts as a suppressor of VSOR and RVD, and suggests that a swelling-induced interaction between ACTN4 and ABCF2 prevents ABCF2 from suppressing VSOR activity in the human epithelial cells. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24051" xmlns="http://purl.org/rss/1.0/"><title>JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy</title><link>http://dx.doi.org/10.1002%2Fjcp.24051</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Serena Delbue</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francesca Elia</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Camilla Carloni</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eleonora Tavazzi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Enrico Marchioni</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Silvia Carluccio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lucia Signorini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stefano Novati</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Renato Maserati</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pasquale Ferrante</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-17T10:19:14.028117-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24051</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24051</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24051</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Progressive multifocal leukoencephalopathy (PML) is a severe disease of the central nervous system (CNS), caused by infection with the Polyomavirus JC virus (JCV). Because there are no known treatments or prognostic factors, we performed a long-term study focusing mainly on cerebrospinal fluid (CSF) samples from PML patients to describe the virological features akin to the different forms of the disease. Twenty-eight PML patients were enrolled: 10 HIV-1+ patients with classical PML (CPML), 9 HIV-1+ patients with slowly progressing or stable neurological symptoms (benign PML), 3 HIV-1+ asymptomatic patients and 6 HIV-1-negative patients. CSF, urine and blood samples were collected at the enrollment (baseline) and every six months afterwards when possible. The JCV DNA and HIV-1 RNA loads were determined, and the JCV strains were characterized.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>At baseline, the mean CSF JCV load was log 6.0 ± 1.2 copies/ml for CPML patients, log 4.0 ± 1.0 copies/ml for benign PML patients, log 4.2 ± 0.5 copies/ml for asymptomatic PML patients and log 5.8 ± 1.3 copies/ml for HIV-1-negative PML patients (CPML versus benign: p &lt; 0.01; CPML versus asymptomatic: p &lt; 0.05; HIV-1 negative versus benign: p &lt; 0.01). Organization of the JCV transcriptional control region (TCR) showed unusual archetype structures in 2 long-term survival patients; the NF1 sequence was found most commonly, whereas the Sp1 binding site was the most common for both CPML patients and HIV-1 negative patients.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Our results suggest that the JCV load in the CSF and the organization of the TCR should be considered as indicators of PML clinical outcome. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Progressive multifocal leukoencephalopathy (PML) is a severe disease of the central nervous system (CNS), caused by infection with the Polyomavirus JC virus (JCV). Because there are no known treatments or prognostic factors, we performed a long-term study focusing mainly on cerebrospinal fluid (CSF) samples from PML patients to describe the virological features akin to the different forms of the disease. Twenty-eight PML patients were enrolled: 10 HIV-1+ patients with classical PML (CPML), 9 HIV-1+ patients with slowly progressing or stable neurological symptoms (benign PML), 3 HIV-1+ asymptomatic patients and 6 HIV-1-negative patients. CSF, urine and blood samples were collected at the enrollment (baseline) and every six months afterwards when possible. The JCV DNA and HIV-1 RNA loads were determined, and the JCV strains were characterized.At baseline, the mean CSF JCV load was log 6.0 ± 1.2 copies/ml for CPML patients, log 4.0 ± 1.0 copies/ml for benign PML patients, log 4.2 ± 0.5 copies/ml for asymptomatic PML patients and log 5.8 ± 1.3 copies/ml for HIV-1-negative PML patients (CPML versus benign: p &lt; 0.01; CPML versus asymptomatic: p &lt; 0.05; HIV-1 negative versus benign: p &lt; 0.01). Organization of the JCV transcriptional control region (TCR) showed unusual archetype structures in 2 long-term survival patients; the NF1 sequence was found most commonly, whereas the Sp1 binding site was the most common for both CPML patients and HIV-1 negative patients.Our results suggest that the JCV load in the CSF and the organization of the TCR should be considered as indicators of PML clinical outcome. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24049" xmlns="http://purl.org/rss/1.0/"><title>Biological effects of the plant-derived polyphenol resveratrol in human articular cartilage and chondrosarcoma cells</title><link>http://dx.doi.org/10.1002%2Fjcp.24049</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Biological effects of the plant-derived polyphenol resveratrol in human articular cartilage and chondrosarcoma cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hee-Jeong Im</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xin Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Di Chen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dongyao Yan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jaesung Kim</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael B Ellman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gary S. Stein</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Brian Cole</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ranjan KC</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gabriella Cs-Szabo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andre J van Wijnen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-17T10:19:12.239985-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24049</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24049</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24049</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The natural phytoestrogen resveratrol (RSV) may have therapeutic potential for arthritic conditions.   RSV is chondroprotective for articular cartilage in rabbit models for arthritis, but its biological effects on human articular cartilage and chondrosarcoma cells are unknown.  Effects of RSV on human articular cartilage homeostasis were studied by assessing production of matrix-degrading enzymes (MMP-13, ADAMTS-4, and ADAMTS-5), as well as proteoglycan production and synthesis.  The counteractions of RSV against catabolic factors (e.g., FGF-2 or IL-1β) were examined by <em>in vitro</em> and <em>ex vivo</em> using monolayer, three-dimensional alginate beads and cartilage explants cultures, respectively.  RSV improves cell viability of articular chondrocytes and effectively antagonizes cartilage-degrading protease production that was initiated by catabolic and/or anti-anabolic cytokines in human articular chondrocytes.  RSV significantly also enhances BMP7-promoted proteoglycan synthesis as assessed by <sup>35</sup>S-sulfate incorporation.  Protein-DNA interaction arrays suggest that RSV inhibits the activation of transcription factors involved in inflammation and cartilage catabolic signaling pathways, including direct downstream regulators of MAPK (e.g., AP-1, PEA3) and NFκB.  RSV selectively compromises survival of human chondrosarcoma cells, but not primary articular chondrocytes, revealing cell-specific activity of RSV on non-tumorigenic versus tumor-derived cells.  We propose that RSV exerts its chondroprotective functions, in part, by deactivating p53-induced apoptosis in human primary chondrocytes, but not human chondrosarcoma.  Our findings suggest that RSV has potential as a unique biologic treatment for both prevention and treatment of cartilage degenerative diseases. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The natural phytoestrogen resveratrol (RSV) may have therapeutic potential for arthritic conditions.   RSV is chondroprotective for articular cartilage in rabbit models for arthritis, but its biological effects on human articular cartilage and chondrosarcoma cells are unknown.  Effects of RSV on human articular cartilage homeostasis were studied by assessing production of matrix-degrading enzymes (MMP-13, ADAMTS-4, and ADAMTS-5), as well as proteoglycan production and synthesis.  The counteractions of RSV against catabolic factors (e.g., FGF-2 or IL-1β) were examined by in vitro and ex vivo using monolayer, three-dimensional alginate beads and cartilage explants cultures, respectively.  RSV improves cell viability of articular chondrocytes and effectively antagonizes cartilage-degrading protease production that was initiated by catabolic and/or anti-anabolic cytokines in human articular chondrocytes.  RSV significantly also enhances BMP7-promoted proteoglycan synthesis as assessed by 35S-sulfate incorporation.  Protein-DNA interaction arrays suggest that RSV inhibits the activation of transcription factors involved in inflammation and cartilage catabolic signaling pathways, including direct downstream regulators of MAPK (e.g., AP-1, PEA3) and NFκB.  RSV selectively compromises survival of human chondrosarcoma cells, but not primary articular chondrocytes, revealing cell-specific activity of RSV on non-tumorigenic versus tumor-derived cells.  We propose that RSV exerts its chondroprotective functions, in part, by deactivating p53-induced apoptosis in human primary chondrocytes, but not human chondrosarcoma.  Our findings suggest that RSV has potential as a unique biologic treatment for both prevention and treatment of cartilage degenerative diseases. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24048" xmlns="http://purl.org/rss/1.0/"><title>Osteoclastogenesis is negatively regulated by D-serine produced by osteoblasts</title><link>http://dx.doi.org/10.1002%2Fjcp.24048</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Osteoclastogenesis is negatively regulated by D-serine produced by osteoblasts</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takeshi Takarada</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mika Takarada-Iemata</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yoshifumi Takahata</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daisuke Yamada</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tomomi Yamamoto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yukari Nakamura</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eiichi Hinoi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yukio Yoneda</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-17T10:19:11.601046-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24048</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24048</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24048</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We have shown the functional expression by chondrocytes of serine racemase (SR) which is responsible for the synthesis of D-Serine (Ser) from L-Ser in cartilage. In this study, we evaluated the possible functional expression of SR by bone-forming osteoblasts and bone-resorbing osteoclasts. Expression of SR mRNA was seen in osteoblasts localized at the cancellous bone surface in neonatal rat tibial sections, and in cultured rat calvarial osteoblasts endowed to release D-Ser into extracellular medium, but not in cultured osteoclasts differentiated from murine bone marrow progenitor cells. Sustained exposure to D-Ser failed to significantly affect alkaline phosphatase activity and Ca<sup>2+</sup> accumulation in cultured osteoblasts, but significantly inhibited differentiation and maturation in a concentration-dependent manner at a concentration range of 0.1 to 1 mM without affecting cellular survival in cultured osteoclasts. By contrast, L-Ser promoted osteoclastic differentiation in a manner sensitive to the inhibition by D-Ser. Matured osteoclasts expressed mRNA for the amino acid transporter B<sub>0,+</sub> (ATB<sub>0,+</sub>) and the system alanine, serine and cysteine amino acid transporter-2 (ASCT2), which are individually capable of similarly incorporating extracellular L- and D-Ser. Knockdown of these transporters by siRNA prevented both the promotion by L-Ser and the inhibition by D-Ser of osteoclastic differentiation in pre-osteoclastic RAW264.7 cells. These results suggest that D-Ser may play a pivotal role in osteoclastogenesis through a mechanism related to the incorporation mediated by both ATB<sub>0,+</sub> and ASCT2 of serine enantiomers in osteoclasts after the synthesis and subsequent release from adjacent osteoblasts. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>We have shown the functional expression by chondrocytes of serine racemase (SR) which is responsible for the synthesis of D-Serine (Ser) from L-Ser in cartilage. In this study, we evaluated the possible functional expression of SR by bone-forming osteoblasts and bone-resorbing osteoclasts. Expression of SR mRNA was seen in osteoblasts localized at the cancellous bone surface in neonatal rat tibial sections, and in cultured rat calvarial osteoblasts endowed to release D-Ser into extracellular medium, but not in cultured osteoclasts differentiated from murine bone marrow progenitor cells. Sustained exposure to D-Ser failed to significantly affect alkaline phosphatase activity and Ca2+ accumulation in cultured osteoblasts, but significantly inhibited differentiation and maturation in a concentration-dependent manner at a concentration range of 0.1 to 1 mM without affecting cellular survival in cultured osteoclasts. By contrast, L-Ser promoted osteoclastic differentiation in a manner sensitive to the inhibition by D-Ser. Matured osteoclasts expressed mRNA for the amino acid transporter B0,+ (ATB0,+) and the system alanine, serine and cysteine amino acid transporter-2 (ASCT2), which are individually capable of similarly incorporating extracellular L- and D-Ser. Knockdown of these transporters by siRNA prevented both the promotion by L-Ser and the inhibition by D-Ser of osteoclastic differentiation in pre-osteoclastic RAW264.7 cells. These results suggest that D-Ser may play a pivotal role in osteoclastogenesis through a mechanism related to the incorporation mediated by both ATB0,+ and ASCT2 of serine enantiomers in osteoclasts after the synthesis and subsequent release from adjacent osteoblasts. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24042" xmlns="http://purl.org/rss/1.0/"><title>The effect of exogenous histone H1 on rat adipose-derived stem cell proliferation, migration, and osteogenic differentiation in vitro</title><link>http://dx.doi.org/10.1002%2Fjcp.24042</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The effect of exogenous histone H1 on rat adipose-derived stem cell proliferation, migration, and osteogenic differentiation in vitro</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Li-Wen Hsu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shigeru Goto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Toshiaki Nakano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kuang-Den Chen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chih-Chi Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chia-Yun Lai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chiung-Hui Hou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yen-Chen Chang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yu-Fan Cheng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">King-Wah Chiu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chien-Chih Chen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shu-Hui Chen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chao-Long Chen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:57:31.106548-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24042</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24042</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24042</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Adipose-derived stem cells (ASCs) are of great interest for the development of novel cell therapies due to their ease of isolation and expansion, immunosuppressive activity and multilineage differentiation potential. However, the mechanisms underlying the therapeutic potential of ASCs remain to be elucidated. Others and we have shown that nuclear proteins such as histone H1 and high mobility group box 1 (HMGB1) play important roles in the maturation of dendritic cells (DCs). Furthermore, we previously demonstrated translocation of histone H1 from the nucleus to the cytoplasm and activation of mitogen-activated protein kinases (MAPKs) in DCs. In the present study, we confirmed that histone H1 does not alter the immunophenotype and immunosuppression potential of ASCs, but that histone H1 enhanced wound healing and increased interleukin (IL)-6 expression. Moreover, histone H1 treated-ASCs showed up-regulation of mitogen-activated protein kinases (MAPKs) extracellular-regulated kinase 1/2 (ERK1/2) and sequential NF-κB translocation. Finally, we found that culture in differentiation media supplemented with histone H1 enhanced ASC osteogenesis. In contrast, inhibition of histone H1 by small interfering RNA (siRNA) reduced osteogenic differentiation markers including ALP. These results suggest that histone H1 may be useful for induction of mesenchymal stem cells in tissue engineering and future potential ASC therapies. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Adipose-derived stem cells (ASCs) are of great interest for the development of novel cell therapies due to their ease of isolation and expansion, immunosuppressive activity and multilineage differentiation potential. However, the mechanisms underlying the therapeutic potential of ASCs remain to be elucidated. Others and we have shown that nuclear proteins such as histone H1 and high mobility group box 1 (HMGB1) play important roles in the maturation of dendritic cells (DCs). Furthermore, we previously demonstrated translocation of histone H1 from the nucleus to the cytoplasm and activation of mitogen-activated protein kinases (MAPKs) in DCs. In the present study, we confirmed that histone H1 does not alter the immunophenotype and immunosuppression potential of ASCs, but that histone H1 enhanced wound healing and increased interleukin (IL)-6 expression. Moreover, histone H1 treated-ASCs showed up-regulation of mitogen-activated protein kinases (MAPKs) extracellular-regulated kinase 1/2 (ERK1/2) and sequential NF-κB translocation. Finally, we found that culture in differentiation media supplemented with histone H1 enhanced ASC osteogenesis. In contrast, inhibition of histone H1 by small interfering RNA (siRNA) reduced osteogenic differentiation markers including ALP. These results suggest that histone H1 may be useful for induction of mesenchymal stem cells in tissue engineering and future potential ASC therapies. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24043" xmlns="http://purl.org/rss/1.0/"><title>Scriptaid effects on breast cancer cell lines</title><link>http://dx.doi.org/10.1002%2Fjcp.24043</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Scriptaid effects on breast cancer cell lines</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">L. Giacinti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">C. Giacinti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">C. Gabellini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">E. Rizzuto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">M. Lopez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">A. Giordano</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:57:27.677628-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24043</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24043</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24043</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In breast cancer tumor expression of estrogen receptors (ERs) is important as a marker of prognosis and mostly as a predictor of response to endocrine therapy. In fact, the loss of α-ER expression leads to unresponsiveness to anti-hormone treatment. In a significant fraction of breast cancers, this loss of expression is a result of epigenetic mechanisms, such as DNA methylation and histone deacetylation, within the α-ER promoter. Previous studies have shown that pharmacologic inhibition of these mechanisms using the DNA methyltransferase inhibitor, 5-aza-2-deoxycytidine (AZA), and the histone deacetylase (HDAC) inhibitor, Trichostatin A (TSA), results in expression of functional α-ER mRNA and protein. Moreover, the activity of a novel HDAC inhibitor, Scriptaid, has been shown to induce inhibition of tumor growth in breast cancer and to cause re-expression of functional α-ER in α-ER negative breast cancer cells.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We sought to better characterize the effects of Scriptaid on cell growth, apoptosis and α-ER expression in α-ER-positive (MCF-7), α-ER-negative (MDA-MB-231) and α-ER-negative/Her-2 over-expressing (SKBr-3) human breast cancer cell lines. In all of these cell lines Scriptaid treatment resulted in significant growth inhibition and apoptosis, and RT-PCR confirmed an increase of α-ER mRNA transcript in MDA-MB-231 after 48 h of Scriptaid treatment. Furthermore, following treatment with Scriptaid, the formerly unresponsive MDA-MB-231 and SKBr-3 breast cancer cells became responsive to tamoxifen.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>These results show that the HDAC inhibitor Scriptaid is able to sensitize tamoxifen hormone-resistant breast cancer cells, and that Scriptaid or related HDAC inhibitors are candidates for further study in breast cancer. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>In breast cancer tumor expression of estrogen receptors (ERs) is important as a marker of prognosis and mostly as a predictor of response to endocrine therapy. In fact, the loss of α-ER expression leads to unresponsiveness to anti-hormone treatment. In a significant fraction of breast cancers, this loss of expression is a result of epigenetic mechanisms, such as DNA methylation and histone deacetylation, within the α-ER promoter. Previous studies have shown that pharmacologic inhibition of these mechanisms using the DNA methyltransferase inhibitor, 5-aza-2-deoxycytidine (AZA), and the histone deacetylase (HDAC) inhibitor, Trichostatin A (TSA), results in expression of functional α-ER mRNA and protein. Moreover, the activity of a novel HDAC inhibitor, Scriptaid, has been shown to induce inhibition of tumor growth in breast cancer and to cause re-expression of functional α-ER in α-ER negative breast cancer cells.We sought to better characterize the effects of Scriptaid on cell growth, apoptosis and α-ER expression in α-ER-positive (MCF-7), α-ER-negative (MDA-MB-231) and α-ER-negative/Her-2 over-expressing (SKBr-3) human breast cancer cell lines. In all of these cell lines Scriptaid treatment resulted in significant growth inhibition and apoptosis, and RT-PCR confirmed an increase of α-ER mRNA transcript in MDA-MB-231 after 48 h of Scriptaid treatment. Furthermore, following treatment with Scriptaid, the formerly unresponsive MDA-MB-231 and SKBr-3 breast cancer cells became responsive to tamoxifen.These results show that the HDAC inhibitor Scriptaid is able to sensitize tamoxifen hormone-resistant breast cancer cells, and that Scriptaid or related HDAC inhibitors are candidates for further study in breast cancer. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24044" xmlns="http://purl.org/rss/1.0/"><title>Effect of 17β–estradiol and flavonoids on the regulation of expression of newly identified estrogen responsive genes in a rat raphe nuclei–derived cell line</title><link>http://dx.doi.org/10.1002%2Fjcp.24044</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Effect of 17β–estradiol and flavonoids on the regulation of expression of newly identified estrogen responsive genes in a rat raphe nuclei–derived cell line</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dena A. M. Amer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria Jähne</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carmen Weigt</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Georg Kretzschmar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Günter Vollmer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:57:25.81096-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24044</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24044</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24044</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Due to the <em>health risks</em> attributed to perimenopausal hormone therapy, phytoestrogens such as flavonoids are receiving widespread attention to help alleviate menopausal symptoms, including hormone–driven mood disorders. Based on our previous reporter gene study regarding their transactivational activity in raphe nuclei cells from a brain region involved in regulation of mood disturbances, we herein study their effects on the regulation of expression of 17β–Estradiol (E2)–regulated genes. DNA microarray was used to globally assess E2–induced gene expression in RNDA cells, a rat raphe nuclei–derived cellular model expressing estrogen receptor β. Out of 212 regulated genes, six were selected for verification and as endpoints for the effect of flavonoids on the regulation of mRNA expression in proliferating as well as differentiating RNDA cells. Under proliferative conditions, E2 up–regulated mRNA expression of <em>Cml</em>–<em>5, Sox</em>–<em>18</em> and <em>Krt</em>–<em>19</em>. Similar effects were observed in response to 8–Prenylnaringenin (8–PN), Genistein (GEN), Daidzein (DAI) and Equol (EQ). In line with E2, mRNA expression of <em>Nefm</em> and <em>Zdhhc</em>–<em>2</em> was down–regulated following 8–PN, GEN, DAI, EQ and Naringenin treatment. No regulation was observed on <em>Slc6a4</em> mRNA expression in response to E2 or the flavonoids in proliferating RNDA cells. When cells were shifted to conditions promoting differentiation, changes in cell morphology, in mRNA expression levels and in responsiveness towards E2 and the tested flavonoids were noticed. These expression studies additionally highlighted some of the genes as markers for RNDA cellular differentiation. RNDA cells should prove useful to elucidate molecular and cellular mechanisms of exogenous estrogen receptor ligands with neural cell populations. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Due to the health risks attributed to perimenopausal hormone therapy, phytoestrogens such as flavonoids are receiving widespread attention to help alleviate menopausal symptoms, including hormone–driven mood disorders. Based on our previous reporter gene study regarding their transactivational activity in raphe nuclei cells from a brain region involved in regulation of mood disturbances, we herein study their effects on the regulation of expression of 17β–Estradiol (E2)–regulated genes. DNA microarray was used to globally assess E2–induced gene expression in RNDA cells, a rat raphe nuclei–derived cellular model expressing estrogen receptor β. Out of 212 regulated genes, six were selected for verification and as endpoints for the effect of flavonoids on the regulation of mRNA expression in proliferating as well as differentiating RNDA cells. Under proliferative conditions, E2 up–regulated mRNA expression of Cml–5, Sox–18 and Krt–19. Similar effects were observed in response to 8–Prenylnaringenin (8–PN), Genistein (GEN), Daidzein (DAI) and Equol (EQ). In line with E2, mRNA expression of Nefm and Zdhhc–2 was down–regulated following 8–PN, GEN, DAI, EQ and Naringenin treatment. No regulation was observed on Slc6a4 mRNA expression in response to E2 or the flavonoids in proliferating RNDA cells. When cells were shifted to conditions promoting differentiation, changes in cell morphology, in mRNA expression levels and in responsiveness towards E2 and the tested flavonoids were noticed. These expression studies additionally highlighted some of the genes as markers for RNDA cellular differentiation. RNDA cells should prove useful to elucidate molecular and cellular mechanisms of exogenous estrogen receptor ligands with neural cell populations. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24045" xmlns="http://purl.org/rss/1.0/"><title>Targeting Runx2 expression in hypertrophic chondrocytes impairs endochondral ossification during early skeletal development</title><link>http://dx.doi.org/10.1002%2Fjcp.24045</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Targeting Runx2 expression in hypertrophic chondrocytes impairs endochondral ossification during early skeletal development</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ming Ding</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yaojuan Lu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sam Abbassi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Feifei Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xin Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yu Song</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Valérie Geoffroy</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hee-Jeong Im</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Qiping Zheng</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:57:23.18082-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24045</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24045</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24045</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Runx2 is a known master transcription factor for osteoblast differentiation, as well as an essential regulator for chondrocyte maturation. Recently, more and more data has shown that Runx2 regulates hypertrophic chondrocyte-specific type X collagen gene (<em>Col10a1</em>) expression in different species. However, how Runx2 regulation of <em>Col10a1</em> expression impacts chondrocyte maturation, an essential step of endochondral bone formation, remains unknown. We have recently generated transgenic mice in which flag-tagged <em>Runx2</em> was driven by a cell-specific <em>Col10a1</em> control element. Significantly increased level of <em>Runx2</em> and <em>Col10a1</em> mRNA transcripts were detected in transgenic mouse limbs at both E17.5 (embryonic day 17.5) and P1 (postnatal day1) stages, suggesting an in vivo correlation of <em>Runx2</em> and <em>Col10a1</em> expression. Surprisingly, skeletal staining suggested delayed ossification in both the axial and the appendicular skeleton of transgenic mice from E14.5 until P6. Histological analysis showed elongated hypertrophic zones in transgenic mice, with less von Kossa and TUNEL staining in long bone sections at both E17.5 and P1 stages, suggesting defective mineralization due to delayed chondrocyte maturation or apoptosis. Indeed, we detected increased level of anti-apoptotic genes <em>Bcl-2</em>, <em>Opn</em>, and <em>Sox9</em> in transgenic mice by real-time RT-PCR. Moreover, immunohistochemistry and Western blotting analysis also suggested increased Sox9 expression in hypertrophic chondrocytes of transgenic mice. Together, our data suggest that targeting Runx2 in hypertrophic chondrocytes upregulates expression of <em>Col10a1</em> and other marker genes (such as <em>Sox9</em> etc.). This will change the local matrix environment, delay chondrocyte maturation, reduce apoptosis and matrix mineralization, and eventually, lead to impaired endochondral ossification. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Runx2 is a known master transcription factor for osteoblast differentiation, as well as an essential regulator for chondrocyte maturation. Recently, more and more data has shown that Runx2 regulates hypertrophic chondrocyte-specific type X collagen gene (Col10a1) expression in different species. However, how Runx2 regulation of Col10a1 expression impacts chondrocyte maturation, an essential step of endochondral bone formation, remains unknown. We have recently generated transgenic mice in which flag-tagged Runx2 was driven by a cell-specific Col10a1 control element. Significantly increased level of Runx2 and Col10a1 mRNA transcripts were detected in transgenic mouse limbs at both E17.5 (embryonic day 17.5) and P1 (postnatal day1) stages, suggesting an in vivo correlation of Runx2 and Col10a1 expression. Surprisingly, skeletal staining suggested delayed ossification in both the axial and the appendicular skeleton of transgenic mice from E14.5 until P6. Histological analysis showed elongated hypertrophic zones in transgenic mice, with less von Kossa and TUNEL staining in long bone sections at both E17.5 and P1 stages, suggesting defective mineralization due to delayed chondrocyte maturation or apoptosis. Indeed, we detected increased level of anti-apoptotic genes Bcl-2, Opn, and Sox9 in transgenic mice by real-time RT-PCR. Moreover, immunohistochemistry and Western blotting analysis also suggested increased Sox9 expression in hypertrophic chondrocytes of transgenic mice. Together, our data suggest that targeting Runx2 in hypertrophic chondrocytes upregulates expression of Col10a1 and other marker genes (such as Sox9 etc.). This will change the local matrix environment, delay chondrocyte maturation, reduce apoptosis and matrix mineralization, and eventually, lead to impaired endochondral ossification. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24046" xmlns="http://purl.org/rss/1.0/"><title>Agonist-activated Ca2+ influx and Ca2+-dependent Cl− channels in xenopus ovarian follicular cells: functional heterogeneity within the cell monolayer</title><link>http://dx.doi.org/10.1002%2Fjcp.24046</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Agonist-activated Ca2+ influx and Ca2+-dependent Cl− channels in xenopus ovarian follicular cells: functional heterogeneity within the cell monolayer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rogelio O. Arellano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Leticia Robles-Martínez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bárbara Serrano-Flores</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francisco Vázquez-Cuevas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Edith Garay</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:57:18.963912-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24046</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24046</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24046</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Xenopus</em> follicles are endowed with specific receptors for ATP, ACh, and AII, transmitters proposed as follicular modulators of gamete growth and maturation in several species. Here, we studied ion-current responses elicited by stimulation of these receptors and their activation mechanisms using the voltage-clamp technique. All agonists elicited Cl<sup>-</sup> currents that depended on coupling between oocyte and follicular cells and on an increase in intracellular Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>i</sub>), but they differed in their activation mechanisms and in the localization of the molecules involved. Both ATP and ACh generated fast Cl<sup>-</sup> (<em>F</em><sub>Cl</sub>) currents, while AII activated an oscillatory response; a robust Ca<sup>2+</sup> influx linked specifically to <em>F</em><sub>Cl</sub> activation elicited an inward current (<em>I</em><sub>iw,Ca</sub>) which was carried mainly by Cl<sup>-</sup> ions, through channels with a sequence of permeability of SCN<sup>-</sup> &gt; I<sup>-</sup> &gt; Br<sup>-</sup> &gt; Cl<sup>-</sup>. Like <em>F</em><sub>Cl</sub>, <em>I</em><sub>iw,Ca</sub> was not dependent on oocyte [Ca<sup>2+</sup>]<sub>i</sub>; instead both were eliminated by preventing [Ca<sup>2+</sup>]<sub>i</sub> increase in the follicular cells, and also by U73122 and 2-APB, drugs that inhibit the phospolipase C (PLC) pathway. The results indicated that <em>F</em><sub>Cl</sub> and <em>I</em><sub>iw,Ca</sub> were produced by the expected, PLC-stimulated Ca<sup>2+</sup>-release and Ca<sup>2+</sup>-influx, respectively, and by opening of <em>I</em><sub>Cl(Ca)</sub> channels located in the follicular cells. Given their pharmacological characteristics and behavior in conditions of divalent cation deprivation, Ca<sup>2+</sup>-influx appeared to be driven through store-operated, calcium-like channels. The AII response, which is also known to require PLC activation, did not activate <em>I</em><sub>iw,Ca</sub> and was strictly dependent on oocyte [Ca<sup>2+</sup>]<sub>i</sub> increase; thus, ATP and ACh receptors seem to be expressed in a population of follicular cells different from that expressing AII receptors, which were coupled to the oocyte through distinct gap-junction channels. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Xenopus follicles are endowed with specific receptors for ATP, ACh, and AII, transmitters proposed as follicular modulators of gamete growth and maturation in several species. Here, we studied ion-current responses elicited by stimulation of these receptors and their activation mechanisms using the voltage-clamp technique. All agonists elicited Cl- currents that depended on coupling between oocyte and follicular cells and on an increase in intracellular Ca2+ concentration ([Ca2+]i), but they differed in their activation mechanisms and in the localization of the molecules involved. Both ATP and ACh generated fast Cl- (FCl) currents, while AII activated an oscillatory response; a robust Ca2+ influx linked specifically to FCl activation elicited an inward current (Iiw,Ca) which was carried mainly by Cl- ions, through channels with a sequence of permeability of SCN- &gt; I- &gt; Br- &gt; Cl-. Like FCl, Iiw,Ca was not dependent on oocyte [Ca2+]i; instead both were eliminated by preventing [Ca2+]i increase in the follicular cells, and also by U73122 and 2-APB, drugs that inhibit the phospolipase C (PLC) pathway. The results indicated that FCl and Iiw,Ca were produced by the expected, PLC-stimulated Ca2+-release and Ca2+-influx, respectively, and by opening of ICl(Ca) channels located in the follicular cells. Given their pharmacological characteristics and behavior in conditions of divalent cation deprivation, Ca2+-influx appeared to be driven through store-operated, calcium-like channels. The AII response, which is also known to require PLC activation, did not activate Iiw,Ca and was strictly dependent on oocyte [Ca2+]i increase; thus, ATP and ACh receptors seem to be expressed in a population of follicular cells different from that expressing AII receptors, which were coupled to the oocyte through distinct gap-junction channels. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24047" xmlns="http://purl.org/rss/1.0/"><title>Cardiac and skeletal muscle expression of mutant β-myosin heavy chains, degree of functional impairment and phenotypic heterogeneity in hypertrophic cardiomyopathy</title><link>http://dx.doi.org/10.1002%2Fjcp.24047</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cardiac and skeletal muscle expression of mutant β-myosin heavy chains, degree of functional impairment and phenotypic heterogeneity in hypertrophic cardiomyopathy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marina Di Domenico</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rita Casadonte</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pietroantonio Ricci</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carmela Ricciardi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giacomo Frati</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alfonso Fiorelli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mario Santini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elvira Parrotta</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Barbara Quaresima</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Concetta M. Faniello</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francesco Costanzo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giovanni Cuda</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:57:14.989771-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24047</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24047</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24047</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Several mutations in distinct genes, all coding for sarcomeric proteins, have been reported in unrelated kindreds with familial hypertrophic cardiomyopathy (FHC). We have identified 9 individuals from 3 families harbouring 2 distinct mutations in one copy of the β-myosin heavy chain (β-MHC) gene. In this study, the expression of the mutant β-myosin protein isoform, isolated from slow-twitch fibres of skeletal muscle, was demonstrated by Northern and Western blot analysis; this myosin showed a decreased in vitro motility activity and produced a lower actin-activated ATPase activity. Isometric tension, measured in single slow-twitch fibres isolated from the affected individuals, also showed a significant decrease. The degree of impairment of β-myosin function, as well as the loss in isometric tension development, were strictly dependent on the amount of the isoform transcribed from the mutated allele. Interestingly, a strong correlation was also demonstrated between mutant β-myosin content and clinical features of FHC. On the other hand, we were unable to detect any correlation between mutant β-myosin expression and degree of cardiac hypertrophy, thereby strengthening the hypothesis that hypertrophy, one of the hallmarks of FHC, might not necessarily be related to the clinical evolution of this disease.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>These findings lend support to the notion that additional factors rather than the mutated gene may play a pathogenetic role in cardiac wall thickening, whereas the prognosis appears to be strongly related to the amount of mutant protein. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Several mutations in distinct genes, all coding for sarcomeric proteins, have been reported in unrelated kindreds with familial hypertrophic cardiomyopathy (FHC). We have identified 9 individuals from 3 families harbouring 2 distinct mutations in one copy of the β-myosin heavy chain (β-MHC) gene. In this study, the expression of the mutant β-myosin protein isoform, isolated from slow-twitch fibres of skeletal muscle, was demonstrated by Northern and Western blot analysis; this myosin showed a decreased in vitro motility activity and produced a lower actin-activated ATPase activity. Isometric tension, measured in single slow-twitch fibres isolated from the affected individuals, also showed a significant decrease. The degree of impairment of β-myosin function, as well as the loss in isometric tension development, were strictly dependent on the amount of the isoform transcribed from the mutated allele. Interestingly, a strong correlation was also demonstrated between mutant β-myosin content and clinical features of FHC. On the other hand, we were unable to detect any correlation between mutant β-myosin expression and degree of cardiac hypertrophy, thereby strengthening the hypothesis that hypertrophy, one of the hallmarks of FHC, might not necessarily be related to the clinical evolution of this disease.These findings lend support to the notion that additional factors rather than the mutated gene may play a pathogenetic role in cardiac wall thickening, whereas the prognosis appears to be strongly related to the amount of mutant protein. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24041" xmlns="http://purl.org/rss/1.0/"><title>VE-cadherin trans-interactions modulate Rac activation and enhancement of lung endothelial barrier by iloprost</title><link>http://dx.doi.org/10.1002%2Fjcp.24041</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">VE-cadherin trans-interactions modulate Rac activation and enhancement of lung endothelial barrier by iloprost</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anna A. Birukova</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yufeng Tian</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Oleksii Dubrovskyi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Noureddine Zebda</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicolene Sarich</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xinyong Tian</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yingxiao Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Konstantin G. Birukov</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:57:13.468327-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24041</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24041</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24041</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Small GTPase Rac is important regulator of endothelial cell (EC) barrier enhancement by prostacyclin characterized by increased peripheral actin cytoskeleton and increased interactions between VE-cadherin and other adherens junction (AJ) proteins. This study utilized complementary approaches including siRNA knockdown, culturing in Ca<sup>2+</sup>-free medium, and VE-cadherin blocking antibody to alter VE-cadherin extracellular interactions to investigate the role of VE-cadherin outside-in signaling in modulation of Rac activation and EC barrier regulation by prostacyclin analog iloprost. Spatial analysis of Rac activation in pulmonary EC by FRET revealed additional spike in iloprost-induced Rac activity at the sites of newly formed cell-cell junctions. In contrast, disruption of VE-cadherin extracellular trans-interactions suppressed iloprost-activated Rac signaling and attenuated EC barrier enhancement and cytoskeletal remodeling. These inhibitory effects were associated with decreased membrane accumulation and activation of Rac-specific guanine nucleotide exchange factors (GEF) Tiam1 and Vav2. Conversely, plating of pulmonary EC on surfaces coated with extracellular VE-cadherin domain further promoted iloprost-induced Rac signaling. In the model of thrombin-induced EC barrier recovery, blocking of VE-cadherin trans-interactions attenuated activation of Rac pathway during recovery phase and delayed suppression of Rho signaling and restoration of EC barrier properties. These results suggest that VE-cadherin outside-in signaling controls locally Rac activity stimulated by barrier protective agonists. This control is essential for maximal EC barrier enhancement and accelerated barrier recovery. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Small GTPase Rac is important regulator of endothelial cell (EC) barrier enhancement by prostacyclin characterized by increased peripheral actin cytoskeleton and increased interactions between VE-cadherin and other adherens junction (AJ) proteins. This study utilized complementary approaches including siRNA knockdown, culturing in Ca2+-free medium, and VE-cadherin blocking antibody to alter VE-cadherin extracellular interactions to investigate the role of VE-cadherin outside-in signaling in modulation of Rac activation and EC barrier regulation by prostacyclin analog iloprost. Spatial analysis of Rac activation in pulmonary EC by FRET revealed additional spike in iloprost-induced Rac activity at the sites of newly formed cell-cell junctions. In contrast, disruption of VE-cadherin extracellular trans-interactions suppressed iloprost-activated Rac signaling and attenuated EC barrier enhancement and cytoskeletal remodeling. These inhibitory effects were associated with decreased membrane accumulation and activation of Rac-specific guanine nucleotide exchange factors (GEF) Tiam1 and Vav2. Conversely, plating of pulmonary EC on surfaces coated with extracellular VE-cadherin domain further promoted iloprost-induced Rac signaling. In the model of thrombin-induced EC barrier recovery, blocking of VE-cadherin trans-interactions attenuated activation of Rac pathway during recovery phase and delayed suppression of Rho signaling and restoration of EC barrier properties. These results suggest that VE-cadherin outside-in signaling controls locally Rac activity stimulated by barrier protective agonists. This control is essential for maximal EC barrier enhancement and accelerated barrier recovery. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24039" xmlns="http://purl.org/rss/1.0/"><title>Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity</title><link>http://dx.doi.org/10.1002%2Fjcp.24039</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anna Tesei</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giovanni Brigliadori</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Silvia Carloni</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francesco Fabbri</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paola Ulivi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chiara Arienti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anna Sparatore</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Piero Del Soldato</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alice Pasini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dino Amadori</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rosella Silvestrini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wainer Zoli</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:57:11.459064-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24039</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24039</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24039</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Lung cancer is the leading cause of cancer mortality worldwide and despite efforts made to improve clinical results, continuing poor survival rates indicate that novel therapeutic approaches are needed. Valproic acid (VPA), a short-chain branched fatty acid used mainly for the treatment of epilepsy and bipolar disorder, has been shown to inhibit class I histone deacetylases (HDAC-I), a group of enzymes involved in chromatin remodelling and which are thought to play a role in tumor development. Although evidence of VPA's therapeutic efficacy has also been observed in patients with solid tumors, the very high concentration required to induce antitumor activity limits its clinical usefulness. We used a panel of NSCLC cell lines to evaluate the activity and mechanisms of action of organosulfur valproic acid derivatives, a promising new class of compounds designed to improve the safety and efficacy of the valproic acid molecule and created by coupling it with a hydrogen sulphide (H<sub>2</sub>S)-releasing moiety. Our results highlighted the increased cytotoxic activity of the novel organosulfur derivatives, ACS33 and ACS2, with respect to VPA, starting from low concentrations. In particular, ACS2 exhibited important pro-apoptotic activity triggered by the mitochondrial pathway and also showed anti-invasion potential. Furthermore, our in vitro results identified a highly effective combination schedule (ACS2 + cisplatin) capable of inducing a synergistic interaction even when the two drugs were used at low concentrations, which could prove a valid alternative to traditional chemotherapeutic regimens used for advanced lung cancer. Further studies are needed to confirm these preliminary findings. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Lung cancer is the leading cause of cancer mortality worldwide and despite efforts made to improve clinical results, continuing poor survival rates indicate that novel therapeutic approaches are needed. Valproic acid (VPA), a short-chain branched fatty acid used mainly for the treatment of epilepsy and bipolar disorder, has been shown to inhibit class I histone deacetylases (HDAC-I), a group of enzymes involved in chromatin remodelling and which are thought to play a role in tumor development. Although evidence of VPA's therapeutic efficacy has also been observed in patients with solid tumors, the very high concentration required to induce antitumor activity limits its clinical usefulness. We used a panel of NSCLC cell lines to evaluate the activity and mechanisms of action of organosulfur valproic acid derivatives, a promising new class of compounds designed to improve the safety and efficacy of the valproic acid molecule and created by coupling it with a hydrogen sulphide (H2S)-releasing moiety. Our results highlighted the increased cytotoxic activity of the novel organosulfur derivatives, ACS33 and ACS2, with respect to VPA, starting from low concentrations. In particular, ACS2 exhibited important pro-apoptotic activity triggered by the mitochondrial pathway and also showed anti-invasion potential. Furthermore, our in vitro results identified a highly effective combination schedule (ACS2 + cisplatin) capable of inducing a synergistic interaction even when the two drugs were used at low concentrations, which could prove a valid alternative to traditional chemotherapeutic regimens used for advanced lung cancer. Further studies are needed to confirm these preliminary findings. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24040" xmlns="http://purl.org/rss/1.0/"><title>Mechanisms of cytosolic targeting of matrix metalloproteinase-2</title><link>http://dx.doi.org/10.1002%2Fjcp.24040</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Mechanisms of cytosolic targeting of matrix metalloproteinase-2</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mohammad A. M. Ali</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ava K. Chow</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Arulmozhi D. Kandasamy</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiaohu Fan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lori J. West</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bryan D. Crawford</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas Simmen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richard Schulz</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:57:07.927329-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24040</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24040</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24040</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Matrix metalloproteinase-2 (MMP-2) is best understood for its biological actions outside the cell. However, MMP-2 also localizes to intracellular compartments and the cytosol where it has several substrates, including troponin I (TnI). Despite a growing list of cytosolic substrates, we currently do not know the mechanism(s) that give rise to the equilibrium between intracellular and secreted MMP-2 moieties. Therefore, we explored how cells achieve the unique distribution of this protease. Our data show that endogenous MMP-2 targets inefficiently to the endoplasmic reticulum (ER) and shows significant amounts in the cytosol. Transfection of canonical MMP-2 essentially reproduces this targeting pattern, suggesting it is the quality of MMP-2 signal sequence that predominantly determines MMP-2 targeting. However, we also found that human cardiomyocytes express an MMP-2 splice variant, which entirely lacks the signal sequence. Like the fraction of ER-excluded full-length MMP-2, this variant MMP-2 is restricted to the cytosol and specifically enhances TnI cleavage upon hypoxia-reoxygenation injury in cardiomyocytes. Together, our findings describe for the first time a set of mechanisms that cells utilize to equilibrate MMP-2 both in the extracellular milieu and intracellular, cytosolic locations. Our results also suggest approaches to specifically investigate the overlooked intracellular biology of MMP-2. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Matrix metalloproteinase-2 (MMP-2) is best understood for its biological actions outside the cell. However, MMP-2 also localizes to intracellular compartments and the cytosol where it has several substrates, including troponin I (TnI). Despite a growing list of cytosolic substrates, we currently do not know the mechanism(s) that give rise to the equilibrium between intracellular and secreted MMP-2 moieties. Therefore, we explored how cells achieve the unique distribution of this protease. Our data show that endogenous MMP-2 targets inefficiently to the endoplasmic reticulum (ER) and shows significant amounts in the cytosol. Transfection of canonical MMP-2 essentially reproduces this targeting pattern, suggesting it is the quality of MMP-2 signal sequence that predominantly determines MMP-2 targeting. However, we also found that human cardiomyocytes express an MMP-2 splice variant, which entirely lacks the signal sequence. Like the fraction of ER-excluded full-length MMP-2, this variant MMP-2 is restricted to the cytosol and specifically enhances TnI cleavage upon hypoxia-reoxygenation injury in cardiomyocytes. Together, our findings describe for the first time a set of mechanisms that cells utilize to equilibrate MMP-2 both in the extracellular milieu and intracellular, cytosolic locations. Our results also suggest approaches to specifically investigate the overlooked intracellular biology of MMP-2. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24034" xmlns="http://purl.org/rss/1.0/"><title>Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α-β catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas</title><link>http://dx.doi.org/10.1002%2Fjcp.24034</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α-β catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laura Masuelli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alfredo Budillon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laura Marzocchella</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marie-Agnes Mrozek</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Domenico Vitolo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elena Di Gennaro</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Simona Losito</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Patrizio Sale</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francesco Longo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Franco Ionna</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Florigio Lista</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Raffaella Muraro</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrea Modesti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roberto Bei</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:57:04.84542-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24034</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24034</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24034</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The presence of lymph node metastases is one of the most important prognostic indicators in head and neck squamous cell carcinomas (HNSCCs). An alteration of the E-cadherin-catenins complex and EGFR is essential for the invasiveness of cancer cells. Caveolin-1, the major structural protein of the caveolae, represents a scaffolding molecule for several signaling proteins including EGFR. Although caveolin-1 has been shown to play a role in inducing the invasive phenotype of cancer cells, its role appears to be cell-type specific and for some tumors it has not been defined yet. In this study we used 57 HNSCC specimens to investigate whether the abnormal expression of caveolin-1 was associated with the derangement of the E-cadherin-catenins complex and with the overexpression of ErbB receptors. We demonstrate that in HNSCCs caveolin-1 overexpression is associated with the simultaneous abnormal expression of at least one member of the E-cadherin/α-β catenins complex and multiple ErbB receptors as well as with lymph node metastases. We also demonstrate that chronic stimulation of a human hypopharyngeal carcinoma cell line (FaDu) with EGF induced the internalization of β-catenin and caveolin-1 and their co-localization with EGFR. Moreover, EGF treatment induced an increased physical interaction between EGFR/β-catenin/caveolin-1 and between E-cadherin/β-catenin/caveolin-1. These molecular events were associated with an increased directional motility of FaDu cells in vitro. These findings may provide new insight into the biology of HNSCC progression and help to identify subgroups of primary HNSCCs with a more aggressive behaviour. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The presence of lymph node metastases is one of the most important prognostic indicators in head and neck squamous cell carcinomas (HNSCCs). An alteration of the E-cadherin-catenins complex and EGFR is essential for the invasiveness of cancer cells. Caveolin-1, the major structural protein of the caveolae, represents a scaffolding molecule for several signaling proteins including EGFR. Although caveolin-1 has been shown to play a role in inducing the invasive phenotype of cancer cells, its role appears to be cell-type specific and for some tumors it has not been defined yet. In this study we used 57 HNSCC specimens to investigate whether the abnormal expression of caveolin-1 was associated with the derangement of the E-cadherin-catenins complex and with the overexpression of ErbB receptors. We demonstrate that in HNSCCs caveolin-1 overexpression is associated with the simultaneous abnormal expression of at least one member of the E-cadherin/α-β catenins complex and multiple ErbB receptors as well as with lymph node metastases. We also demonstrate that chronic stimulation of a human hypopharyngeal carcinoma cell line (FaDu) with EGF induced the internalization of β-catenin and caveolin-1 and their co-localization with EGFR. Moreover, EGF treatment induced an increased physical interaction between EGFR/β-catenin/caveolin-1 and between E-cadherin/β-catenin/caveolin-1. These molecular events were associated with an increased directional motility of FaDu cells in vitro. These findings may provide new insight into the biology of HNSCC progression and help to identify subgroups of primary HNSCCs with a more aggressive behaviour. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24033" xmlns="http://purl.org/rss/1.0/"><title>Biochemical and proteomic characterization of alkaptonuric chondrocytes</title><link>http://dx.doi.org/10.1002%2Fjcp.24033</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Biochemical and proteomic characterization of alkaptonuric chondrocytes</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniela Braconi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giulia Bernardini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Claretta Bianchini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marcella Laschi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lia Millucci</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Loredana Amato</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laura Tinti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tommaso Serchi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Federico Chellini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adriano Spreafico</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Annalisa Santucci</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:57:03.317816-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24033</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24033</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24033</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Alkaptonuria (AKU) is a rare genetic disease associated with the accumulation of homogentisic acid (HGA) and its oxidized/polymerized products which leads to the deposition of melanin-like pigments (ochronosis) in connective tissues. Although numerous case reports have described ochronosis in joints, little is known on the molecular mechanisms leading to such a phenomenon. For this reason, we characterized biochemically chondrocytes isolated from the ochronotic cartilage of AKU patients. Based on the macroscopic appearance of the ochronotic cartilage, two sub-populations were identified: cells coming from the black portion of the cartilage were referred to as ‘black’ AKU chondrocytes, while those coming from the white portion were referred to as ‘white’ AKU chondrocytes. Notably, both AKU chondrocytic types were characterized by increased apoptosis, NO release and levels of pro-inflammatory cytokines. Transmission electron microscopy also revealed that intracellular ochronotic pigment deposition was common to both ‘white’ and ‘black’ AKU cells. We then undertook a proteomic and redox-proteomic analysis of AKU chondrocytes which revealed profound alterations in the levels of proteins involved in cell defence, protein folding and cell organization. An increased post-translational oxidation of proteins, which also involved high molecular weight protein aggregates, was found to be particularly relevant in ‘black’ AKU chondrocytes. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Alkaptonuria (AKU) is a rare genetic disease associated with the accumulation of homogentisic acid (HGA) and its oxidized/polymerized products which leads to the deposition of melanin-like pigments (ochronosis) in connective tissues. Although numerous case reports have described ochronosis in joints, little is known on the molecular mechanisms leading to such a phenomenon. For this reason, we characterized biochemically chondrocytes isolated from the ochronotic cartilage of AKU patients. Based on the macroscopic appearance of the ochronotic cartilage, two sub-populations were identified: cells coming from the black portion of the cartilage were referred to as ‘black’ AKU chondrocytes, while those coming from the white portion were referred to as ‘white’ AKU chondrocytes. Notably, both AKU chondrocytic types were characterized by increased apoptosis, NO release and levels of pro-inflammatory cytokines. Transmission electron microscopy also revealed that intracellular ochronotic pigment deposition was common to both ‘white’ and ‘black’ AKU cells. We then undertook a proteomic and redox-proteomic analysis of AKU chondrocytes which revealed profound alterations in the levels of proteins involved in cell defence, protein folding and cell organization. An increased post-translational oxidation of proteins, which also involved high molecular weight protein aggregates, was found to be particularly relevant in ‘black’ AKU chondrocytes. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24035" xmlns="http://purl.org/rss/1.0/"><title>Oldenlandia Diffusa extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERα/Sp1-mediated p53 activation</title><link>http://dx.doi.org/10.1002%2Fjcp.24035</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Oldenlandia Diffusa extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERα/Sp1-mediated p53 activation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Guowei Gu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ines Barone</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luca Gelsomino</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cinzia Giordano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniela Bonofiglio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giancarlo Statti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francesco Menichini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stefania Catalano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sebastiano Andò</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:57:00.550721-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24035</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24035</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24035</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Breast cancer is the most frequent tumor and a major cause of death among women. Estrogens play a crucial role in breast tumor growth, which is the rationale for the use of hormonal antiestrogen therapies. Unfortunately, not all therapeutic modalities are efficacious and it is imperative to develop new effective antitumoral drugs. <em>Oldenlandia Diffusa</em> (OD) is a well-known medicinal plant used to prevent and treat many disorders, especially cancers. The aim of this study was to investigate the effects of OD extracts on breast cancer cell proliferation. We observed that OD extracts strongly inhibited anchorage-dependent and –independent cell growth and induced apoptosis in Estrogen Receptor alpha (ERα)-positive breast cancer cells, whereas proliferation and apoptotic responses of MCF-10A normal breast epithelial cells were unaffected. Mechanistically, OD extracts enhance the tumor suppressor p53 expression as a result of an increased binding of ERα/Sp1 complex to the p53 promoter region. Finally, we isolated ursolic and oleanolic acids as the bioactive compounds able to upregulate p53 expression and inhibit breast cancer cell growth. These acids were greatly effective in reducing tamoxifen-resistant growth of a derivative MCF-7 breast cancer cell line resistant to the antiestrogen treatment.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Our results evidence how OD, and its bioactive compounds, exert antiproliferative and apoptotic effects selectively in ERα-positive breast cancer cells, highlighting the potential use of these herbal extracts as breast cancer preventive and/or therapeutic agents. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Breast cancer is the most frequent tumor and a major cause of death among women. Estrogens play a crucial role in breast tumor growth, which is the rationale for the use of hormonal antiestrogen therapies. Unfortunately, not all therapeutic modalities are efficacious and it is imperative to develop new effective antitumoral drugs. Oldenlandia Diffusa (OD) is a well-known medicinal plant used to prevent and treat many disorders, especially cancers. The aim of this study was to investigate the effects of OD extracts on breast cancer cell proliferation. We observed that OD extracts strongly inhibited anchorage-dependent and –independent cell growth and induced apoptosis in Estrogen Receptor alpha (ERα)-positive breast cancer cells, whereas proliferation and apoptotic responses of MCF-10A normal breast epithelial cells were unaffected. Mechanistically, OD extracts enhance the tumor suppressor p53 expression as a result of an increased binding of ERα/Sp1 complex to the p53 promoter region. Finally, we isolated ursolic and oleanolic acids as the bioactive compounds able to upregulate p53 expression and inhibit breast cancer cell growth. These acids were greatly effective in reducing tamoxifen-resistant growth of a derivative MCF-7 breast cancer cell line resistant to the antiestrogen treatment.Our results evidence how OD, and its bioactive compounds, exert antiproliferative and apoptotic effects selectively in ERα-positive breast cancer cells, highlighting the potential use of these herbal extracts as breast cancer preventive and/or therapeutic agents. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24038" xmlns="http://purl.org/rss/1.0/"><title>Wnt3a stimulates Mepe, matrix extracellular phosphoglycoprotein, expression directly by the activation of the canonical Wnt signaling pathway and indirectly through the stimulation of autocrine Bmp-2 expression</title><link>http://dx.doi.org/10.1002%2Fjcp.24038</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Wnt3a stimulates Mepe, matrix extracellular phosphoglycoprotein, expression directly by the activation of the canonical Wnt signaling pathway and indirectly through the stimulation of autocrine Bmp-2 expression</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Young-Dan Cho</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Woo-Jin Kim</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Won-Joon Yoon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kyung-Mi Woo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeong-Hwa Baek</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gene Lee</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gwan-Shik Kim</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hyun-Mo Ryoo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:56:56.436513-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24038</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24038</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24038</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Rapid Communication</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><span class="underlined ">M</span>atrix <span class="underlined ">e</span>xtracellular <span class="underlined ">p</span>hosphoglycoprot<span class="underlined ">e</span>in (MEPE) is a specific marker of mineralizing osteoblasts and osteocytes. Canonical BMP and Wnt signaling pathways are two of the strongest paracrine signals stimulating osteogenesis. Our previous results indicated that <em>Mepe</em> expression is stimulated by the BMP-2-signaling pathway. The specific aim of this study addressed whether <em>Mepe</em> expression is also controlled by Wnt signaling, and whether there is a cross-regulation between two major osteogenic signaling pathways. Treatment with Wnt3a, a canonical Wnt signaling stimulator, strongly enhanced <em>Mepe</em> mRNA expression. Knock-down of β-catenin with siRNA completely reversed Wnt3a-stimulated <em>Mepe</em> expression. The <em>Mepe</em> mRNA expression level was increased by overexpression of β-catenin and Lef-1, even in the absence of Wnt3a. Highly conserved Lef-1 response elements were identified in the mouse <em>Mepe</em> promoter. The direct binding of Lef-1 to these elements is critical for <em>Mepe</em> expression, indicating that <em>Mepe</em> is a direct target of canonical Wnt signaling. Meanwhile, we also found that Wnt3a treatment strongly stimulated <em>Bmp-2</em> expression, and that the subsequent increase in Bmp-2 protein was determined in Wnt3a-treated conditioned medium (CM). Treatment of MC3T3-E1 cells with CM stimulated phosphorylation of the Smad1/5 proteins and their downstream <em>Dlx5</em> mRNA expression. The CM-mediated increases of phospho-Smad and <em>Dlx5</em> expression were not blocked completely by a Wnt3a antagonist, Dkk-1, but were almost completely suppressed by the addition of a Bmp-2 antagonist, Noggin. Collectively, Wnt3a stimulates <em>Mepe</em> transcription directly by a canonical Wnt signaling pathway through β-catenin and Lef-1 and indirectly through the activation of a Bmp-2 autocrine loop. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Matrix extracellular phosphoglycoprotein (MEPE) is a specific marker of mineralizing osteoblasts and osteocytes. Canonical BMP and Wnt signaling pathways are two of the strongest paracrine signals stimulating osteogenesis. Our previous results indicated that Mepe expression is stimulated by the BMP-2-signaling pathway. The specific aim of this study addressed whether Mepe expression is also controlled by Wnt signaling, and whether there is a cross-regulation between two major osteogenic signaling pathways. Treatment with Wnt3a, a canonical Wnt signaling stimulator, strongly enhanced Mepe mRNA expression. Knock-down of β-catenin with siRNA completely reversed Wnt3a-stimulated Mepe expression. The Mepe mRNA expression level was increased by overexpression of β-catenin and Lef-1, even in the absence of Wnt3a. Highly conserved Lef-1 response elements were identified in the mouse Mepe promoter. The direct binding of Lef-1 to these elements is critical for Mepe expression, indicating that Mepe is a direct target of canonical Wnt signaling. Meanwhile, we also found that Wnt3a treatment strongly stimulated Bmp-2 expression, and that the subsequent increase in Bmp-2 protein was determined in Wnt3a-treated conditioned medium (CM). Treatment of MC3T3-E1 cells with CM stimulated phosphorylation of the Smad1/5 proteins and their downstream Dlx5 mRNA expression. The CM-mediated increases of phospho-Smad and Dlx5 expression were not blocked completely by a Wnt3a antagonist, Dkk-1, but were almost completely suppressed by the addition of a Bmp-2 antagonist, Noggin. Collectively, Wnt3a stimulates Mepe transcription directly by a canonical Wnt signaling pathway through β-catenin and Lef-1 and indirectly through the activation of a Bmp-2 autocrine loop. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24036" xmlns="http://purl.org/rss/1.0/"><title>Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer</title><link>http://dx.doi.org/10.1002%2Fjcp.24036</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shadan Ali</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sanjeev Banerjee</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Farah Logna</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bin Bao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Philip A. Philip</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Murray Korc</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fazlul H. Sarkar</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:56:53.428893-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24036</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24036</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24036</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Human Pancreatic Cancer (PC) is an aggressive disease, which has been recapitulated in transgenic animal model that provides unique opportunity for mechanistic understanding of disease progression and also for testing the efficacy of novel therapeutics. Emerging evidence suggests deregulated expression of microRNAs (miRNAs) in human PC, and thus we investigated the expression of miRNAs in pancreas tissues obtained from transgenic mouse models of K-Ras (K), Pdx1-Cre (C), K-Ras;Pdx1-Cre (KC) and K-Ras;Pdx1-Cre;INK4a/Arf (KCI), initially from pooled RNA samples using miRNA profiling, and further confirmed in individual specimens by quantitative RT-PCR. We found over-expression of <em>miR-21</em>, <em>miR-221</em>, <em>miR-27a</em>, <em>miR-27b</em> and <em>miR-155</em>, and down-regulation of <em>miR-216a</em>, <em>miR-216b</em>, <em>miR-217</em> and <em>miR-146a</em> expression in tumors derived from KC and KCI mouse model, which was consistent with data from KCI-derived RInk-1 cells. Mechanistic investigations revealed a significant induction of EGFR, K-Ras, and MT1-MMP protein expression in tissues from both KC and KCI mouse compared to tissues from K or C, and these results were consistent with similar findings in RInk-1 cells compared to human MIAPaCa-2 cells. Furthermore, <em>miR-155</em> knock-down in RInk-1 cells resulted in the inhibition of cell growth and colony formation consistent with down-regulation of EGFR, MT1-MMP and K-Ras expression. In addition, <em>miR-216b</em> which target Ras, and forced re-expression of <em>miR-216b</em> in RInk-1 cells showed inhibition of cell proliferation and colony formation, which was correlated with reduced expression of Ras, EGFR and MT1-MMP. These findings suggest that these models would be useful for preclinical evaluation of novel miRNA-targeted agents for designing personalized therapy for PC. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Human Pancreatic Cancer (PC) is an aggressive disease, which has been recapitulated in transgenic animal model that provides unique opportunity for mechanistic understanding of disease progression and also for testing the efficacy of novel therapeutics. Emerging evidence suggests deregulated expression of microRNAs (miRNAs) in human PC, and thus we investigated the expression of miRNAs in pancreas tissues obtained from transgenic mouse models of K-Ras (K), Pdx1-Cre (C), K-Ras;Pdx1-Cre (KC) and K-Ras;Pdx1-Cre;INK4a/Arf (KCI), initially from pooled RNA samples using miRNA profiling, and further confirmed in individual specimens by quantitative RT-PCR. We found over-expression of miR-21, miR-221, miR-27a, miR-27b and miR-155, and down-regulation of miR-216a, miR-216b, miR-217 and miR-146a expression in tumors derived from KC and KCI mouse model, which was consistent with data from KCI-derived RInk-1 cells. Mechanistic investigations revealed a significant induction of EGFR, K-Ras, and MT1-MMP protein expression in tissues from both KC and KCI mouse compared to tissues from K or C, and these results were consistent with similar findings in RInk-1 cells compared to human MIAPaCa-2 cells. Furthermore, miR-155 knock-down in RInk-1 cells resulted in the inhibition of cell growth and colony formation consistent with down-regulation of EGFR, MT1-MMP and K-Ras expression. In addition, miR-216b which target Ras, and forced re-expression of miR-216b in RInk-1 cells showed inhibition of cell proliferation and colony formation, which was correlated with reduced expression of Ras, EGFR and MT1-MMP. These findings suggest that these models would be useful for preclinical evaluation of novel miRNA-targeted agents for designing personalized therapy for PC. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24037" xmlns="http://purl.org/rss/1.0/"><title>Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors</title><link>http://dx.doi.org/10.1002%2Fjcp.24037</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luigi Aurisicchio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Emanuele Marra</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laura Luberto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fabrizio Carlomosti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Claudia De Vitis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessia Noto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zeynep Gunes</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuseppe Roscilli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuseppe Mesiti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rita Mancini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maurizio Alimandi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gennaro Ciliberto</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:56:51.071924-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24037</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24037</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24037</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The role of the ErbB3 receptor in signal transduction is to augment the signaling repertoire of active heterodimeric ErbB receptor complexes through activating the PI3K/AKT pathway, which in turn promotes survival and proliferation. ErbB3 has recently been proposed to be involved in acquired resistance to tyrosine kinase inhibitors (TKIs), and is therefore a promising new drug cancer target. Since ErbB3 is a kinase defective receptor, it cannot be targeted by small molecule inhibitors, whereas monoclonal antibodies may offer a viable strategy for pharmacological intervention.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In this study, we have utilized DNA electroporation (DNA-EP) to generate a set of novel hybridomas directed against human ErbB3, which have been characterized for their biochemical and functional properties and selected for their ability to negatively regulate the ErbB3-mediated signaling pathway. <em>In vitro</em>, the anti-ErbB3 antibodies modulate the growth rate of cancer cells of different origins. <em>In vivo</em> they show antitumoral properties in a xenograft model of human pancreatic tumor and in the ErbB2-driven carcinogenesis genetically engineered mouse model (GEMM) for mammary tumor, the BALB/<em>neuT</em>. Our data confirm that downregulating the ErbB3-mediated signals with the use of anti-ErbB3 monoclonal antibodies is both feasible and relevant for therapeutic purposes and provides new opportunities for novel anti-ErbB3 combinatory strategies for cancer treatment. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The role of the ErbB3 receptor in signal transduction is to augment the signaling repertoire of active heterodimeric ErbB receptor complexes through activating the PI3K/AKT pathway, which in turn promotes survival and proliferation. ErbB3 has recently been proposed to be involved in acquired resistance to tyrosine kinase inhibitors (TKIs), and is therefore a promising new drug cancer target. Since ErbB3 is a kinase defective receptor, it cannot be targeted by small molecule inhibitors, whereas monoclonal antibodies may offer a viable strategy for pharmacological intervention.In this study, we have utilized DNA electroporation (DNA-EP) to generate a set of novel hybridomas directed against human ErbB3, which have been characterized for their biochemical and functional properties and selected for their ability to negatively regulate the ErbB3-mediated signaling pathway. In vitro, the anti-ErbB3 antibodies modulate the growth rate of cancer cells of different origins. In vivo they show antitumoral properties in a xenograft model of human pancreatic tumor and in the ErbB2-driven carcinogenesis genetically engineered mouse model (GEMM) for mammary tumor, the BALB/neuT. Our data confirm that downregulating the ErbB3-mediated signals with the use of anti-ErbB3 monoclonal antibodies is both feasible and relevant for therapeutic purposes and provides new opportunities for novel anti-ErbB3 combinatory strategies for cancer treatment. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24032" xmlns="http://purl.org/rss/1.0/"><title>“Annexin A1: Novel roles in skeletal muscle biology”</title><link>http://dx.doi.org/10.1002%2Fjcp.24032</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">“Annexin A1: Novel roles in skeletal muscle biology”</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Valentina Bizzarro</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Antonello Petrella</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luca Parente</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-29T12:56:46.78929-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24032</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24032</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24032</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Annexin A1 (ANXA1, lipocortin-1) is the first characterized member of the annexin superfamily of proteins, so called since their main property is to bind (i.e. to annex) to cellular membranes in a Ca<sup>2+</sup>-dependent manner. ANXA1 has been involved in a broad range of molecular and cellular processes, including anti-inflammatory signalling, kinase activities in signal transduction, maintenance of cytoskeleton and extracellular matrix integrity, tissue growth, apoptosis and differentiation. New insights show that endogenous ANXA1 positively modulates myoblast cell differentiation by promoting migration of satellite cells and, consequently, skeletal muscle differentiation. This suggests that ANXA1 may contribute to the regeneration of skeletal muscle tissue and may have therapeutic implications with respect to the development of ANXA1 mimetics. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Annexin A1 (ANXA1, lipocortin-1) is the first characterized member of the annexin superfamily of proteins, so called since their main property is to bind (i.e. to annex) to cellular membranes in a Ca2+-dependent manner. ANXA1 has been involved in a broad range of molecular and cellular processes, including anti-inflammatory signalling, kinase activities in signal transduction, maintenance of cytoskeleton and extracellular matrix integrity, tissue growth, apoptosis and differentiation. New insights show that endogenous ANXA1 positively modulates myoblast cell differentiation by promoting migration of satellite cells and, consequently, skeletal muscle differentiation. This suggests that ANXA1 may contribute to the regeneration of skeletal muscle tissue and may have therapeutic implications with respect to the development of ANXA1 mimetics. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24019" xmlns="http://purl.org/rss/1.0/"><title>Nuclear IRS-1 and cancer</title><link>http://dx.doi.org/10.1002%2Fjcp.24019</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Nuclear IRS-1 and cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Krzysztof Reiss</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luis Del Valle</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adam Lassak</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joanna Trojanek</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-22T08:10:14.695394-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24019</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24019</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24019</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The family of insulin receptor substrates (IRS) consists of four proteins (IRS-1 - IRS-4), which were initially characterized as typical cytosolic adaptor proteins involved in insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) signaling. The first cloned and characterized member of the IRS family, IRS-1, has predicted molecular weight of 132 kDa, however, as a result of its extensive serine phosphorylation it separates on a SDS gel as a band of approximately 160-185 kDa. In addition to its metabolic and growth-promoting functions, IRS-1 is also suspected to play a role in malignant transformation. The mechanism by which IRS-1 supports tumor growth is not fully understood, and the argument that IRS-1 merely amplifies the signal from the IGF-1R and/or IR requires further investigation. Almost a decade ago, we reported the presence of nuclear IRS-1 in medulloblastoma clinical samples, which express viral oncoprotein, large T-antigen of human polyomavirus JC (JCV T-antigen). This first demonstration of nuclear IRS-1 was confirmed in several other laboratories. The nuclear IRS-1 was also detected by cells expressing the SV40 T-antigen, v-Src, in immortalized fibroblasts stimulated with IGF-I, in hepatocytes, 32D cells, and in an osteosarcoma cell line. More recently, nuclear IRS-1 was detected in breast cancer cells in association with estrogen receptor alpha (ERα), and in JC virus negative medulloblastoma cells expressing ERb, further implicating nuclear IRS-1 in cellular transformation. Here, we discuss how nuclear IRS-1 acting on DNA repair fidelity, transcriptional activity, and cell growth can support tumor development and progression. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The family of insulin receptor substrates (IRS) consists of four proteins (IRS-1 - IRS-4), which were initially characterized as typical cytosolic adaptor proteins involved in insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) signaling. The first cloned and characterized member of the IRS family, IRS-1, has predicted molecular weight of 132 kDa, however, as a result of its extensive serine phosphorylation it separates on a SDS gel as a band of approximately 160-185 kDa. In addition to its metabolic and growth-promoting functions, IRS-1 is also suspected to play a role in malignant transformation. The mechanism by which IRS-1 supports tumor growth is not fully understood, and the argument that IRS-1 merely amplifies the signal from the IGF-1R and/or IR requires further investigation. Almost a decade ago, we reported the presence of nuclear IRS-1 in medulloblastoma clinical samples, which express viral oncoprotein, large T-antigen of human polyomavirus JC (JCV T-antigen). This first demonstration of nuclear IRS-1 was confirmed in several other laboratories. The nuclear IRS-1 was also detected by cells expressing the SV40 T-antigen, v-Src, in immortalized fibroblasts stimulated with IGF-I, in hepatocytes, 32D cells, and in an osteosarcoma cell line. More recently, nuclear IRS-1 was detected in breast cancer cells in association with estrogen receptor alpha (ERα), and in JC virus negative medulloblastoma cells expressing ERb, further implicating nuclear IRS-1 in cellular transformation. Here, we discuss how nuclear IRS-1 acting on DNA repair fidelity, transcriptional activity, and cell growth can support tumor development and progression. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24026" xmlns="http://purl.org/rss/1.0/"><title>NALP-3 inflammasome silencing attenuates ceramide induced transepithelial permeability</title><link>http://dx.doi.org/10.1002%2Fjcp.24026</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">NALP-3 inflammasome silencing attenuates ceramide induced transepithelial permeability</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Narasaiah Kolliputi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lakshmi Galam</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Prasanna Tamarapu Parthasarathy</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Srinivas M. Tipparaju</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richard Lockey</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-14T10:01:06.991975-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24026</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24026</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24026</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The hallmark of acute lung injury (ALI) is the influx of proinflammatory cytokines into lung tissue and alveolar permeability that ultimately leads to pulmonary edema. However, the mechanisms involved in inflammatory cytokine production and alveolar permeability are unclear. Recent studies suggest that excessive production of ceramide has clinical relevance as a mediator of pulmonary edema and ALI. Our earlier studies indicate that the activation of inflammasome promotes the processing and secretion of proinflammatory cytokines and causes alveolar permeability in ALI. However, the role of ceramide in inflammasome activation and the underlying mechanism in relation to alveolar permeability is not known. We hypothesized that ceramide activates the inflammasome and causes inflammatory cytokine production and alveolar epithelial permeability. To test this hypothesis, we analyzed the lung ceramide levels during hyperoxic acute lung injury in mice. The effect of ceramide on activation of inflammasome and production of inflammatory cytokine was assessed in primary mouse alveolar macrophages and THP-1 cells. Alveolar transepithelial permeability was determined in alveolar epithelial type-II cells (AT-II) and THP-1 co-cultures. Our results reveal that ceramide causes inflammasome activation, induction of caspase-1, IL-1β cleavage and release of proinflammatory cytokines. In addition, ceramide further induces alveolar epithelial permeability. Short hairpin RNA silencing of inflammasome components abrogated ceramide-induced secretion of proinflammatory cytokines <em>in vitro</em>. Inflammasome silencing abolishes ceramide induced alveolar epithelial permeability in AT-II. Collectively, our results demonstrate for the first time that ceramide-induced secretion of proinflammatory cytokines and alveolar epithelial permeability occurs though inflammasome activation. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The hallmark of acute lung injury (ALI) is the influx of proinflammatory cytokines into lung tissue and alveolar permeability that ultimately leads to pulmonary edema. However, the mechanisms involved in inflammatory cytokine production and alveolar permeability are unclear. Recent studies suggest that excessive production of ceramide has clinical relevance as a mediator of pulmonary edema and ALI. Our earlier studies indicate that the activation of inflammasome promotes the processing and secretion of proinflammatory cytokines and causes alveolar permeability in ALI. However, the role of ceramide in inflammasome activation and the underlying mechanism in relation to alveolar permeability is not known. We hypothesized that ceramide activates the inflammasome and causes inflammatory cytokine production and alveolar epithelial permeability. To test this hypothesis, we analyzed the lung ceramide levels during hyperoxic acute lung injury in mice. The effect of ceramide on activation of inflammasome and production of inflammatory cytokine was assessed in primary mouse alveolar macrophages and THP-1 cells. Alveolar transepithelial permeability was determined in alveolar epithelial type-II cells (AT-II) and THP-1 co-cultures. Our results reveal that ceramide causes inflammasome activation, induction of caspase-1, IL-1β cleavage and release of proinflammatory cytokines. In addition, ceramide further induces alveolar epithelial permeability. Short hairpin RNA silencing of inflammasome components abrogated ceramide-induced secretion of proinflammatory cytokines in vitro. Inflammasome silencing abolishes ceramide induced alveolar epithelial permeability in AT-II. Collectively, our results demonstrate for the first time that ceramide-induced secretion of proinflammatory cytokines and alveolar epithelial permeability occurs though inflammasome activation. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24031" xmlns="http://purl.org/rss/1.0/"><title>Critical choices for modeling breast cancer in transgenic mouse models</title><link>http://dx.doi.org/10.1002%2Fjcp.24031</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Critical choices for modeling breast cancer in transgenic mouse models</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">I. Caligiuri</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">F. Rizzolio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">S. Boffo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">A. Giordano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">G. Toffoli</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-14T10:01:06.858212-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24031</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24031</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24031</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Mini-Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Modeling breast cancer in the mouse has helped to better define the heterogeneity of human breast cancer. In the recent past, it has become evident that some limitations have restricted the potential benefits that can be achieved with this approach. In this review, we highlight some key points that should be taken into account when the mouse is used, with special emphasis on transgenic models. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Modeling breast cancer in the mouse has helped to better define the heterogeneity of human breast cancer. In the recent past, it has become evident that some limitations have restricted the potential benefits that can be achieved with this approach. In this review, we highlight some key points that should be taken into account when the mouse is used, with special emphasis on transgenic models. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24027" xmlns="http://purl.org/rss/1.0/"><title>Identity and ranking of colonic mesenchymal stromal cells</title><link>http://dx.doi.org/10.1002%2Fjcp.24027</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Identity and ranking of colonic mesenchymal stromal cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michele Signore</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anna Maria Cerio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessandra Boe</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alfredo Pagliuca</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Valentina Zaottini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">laria Schiavoni</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giorgio Fedele</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stefano Petti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Simone Navarra</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Clara Maria Ausiello</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elvira Pelosi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessandro Fatica</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Antonio Sorrentino</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mauro Valtieri</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-14T10:01:03.334038-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24027</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24027</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24027</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Although ongoing clinical trials utilize systemic administration of bone-marrow mesenchymal stromal cells (BM-MSCs) in Crohn's disease (CD), nothing is known about the presence and the function of MSCs in the normal human bowel. MSCs are bone marrow multipotent cells supporting haematopoiesis with the potential to differentiate into multiple skeletal phenotypes. A recently identified new marker, CD146, allowing to prospectively isolate MSCs from bone marrow, renders also possible their identification in different tissues. In order to elucidate the presence and functional role of MSCs in human bowel we analyzed normal adult colon sections and isolated MSCs from them. In colon (C) sections, resident MSCs form a net enveloping crypts in lamina propria, coinciding with structural myofibroblasts or interstitial stromal cells. Nine sub-clonal CD146<sup>+</sup> MSC lines were derived and characterized from colon biopsies, in addition to MSC lines from five other human tissues. In spite of a phenotype qualitative identity between the BM- and C-MSC populations, they were discriminated and categorized. Similarities between C-MSC and BM-MSCs are represented by: osteogenic differentiation, hematopoietic supporting activity, immune-modulation and surface-antigen qualitative expression. The differences between these populations are: C-MSCs mean intensity expression is lower for CD13, CD29 and CD49c surface-antigens, proliferative rate faster, life-span shorter, chondrogenic differentiation rare and adipogenic differentiation completely blocked. Briefly, BM-MSCs, deserve the rank of progenitors whereas C-MSCs belong to the restricted precursor hierarchy. The presence and functional role of MSCs in human colon, provide a rationale for BM-MSC replacement therapy in CD, where resident bowel MSCs might be exhausted or diverted from their physiological functions. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Although ongoing clinical trials utilize systemic administration of bone-marrow mesenchymal stromal cells (BM-MSCs) in Crohn's disease (CD), nothing is known about the presence and the function of MSCs in the normal human bowel. MSCs are bone marrow multipotent cells supporting haematopoiesis with the potential to differentiate into multiple skeletal phenotypes. A recently identified new marker, CD146, allowing to prospectively isolate MSCs from bone marrow, renders also possible their identification in different tissues. In order to elucidate the presence and functional role of MSCs in human bowel we analyzed normal adult colon sections and isolated MSCs from them. In colon (C) sections, resident MSCs form a net enveloping crypts in lamina propria, coinciding with structural myofibroblasts or interstitial stromal cells. Nine sub-clonal CD146+ MSC lines were derived and characterized from colon biopsies, in addition to MSC lines from five other human tissues. In spite of a phenotype qualitative identity between the BM- and C-MSC populations, they were discriminated and categorized. Similarities between C-MSC and BM-MSCs are represented by: osteogenic differentiation, hematopoietic supporting activity, immune-modulation and surface-antigen qualitative expression. The differences between these populations are: C-MSCs mean intensity expression is lower for CD13, CD29 and CD49c surface-antigens, proliferative rate faster, life-span shorter, chondrogenic differentiation rare and adipogenic differentiation completely blocked. Briefly, BM-MSCs, deserve the rank of progenitors whereas C-MSCs belong to the restricted precursor hierarchy. The presence and functional role of MSCs in human colon, provide a rationale for BM-MSC replacement therapy in CD, where resident bowel MSCs might be exhausted or diverted from their physiological functions. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24030" xmlns="http://purl.org/rss/1.0/"><title>MAD2 depletion triggers premature cellular senescence in human primary fibroblasts by activating a P53 pathway preventing aneuploid cells propagation</title><link>http://dx.doi.org/10.1002%2Fjcp.24030</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">MAD2 depletion triggers premature cellular senescence in human primary fibroblasts by activating a P53 pathway preventing aneuploid cells propagation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laura Lentini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Viviana Barra</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tiziana Schillaci</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Aldo Di Leonardo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-14T10:01:02.254332-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24030</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24030</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24030</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The Spindle Assembly Checkpoint (SAC) is a cellular surveillance mechanism that ensures faithful chromosome segregation during mitosis and its failure can result in aneuploidy. Previously, it was suggested that reduction of the <em>MAD2</em> gene, encoding a major component of the SAC, induced aneuploidy in human tumor cells. However, tumor cell lines contain multiple mutations that might affect or exacerbate the cellular response to Mad2 depletion. Thus, the scenario resulting by Mad2 depletion in primary human cells could be different and more complex that the one depicted so far. We used primary human fibroblasts (IMR90) and epithelial breast cells (MCF10A) to gain further insight on the effects of genomic instability caused by transient Mad2 depletion. To this aim we depleted Mad2 by RNAi to a level shown by Mad2 haplo-insufficient cells and found that induced aneuploidy caused premature cellular senescence in IMR90 cells. IMR90 cells showed typical features of senescent cells, like senescence-associated (SA) <span class="math"><img alt="equation image" src="http://onlinelibrary.wiley.com/store/10.1002/jcp.24030/asset/equation/tex2gif-ueqn-1.gif?v=1&amp;t=gyzv69xu&amp;s=552ff20d72e70aacdec8b71c4aa171dd73f403e4" class="inlineGraphic"/></span> galactosidase expression, including up-regulation of p53 and p14ARF proteins and of p21<sup>waf1</sup> as well, but not of p16(INK4A) cyclin-dependent kinase (Cdk) inhibitor. In contrast, after <em>MAD2</em> post-transcriptional silencing MCF10A cells in which the INK4A/ARF locus is deleted, showed both aneuploidy and a small increase of p53 and p21<sup>waf1</sup> proteins, but not premature cellular senescence.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Finally, our results provides an explanation of how a p53 controlled pathway, involving initially p21<sup>waf1</sup> and then p14ARF, could minimize the occurrence of genomic alterations derived from chromosome instability induced by low amounts of MAD2 protein. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The Spindle Assembly Checkpoint (SAC) is a cellular surveillance mechanism that ensures faithful chromosome segregation during mitosis and its failure can result in aneuploidy. Previously, it was suggested that reduction of the MAD2 gene, encoding a major component of the SAC, induced aneuploidy in human tumor cells. However, tumor cell lines contain multiple mutations that might affect or exacerbate the cellular response to Mad2 depletion. Thus, the scenario resulting by Mad2 depletion in primary human cells could be different and more complex that the one depicted so far. We used primary human fibroblasts (IMR90) and epithelial breast cells (MCF10A) to gain further insight on the effects of genomic instability caused by transient Mad2 depletion. To this aim we depleted Mad2 by RNAi to a level shown by Mad2 haplo-insufficient cells and found that induced aneuploidy caused premature cellular senescence in IMR90 cells. IMR90 cells showed typical features of senescent cells, like senescence-associated (SA) ${\tilde {\beta }}$ galactosidase expression, including up-regulation of p53 and p14ARF proteins and of p21waf1 as well, but not of p16(INK4A) cyclin-dependent kinase (Cdk) inhibitor. In contrast, after MAD2 post-transcriptional silencing MCF10A cells in which the INK4A/ARF locus is deleted, showed both aneuploidy and a small increase of p53 and p21waf1 proteins, but not premature cellular senescence.Finally, our results provides an explanation of how a p53 controlled pathway, involving initially p21waf1 and then p14ARF, could minimize the occurrence of genomic alterations derived from chromosome instability induced by low amounts of MAD2 protein. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24028" xmlns="http://purl.org/rss/1.0/"><title>Matrine modulates HSC70 levels and rescues ΔF508-CFTR</title><link>http://dx.doi.org/10.1002%2Fjcp.24028</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Matrine modulates HSC70 levels and rescues ΔF508-CFTR</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anna Basile</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria Pascale</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Silvia Franceschelli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Erika Nieddu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marco T. Mazzei</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paola Fossa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria Caterina Turco</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mauro Mazzei</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-14T10:01:02.210482-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24028</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24028</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24028</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-dependent Cl<sup>-</sup> channel located in the plasma membrane, and its malfunction results in Cystic Fibrosis (CF), the most common lethal genetic disease in Caucasians. Most CF patients carry the deletion of Phe508 (ΔF508 mutation); this mutation prevents the delivery of the CFTR to its correct cellular location, the apical (lumen-facing) membrane of epithelial cells. Molecular chaperones play a central role in determining the fate of ΔF508-CFTR. In this report we show that the Matrine, a quinolizidine alkaloid, downregulates the expression of the molecular chaperone HSC70 and increases the protein levels of ΔF508-CFTR in human alveolar basal epithelial cells (A549 cell line), stably transfected with a ΔF508-CFTR-expressing construct. Moreover, Matrine induced ΔF508-CFTR release from endoplasmic reticulum to cell cytosol and its localization on the cell membrane. Interestingly, downregulation of HSC70 resulted in increased levels of ΔF508-CFTR complexes with the co-chaperone BAG3, that in addition appeared to co-localize with the mutated protein on the cell surface. These results shed new light on ΔF508-CFTR interactions with proteins of the chaperones/co-chaperones system and could be useful in strategies for future medical treatments for Cystic Fibrosis. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-dependent Cl- channel located in the plasma membrane, and its malfunction results in Cystic Fibrosis (CF), the most common lethal genetic disease in Caucasians. Most CF patients carry the deletion of Phe508 (ΔF508 mutation); this mutation prevents the delivery of the CFTR to its correct cellular location, the apical (lumen-facing) membrane of epithelial cells. Molecular chaperones play a central role in determining the fate of ΔF508-CFTR. In this report we show that the Matrine, a quinolizidine alkaloid, downregulates the expression of the molecular chaperone HSC70 and increases the protein levels of ΔF508-CFTR in human alveolar basal epithelial cells (A549 cell line), stably transfected with a ΔF508-CFTR-expressing construct. Moreover, Matrine induced ΔF508-CFTR release from endoplasmic reticulum to cell cytosol and its localization on the cell membrane. Interestingly, downregulation of HSC70 resulted in increased levels of ΔF508-CFTR complexes with the co-chaperone BAG3, that in addition appeared to co-localize with the mutated protein on the cell surface. These results shed new light on ΔF508-CFTR interactions with proteins of the chaperones/co-chaperones system and could be useful in strategies for future medical treatments for Cystic Fibrosis. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24029" xmlns="http://purl.org/rss/1.0/"><title>Artichoke polyphenols induce apoptosis and decrease the invasive potential of the human breast cancer cell line MDA-MB231</title><link>http://dx.doi.org/10.1002%2Fjcp.24029</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Artichoke polyphenols induce apoptosis and decrease the invasive potential of the human breast cancer cell line MDA-MB231</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anna Maria Mileo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Donato Di Venere</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vito Linsalata</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rocco Fraioli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stefania Miccadei</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-14T10:01:01.287838-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24029</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24029</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24029</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The human breast cancer cell line, oestrogen receptor negative, MDA-MB231, was used to evaluate the antitumor effect of polyphenolic extracts from the edible part of artichokes (AEs). Treatment of cancer cells reduced cell viability and inhibited cell growth in a dose-dependent manner. Importantly, AEs did not have any effect on normal breast epithelial cell line, MCF10A. Chlorogenic acid (ChA), the most representative component of the polyphenolic fraction of artichoke, had no prominent effects on the cell death rate of MDA-MB231 cells. The addition of AEs to the cells, rather than ChA, triggered apoptosis via a mitochondrial and a death-receptor pathway, as shown by the activation of caspase-9 and caspase-8, respectively. Furthermore, an increase of the Bax:Bcl2 ratio and up-regulation of cyclin-dependent kinase inhibitor, p21<sup>WAF1</sup>, crucial apoptotic players, were documented. According to our data on activation of caspase-9, a loss of mitochondrial transmembrane potential (Ψ<sub>m</sub>) was shown. Cell motility and invasion capabilities were remarkably inhibited by AEs-treatment in highly invasive MDA-MB231 cells. In addition, a significant decrease of proteolytic activity of metalloproteinase-2 protein (MMP-2), involved in degrading components of the extracellular matrix, was detected. Our findings indicate that AEs reduced cell viability, inhibited cell growth, triggered apoptotic mechanisms and showed inhibitory properties against the invasive behaviour of MDA-MB231cancer cell line. Altogether, these data indicate the potential chemopreventive activity of artichoke polyphenolic extracts. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The human breast cancer cell line, oestrogen receptor negative, MDA-MB231, was used to evaluate the antitumor effect of polyphenolic extracts from the edible part of artichokes (AEs). Treatment of cancer cells reduced cell viability and inhibited cell growth in a dose-dependent manner. Importantly, AEs did not have any effect on normal breast epithelial cell line, MCF10A. Chlorogenic acid (ChA), the most representative component of the polyphenolic fraction of artichoke, had no prominent effects on the cell death rate of MDA-MB231 cells. The addition of AEs to the cells, rather than ChA, triggered apoptosis via a mitochondrial and a death-receptor pathway, as shown by the activation of caspase-9 and caspase-8, respectively. Furthermore, an increase of the Bax:Bcl2 ratio and up-regulation of cyclin-dependent kinase inhibitor, p21WAF1, crucial apoptotic players, were documented. According to our data on activation of caspase-9, a loss of mitochondrial transmembrane potential (Ψm) was shown. Cell motility and invasion capabilities were remarkably inhibited by AEs-treatment in highly invasive MDA-MB231 cells. In addition, a significant decrease of proteolytic activity of metalloproteinase-2 protein (MMP-2), involved in degrading components of the extracellular matrix, was detected. Our findings indicate that AEs reduced cell viability, inhibited cell growth, triggered apoptotic mechanisms and showed inhibitory properties against the invasive behaviour of MDA-MB231cancer cell line. Altogether, these data indicate the potential chemopreventive activity of artichoke polyphenolic extracts. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23028" xmlns="http://purl.org/rss/1.0/"><title>Bone morphogenetic protein receptor type Ia localization causes increased BMP2 signaling in mice exhibiting increased peak bone mass phenotype</title><link>http://dx.doi.org/10.1002%2Fjcp.23028</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Bone morphogenetic protein receptor type Ia localization causes increased BMP2 signaling in mice exhibiting increased peak bone mass phenotype</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Beth Bragdon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeremy Bonor</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kathryn L. Schultz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wesley G. Beamer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Clifford J. Rosen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anja Nohe</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-14T10:01:00.338913-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23028</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23028</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23028</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Bone Morphogenetic Protein 2 (BMP2) is a growth factor that initiates osteoblast differentiation. Recent studies show that BMP2 signaling regulates bone mineral density (BMD). BMP2 interacts with BMP receptor type Ia (BMPRIa) and type II receptor leading to the activation of the Smad signaling pathway. BMPRIa must shuttle between distinct plasma membrane domains, enriched of Caveolin-1 alpha and Caveolin-1 beta isoforms, and receptor activation occurs in these domains. Yet it remains unknown whether the molecular mechanism that regulates BMP2 signaling is driving mineralization and BMD. Therefore the B6.C3H-1-12 congenic mouse model with increased BMD and osteoblast mineralization was utilized in this study. Using the Family Image Correlation Spectroscopy, we determined if BMP2 led to a significant re-localization of BMPRIa to caveolae of the alpha/beta isoforms in bone marrow stromal cells (BMSCs) isolated from B6.C3H-1-12 mice compared to the C57BL/6J mice, which served as controls. The control, C57BL/6J mice, was selected due to only 4Mb of Chromosome 1 from the C3H/HeJ mouse was backcrossed to a C57BL/6J background. Using reporter gene assays, the B6.C3H-1-12 BMSCs responded to BMP2 with increased Smad activation. Furthermore disrupting caveolae reduced the BMP2-induced Smad signaling in BMSCs isolated from B6.C3H-1-12 and C57BL/6J. This study suggests for the first time a regulatory mechanism of BMPRIa signaling at the plasma membrane of BMSCs that 1) associated with genetic differences in the distal Chromosome 1 segment carried by the B6.C3H-1-12 congenic and 2) contributes to increase BMD of the B6.C3H-1-12 compared to the C57BL/6J control mice. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Bone Morphogenetic Protein 2 (BMP2) is a growth factor that initiates osteoblast differentiation. Recent studies show that BMP2 signaling regulates bone mineral density (BMD). BMP2 interacts with BMP receptor type Ia (BMPRIa) and type II receptor leading to the activation of the Smad signaling pathway. BMPRIa must shuttle between distinct plasma membrane domains, enriched of Caveolin-1 alpha and Caveolin-1 beta isoforms, and receptor activation occurs in these domains. Yet it remains unknown whether the molecular mechanism that regulates BMP2 signaling is driving mineralization and BMD. Therefore the B6.C3H-1-12 congenic mouse model with increased BMD and osteoblast mineralization was utilized in this study. Using the Family Image Correlation Spectroscopy, we determined if BMP2 led to a significant re-localization of BMPRIa to caveolae of the alpha/beta isoforms in bone marrow stromal cells (BMSCs) isolated from B6.C3H-1-12 mice compared to the C57BL/6J mice, which served as controls. The control, C57BL/6J mice, was selected due to only 4Mb of Chromosome 1 from the C3H/HeJ mouse was backcrossed to a C57BL/6J background. Using reporter gene assays, the B6.C3H-1-12 BMSCs responded to BMP2 with increased Smad activation. Furthermore disrupting caveolae reduced the BMP2-induced Smad signaling in BMSCs isolated from B6.C3H-1-12 and C57BL/6J. This study suggests for the first time a regulatory mechanism of BMPRIa signaling at the plasma membrane of BMSCs that 1) associated with genetic differences in the distal Chromosome 1 segment carried by the B6.C3H-1-12 congenic and 2) contributes to increase BMD of the B6.C3H-1-12 compared to the C57BL/6J control mice. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23067" xmlns="http://purl.org/rss/1.0/"><title>The role of COX-2/PGE2 in gossypol-induced apoptosis of colorectal carcinoma cells</title><link>http://dx.doi.org/10.1002%2Fjcp.23067</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The role of COX-2/PGE2 in gossypol-induced apoptosis of colorectal carcinoma cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chih Chiang Chien</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ching Huai Ko</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shing Chuan Shen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Liang Yo Yang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yen Chou Chen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-14T10:00:58.841884-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23067</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23067</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23067</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Our previous study showed that gossypol (GOS) exhibits potent cytotoxic effects via apoptosis induction against human colorectal carcinoma cells; however the role of cyclooxygenase (COX)-2/prostaglandin (PG)E<sub>2</sub> on GOS-induced apoptosis is still unknown. In the present study, 12-O-tetradecanoylphorbol-13-acetate (TPA) addition significantly inhibited GOS-induced apoptosis in human colorectal carcinoma HT-29 cells in accordance with inducing COX-2 protein/PGE<sub>2</sub> production. TPA inhibition of GOS-induced apoptosis was blocked by adding protein kinase (PK)C inhibitors including staurosporine (ST), GF109203X (GF), and H7, characterized by the occurrence of cleaved caspase 3 proteins and a decrease in COX-2 protein/PGE<sub>2</sub> production in HT-29 cells. The addition of COX activity inhibitors, including NS398, aspirin (AS), diclofenac (DI), and indomethacin (IN), suppressed TPA protection of GOS-induced apoptosis with decreased PGE<sub>2</sub> production in HT-29 cells. Application of PGE<sub>2</sub>, but not it analogues PGD<sub>2</sub>, PGJ<sub>2</sub>, or PGF<sub>2α</sub>, protected HT-29 cells from GOS-induced DNA ladders, and the EP<sub>1</sub> receptor agonist, 17PT-PGE<sub>2</sub>, mimicked the protection induced by PGE<sub>2</sub>, whereas the selective EP<sub>2</sub> receptor agonist, butaprostol (BUT), the EP<sub>3</sub> receptor agonist, sulprostol (SUL), and the EP<sub>4</sub> receptor agonist, PGE<sub>1</sub> alcohol (PGE<sub>1</sub>), showed no significant effects on GOS-induced apoptosis in HT-29 cells. PGE<sub>2</sub>'s protection against GOS-induced apoptosis was reversed by adding the selective EP<sub>1</sub> receptor antagonist, SC-19220. Furthermore, GOS had an effective apoptotic effect on COLO205 colorectal carcinoma cells which expressed undetectable level of endogenous COX-2 protein than HT-29 cells, and the decreased COX-2 protein level via COX-2 siRNA or addition of COX-2 activity inhibitor NS398 significantly elevated GOS-induced cell death in HT-29 cells. COLO205-T cells were established through sustained TPA incubation of COLO205 cells, and COLO205-T cells showed a lower sensitivity to GOS-induced cell death with increased COX-2 (not Bcl-2 and Mcl-1) protein than parental COLO-205 cells. A decrease in COX-2 protein expression in COLO205-T cells by COX-2 siRNA transfection or enhanced GOS-induced cell death according to an MTT assay and DNA integrity assay. The notion of COX-2/PGE<sub>2</sub> activation against GOS-induced apoptosis in colon carcinoma cells was demonstrated, and the combination of GOS and COX-2 inhibitors to treat colon carcinoma possesses clinical potential worthy of further investigation. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Our previous study showed that gossypol (GOS) exhibits potent cytotoxic effects via apoptosis induction against human colorectal carcinoma cells; however the role of cyclooxygenase (COX)-2/prostaglandin (PG)E2 on GOS-induced apoptosis is still unknown. In the present study, 12-O-tetradecanoylphorbol-13-acetate (TPA) addition significantly inhibited GOS-induced apoptosis in human colorectal carcinoma HT-29 cells in accordance with inducing COX-2 protein/PGE2 production. TPA inhibition of GOS-induced apoptosis was blocked by adding protein kinase (PK)C inhibitors including staurosporine (ST), GF109203X (GF), and H7, characterized by the occurrence of cleaved caspase 3 proteins and a decrease in COX-2 protein/PGE2 production in HT-29 cells. The addition of COX activity inhibitors, including NS398, aspirin (AS), diclofenac (DI), and indomethacin (IN), suppressed TPA protection of GOS-induced apoptosis with decreased PGE2 production in HT-29 cells. Application of PGE2, but not it analogues PGD2, PGJ2, or PGF2α, protected HT-29 cells from GOS-induced DNA ladders, and the EP1 receptor agonist, 17PT-PGE2, mimicked the protection induced by PGE2, whereas the selective EP2 receptor agonist, butaprostol (BUT), the EP3 receptor agonist, sulprostol (SUL), and the EP4 receptor agonist, PGE1 alcohol (PGE1), showed no significant effects on GOS-induced apoptosis in HT-29 cells. PGE2's protection against GOS-induced apoptosis was reversed by adding the selective EP1 receptor antagonist, SC-19220. Furthermore, GOS had an effective apoptotic effect on COLO205 colorectal carcinoma cells which expressed undetectable level of endogenous COX-2 protein than HT-29 cells, and the decreased COX-2 protein level via COX-2 siRNA or addition of COX-2 activity inhibitor NS398 significantly elevated GOS-induced cell death in HT-29 cells. COLO205-T cells were established through sustained TPA incubation of COLO205 cells, and COLO205-T cells showed a lower sensitivity to GOS-induced cell death with increased COX-2 (not Bcl-2 and Mcl-1) protein than parental COLO-205 cells. A decrease in COX-2 protein expression in COLO205-T cells by COX-2 siRNA transfection or enhanced GOS-induced cell death according to an MTT assay and DNA integrity assay. The notion of COX-2/PGE2 activation against GOS-induced apoptosis in colon carcinoma cells was demonstrated, and the combination of GOS and COX-2 inhibitors to treat colon carcinoma possesses clinical potential worthy of further investigation. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24022" xmlns="http://purl.org/rss/1.0/"><title>Bone production by human maxillary sinus mucosa cells</title><link>http://dx.doi.org/10.1002%2Fjcp.24022</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Bone production by human maxillary sinus mucosa cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">A. Graziano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">L. Benedetti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">G. Massei</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">M. G. Cusella de Angelis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">F. Ferrarotti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">M. Aimetti</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:43:00.394727-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24022</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24022</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24022</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The Schneider membrane is the mucosa that covers the inner part of the maxillary sinus cavities. The free surface is a ciliated pseudostratified epithelium, while the deeper portion is a highly vascularised connective tissue. The stromal fraction, bordering the bony wall of the sinus, after tooth loss can exhibit increased osteoclastic activity resulting in resorption of the bone in the posterior maxilla.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Goal of our study was to isolate and characterize mesenchymal progenitors in the Schneider's membrane connective net and to evaluate their self ability to differentiate towards osteoblastic lineage, in absence of osteoinductive factors and osteoconductive biomaterials of support. This should indicate that maxillary sinus membrane represents an useful an approachable source of MSCs for bone tissue engineering and cell therapy and owns the intrinsic capacity to restore maxillary bone after tooth loss without the needing of biomaterials. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The Schneider membrane is the mucosa that covers the inner part of the maxillary sinus cavities. The free surface is a ciliated pseudostratified epithelium, while the deeper portion is a highly vascularised connective tissue. The stromal fraction, bordering the bony wall of the sinus, after tooth loss can exhibit increased osteoclastic activity resulting in resorption of the bone in the posterior maxilla.Goal of our study was to isolate and characterize mesenchymal progenitors in the Schneider's membrane connective net and to evaluate their self ability to differentiate towards osteoblastic lineage, in absence of osteoinductive factors and osteoconductive biomaterials of support. This should indicate that maxillary sinus membrane represents an useful an approachable source of MSCs for bone tissue engineering and cell therapy and owns the intrinsic capacity to restore maxillary bone after tooth loss without the needing of biomaterials. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24023" xmlns="http://purl.org/rss/1.0/"><title>Potential Role of Prolactin in Antipsychotic-Mediated Association of Schizophrenia and Type 2 Diabetes</title><link>http://dx.doi.org/10.1002%2Fjcp.24023</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Potential Role of Prolactin in Antipsychotic-Mediated Association of Schizophrenia and Type 2 Diabetes</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Brandon Oberweis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Claudia Gragnoli</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:58.434096-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24023</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24023</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24023</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>It remains unclear why atypical antipsychotics confer a risk for hyperglycemia compared to typical antipsychotics. Atypical antipsychotics antagonize dopamine receptors-2 (D<sub>2</sub>) and serotonin (5-HT) receptors-2, while typical antipsychotics antagonize only D<sub>2</sub> receptors.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We aimed at elucidating the mechanistic differences between the role of typical and atypical antipsychotics on prolactin levels and glucose regulation.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>A Medline search was conducted during 2010 using the search terms type 2 diabetes (T2D), typical/atypical antipsychotics, schizophrenia, prolactin, and serotonin. We discuss the effect of typical and atypical antipsychotics on prolactin levels and glucose regulation.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Given that prolactin is under negative control by dopamine and positive control by serotonin, typical antipsychotics induce elevations in prolactin, while atypical antipsychotics do not. Research studies show protective effects of prolactin on T2D.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We hypothesize that the difference in induction of T2D between typical and atypical antipsychotics is due to the antipsychotic receptor binding mediated effect in changes in prolactin levels. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>It remains unclear why atypical antipsychotics confer a risk for hyperglycemia compared to typical antipsychotics. Atypical antipsychotics antagonize dopamine receptors-2 (D2) and serotonin (5-HT) receptors-2, while typical antipsychotics antagonize only D2 receptors.We aimed at elucidating the mechanistic differences between the role of typical and atypical antipsychotics on prolactin levels and glucose regulation.A Medline search was conducted during 2010 using the search terms type 2 diabetes (T2D), typical/atypical antipsychotics, schizophrenia, prolactin, and serotonin. We discuss the effect of typical and atypical antipsychotics on prolactin levels and glucose regulation.Given that prolactin is under negative control by dopamine and positive control by serotonin, typical antipsychotics induce elevations in prolactin, while atypical antipsychotics do not. Research studies show protective effects of prolactin on T2D.We hypothesize that the difference in induction of T2D between typical and atypical antipsychotics is due to the antipsychotic receptor binding mediated effect in changes in prolactin levels. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24024" xmlns="http://purl.org/rss/1.0/"><title>TGF β-1 administration during ex-vivo expansion of human articular chondrocytes in a serum-free medium redirects the cell phenotype toward hypertrophy</title><link>http://dx.doi.org/10.1002%2Fjcp.24024</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">TGF β-1 administration during ex-vivo expansion of human articular chondrocytes in a serum-free medium redirects the cell phenotype toward hypertrophy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">R. Narcisi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">R. Quarto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">V. Ulivi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">A. Muraglia</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">L. Molfetta</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">P. Giannoni</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:53.637046-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24024</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24024</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24024</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Cell-based cartilage resurfacing requires ex-vivo expansion of autologous articular chondrocytes. Defined culture conditions minimize expansion-dependent phenotypic alterations but maintenance of the cells' differentiation potential must be carefully assessed. TGF ß-1 positively regulates the expression of several cartilage proteins, but its therapeutic application in damaged cartilage is controversial. Thus we evaluated the phenotypic outcomes of cultured human articular chondrocytes exposed to TGF β-1 during monolayer expansion in a serum-free medium. After 5 doublings cells were transferred to micromass cultures to assess their chondrogenic differentiation, or replated in osteogenic medium. Immunocytostainings of micromasses of TGF-expanded cells showed loss of aggrecan and type II collagen. Positivity was evidenced for RAGE, IHH, type X collagen and for apoptotic cells, paralleling a reduction of BCL-2 levels, suggesting hypertrophic differentiation. TGF β-1-exposed cells also evidenced increased mRNA levels for bone sialoprotein, osteopontin, matrix metalloproteinase-13, TIMP-3, VEGF and SMAD7, enhanced alkaline phosphatase activity and pyrophosphate availability. Conversely, SMAD3 mRNA and protein contents were reduced. After osteogenic induction, only TGF-expanded cells strongly mineralized and impaired p38 kinase activity, a contributor of chondrocytes' differentiation. To evaluate possible endochondral ossification progression, we seeded the chondrocytes on hydroxyapatite scaffolds, subsequently implanted in an in-vivo ectopic setting, but cells failed to reach overt ossification; nonetheless, constructs seeded with TGF-exposed cells displayed blood vessels of the host vascular supply with enlarged diameters, suggestive of vascular remodeling, as in bone growth. Thus TGF-exposure during articular chondrocytes expansion induces a phenotype switch to hypertrophy, an undesirable effect for cells possibly intended for tissue-engineered cartilage repair. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Cell-based cartilage resurfacing requires ex-vivo expansion of autologous articular chondrocytes. Defined culture conditions minimize expansion-dependent phenotypic alterations but maintenance of the cells' differentiation potential must be carefully assessed. TGF ß-1 positively regulates the expression of several cartilage proteins, but its therapeutic application in damaged cartilage is controversial. Thus we evaluated the phenotypic outcomes of cultured human articular chondrocytes exposed to TGF β-1 during monolayer expansion in a serum-free medium. After 5 doublings cells were transferred to micromass cultures to assess their chondrogenic differentiation, or replated in osteogenic medium. Immunocytostainings of micromasses of TGF-expanded cells showed loss of aggrecan and type II collagen. Positivity was evidenced for RAGE, IHH, type X collagen and for apoptotic cells, paralleling a reduction of BCL-2 levels, suggesting hypertrophic differentiation. TGF β-1-exposed cells also evidenced increased mRNA levels for bone sialoprotein, osteopontin, matrix metalloproteinase-13, TIMP-3, VEGF and SMAD7, enhanced alkaline phosphatase activity and pyrophosphate availability. Conversely, SMAD3 mRNA and protein contents were reduced. After osteogenic induction, only TGF-expanded cells strongly mineralized and impaired p38 kinase activity, a contributor of chondrocytes' differentiation. To evaluate possible endochondral ossification progression, we seeded the chondrocytes on hydroxyapatite scaffolds, subsequently implanted in an in-vivo ectopic setting, but cells failed to reach overt ossification; nonetheless, constructs seeded with TGF-exposed cells displayed blood vessels of the host vascular supply with enlarged diameters, suggestive of vascular remodeling, as in bone growth. Thus TGF-exposure during articular chondrocytes expansion induces a phenotype switch to hypertrophy, an undesirable effect for cells possibly intended for tissue-engineered cartilage repair. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24021" xmlns="http://purl.org/rss/1.0/"><title>Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts</title><link>http://dx.doi.org/10.1002%2Fjcp.24021</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hiroyuki Suzuki</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Naoto Suda</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Momotoshi Shiga</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yukiho Kobayashi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Masataka Nakamura</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sachiko Iseki</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Keiji Moriyama</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:46.955186-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24021</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24021</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24021</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Apert syndrome is characterized by craniosynostosis and syndactyly, and is predominantly caused by mutation of either S252W or P253W in the fibroblast growth factor receptor (FGFR) 2 gene. In this study, we characterized the effects of one of the mutations (S252W) using primary calvarial osteoblasts derived from transgenic mice, Ap-Tg and sAp-Tg, that expressed an Apert-type mutant FGFR2 (FGFR2IIIc-S252W; FGFR2IIIc-Ap), and the soluble form (extracellular domain only) of the mutant FGFR2 (sFGFR2IIIc-Ap), respectively. Compared to WT-derived osteoblasts, osteoblasts from Ap-Tg mouse showed a higher proliferative activity and enhanced differentiation, while those from sAp-Tg mouse exhibited reduced potential for proliferation and osteogenic differentiation. When transplanted with β-tricalcium phosphate (β-TCP) granules into immunodeficient mice, Ap-Tg-derived osteoblasts showed a higher bone forming capacity, whereas sAp-Tg-derived osteoblasts were completely deficient for this phenotype. Phosphorylation of ERK, MEK, PLCg, and p38 was increased in Ap-Tg-derived osteoblasts, whereas phosphorylation of these signaling molecules was reduced in sAp-Tg-derived osteoblasts. Interestingly, when these experiments were carried out using osteoblasts from the mice generated by crossing Ap-Tg and sAp-Tg (Ap/sAp-Tg), which co-expressed FGFR2IIIc-Ap and sFGFR2IIIc-Ap, the results were comparable to those obtained from WT-derived osteoblasts. Taken together, these results indicate that osteoblasts expressing FGFR2IIIc-Ap proliferate and differentiate via highly activated MEK, ERK and p38 pathways, while these pathways are suppressed in osteoblasts expressing sFGFR2IIIc-Ap. Our findings also suggest that altered FGFR2IIIc signaling in osteoblasts is mostly responsible for the phenotypes seen in Apert syndrome, therefore these osteoblast cell lines are useful tools for investigating the pathogenesis of Apert syndrome. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Apert syndrome is characterized by craniosynostosis and syndactyly, and is predominantly caused by mutation of either S252W or P253W in the fibroblast growth factor receptor (FGFR) 2 gene. In this study, we characterized the effects of one of the mutations (S252W) using primary calvarial osteoblasts derived from transgenic mice, Ap-Tg and sAp-Tg, that expressed an Apert-type mutant FGFR2 (FGFR2IIIc-S252W; FGFR2IIIc-Ap), and the soluble form (extracellular domain only) of the mutant FGFR2 (sFGFR2IIIc-Ap), respectively. Compared to WT-derived osteoblasts, osteoblasts from Ap-Tg mouse showed a higher proliferative activity and enhanced differentiation, while those from sAp-Tg mouse exhibited reduced potential for proliferation and osteogenic differentiation. When transplanted with β-tricalcium phosphate (β-TCP) granules into immunodeficient mice, Ap-Tg-derived osteoblasts showed a higher bone forming capacity, whereas sAp-Tg-derived osteoblasts were completely deficient for this phenotype. Phosphorylation of ERK, MEK, PLCg, and p38 was increased in Ap-Tg-derived osteoblasts, whereas phosphorylation of these signaling molecules was reduced in sAp-Tg-derived osteoblasts. Interestingly, when these experiments were carried out using osteoblasts from the mice generated by crossing Ap-Tg and sAp-Tg (Ap/sAp-Tg), which co-expressed FGFR2IIIc-Ap and sFGFR2IIIc-Ap, the results were comparable to those obtained from WT-derived osteoblasts. Taken together, these results indicate that osteoblasts expressing FGFR2IIIc-Ap proliferate and differentiate via highly activated MEK, ERK and p38 pathways, while these pathways are suppressed in osteoblasts expressing sFGFR2IIIc-Ap. Our findings also suggest that altered FGFR2IIIc signaling in osteoblasts is mostly responsible for the phenotypes seen in Apert syndrome, therefore these osteoblast cell lines are useful tools for investigating the pathogenesis of Apert syndrome. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24018" xmlns="http://purl.org/rss/1.0/"><title>Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: Implications in alkaptonuria</title><link>http://dx.doi.org/10.1002%2Fjcp.24018</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: Implications in alkaptonuria</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marcella Laschi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laura Tinti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniela Braconi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lia Millucci</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lorenzo Ghezzi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Loredana Amato</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Enrico Selvi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adriano Spreafico</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giulia Bernardini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Annalisa Santucci</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:42.398872-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24018</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24018</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24018</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Alkaptonuria (AKU) results from defective homogentisate1,2-dioxygenase (HGD), causing degenerative arthropathy. The deposition of ochronotic pigment in joints is so far attributed to homogentisic acid produced by the liver, circulating in the blood and accumulating locally. Human normal and AKU osteoarticular cells were tested for <em>HGD</em> gene expression by RT-PCR, mono- and 2D-western blotting. <em>HGD</em> gene expression was revealed in chondrocytes, synoviocytes, osteoblasts. Furthermore, HGD expression was confirmed by western blotting, that also revealed the presence of five enzymatic molecular species. Our findings indicate that AKU osteoarticular cells produce the ochronotic pigment <em>in loco</em> and this may strongly contribute to induction of ochronotic arthropathy. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Alkaptonuria (AKU) results from defective homogentisate1,2-dioxygenase (HGD), causing degenerative arthropathy. The deposition of ochronotic pigment in joints is so far attributed to homogentisic acid produced by the liver, circulating in the blood and accumulating locally. Human normal and AKU osteoarticular cells were tested for HGD gene expression by RT-PCR, mono- and 2D-western blotting. HGD gene expression was revealed in chondrocytes, synoviocytes, osteoblasts. Furthermore, HGD expression was confirmed by western blotting, that also revealed the presence of five enzymatic molecular species. Our findings indicate that AKU osteoarticular cells produce the ochronotic pigment in loco and this may strongly contribute to induction of ochronotic arthropathy. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24020" xmlns="http://purl.org/rss/1.0/"><title>Evidence of Vitamin D and interferon-β cross-talk in human osteoblasts with 1α,25-dihydroxyvitamin D3 being dominant over interferon-β in stimulating mineralization</title><link>http://dx.doi.org/10.1002%2Fjcp.24020</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Evidence of Vitamin D and interferon-β cross-talk in human osteoblasts with 1α,25-dihydroxyvitamin D3 being dominant over interferon-β in stimulating mineralization</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">VJ Woeckel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">M Koedam</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">J. van de Peppel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">H Chiba</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">BCJ van der Eerden</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">JPTM van Leeuwen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:37.526245-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24020</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24020</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24020</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>It is well established that 1a-25-dihydroxyvitamin D3 (1,25D3) regulates osteoblast function and stimulates mineralization by human osteoblasts. The aim of this study was to identify processes underlying the 1,25D3 effects on mineralization. We started with gene expression profiling analyses of differentiating human pre-osteoblast treated with 1,25D3. Bioinformatic analyses showed interferon-related and -regulated genes (ISG) to be overrepresented in the set of 1,25D3-regulated genes. 1,25D3 down-regulated ISGs predominantly during the pre-mineralization period. This pointed to an interaction between the vitamin D and IFN signaling cascades in the regulation of osteoblast function. Separately, 1,25D3 enhances while IFNβ inhibits mineralization. Treatment of human osteoblasts with 1,25D3 and IFNβ showed that 1,25D3 completely overrules the IFNβ inhibition of mineralization. This was supported by analyses of extracellular matrix gene expression, showing a dominant effect of 1,25D3 over the inhibitory effect of IFNβ. We identified processes shared by IFNβ- and 1,25D3-mediated signaling by performing gene expression profiling during early osteoblast differentiation. Bioinformatic analyses revealed that genes being correlated or anti-correlated with Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) were associated with osteoblast proliferation. In conclusion, the current study demonstrates a cross-talk between 1,25D3 and IFNβ in osteoblast differentiation and bone formation/mineralization. The interaction is complex and depends on the process but importantly, 1,25D3 stimulation of mineralization is dominant over the inhibitory effect of IFNβ. These observations are of potential clinical relevance considering the impact of the immune system on bone metabolism in conditions such as rheumatoid arthritis. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>It is well established that 1a-25-dihydroxyvitamin D3 (1,25D3) regulates osteoblast function and stimulates mineralization by human osteoblasts. The aim of this study was to identify processes underlying the 1,25D3 effects on mineralization. We started with gene expression profiling analyses of differentiating human pre-osteoblast treated with 1,25D3. Bioinformatic analyses showed interferon-related and -regulated genes (ISG) to be overrepresented in the set of 1,25D3-regulated genes. 1,25D3 down-regulated ISGs predominantly during the pre-mineralization period. This pointed to an interaction between the vitamin D and IFN signaling cascades in the regulation of osteoblast function. Separately, 1,25D3 enhances while IFNβ inhibits mineralization. Treatment of human osteoblasts with 1,25D3 and IFNβ showed that 1,25D3 completely overrules the IFNβ inhibition of mineralization. This was supported by analyses of extracellular matrix gene expression, showing a dominant effect of 1,25D3 over the inhibitory effect of IFNβ. We identified processes shared by IFNβ- and 1,25D3-mediated signaling by performing gene expression profiling during early osteoblast differentiation. Bioinformatic analyses revealed that genes being correlated or anti-correlated with Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) were associated with osteoblast proliferation. In conclusion, the current study demonstrates a cross-talk between 1,25D3 and IFNβ in osteoblast differentiation and bone formation/mineralization. The interaction is complex and depends on the process but importantly, 1,25D3 stimulation of mineralization is dominant over the inhibitory effect of IFNβ. These observations are of potential clinical relevance considering the impact of the immune system on bone metabolism in conditions such as rheumatoid arthritis. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24017" xmlns="http://purl.org/rss/1.0/"><title>Proteotoxic stress of cancer: implication of the heat-shock response in oncogenesis</title><link>http://dx.doi.org/10.1002%2Fjcp.24017</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Proteotoxic stress of cancer: implication of the heat-shock response in oncogenesis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chengkai Dai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Siyuan Dai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Junyue Cao</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:35.270765-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24017</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24017</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24017</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Mini-Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Organisms frequently encounter a wide variety of proteotoxic stressors. The heat-shock response, an ancient cytoprotective mechanism, has evolved to augment organismal survival and longevity in the face of proteotoxic stress from without and within. These broadly recognized beneficial effects, ironically, contrast sharply with its emerging role as a culprit in the pathogenesis of cancers. Here, we present an overview of the normal biology of the heat-shock response and highlight its implications in oncogenic processes, including the proteotoxic stress phenotype of cancer; the function of this stress response in helping cancer survive and adapt to proteotoxic stress; and perturbation of proteome homeostasis in cancer as a potential therapeutic avenue. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Organisms frequently encounter a wide variety of proteotoxic stressors. The heat-shock response, an ancient cytoprotective mechanism, has evolved to augment organismal survival and longevity in the face of proteotoxic stress from without and within. These broadly recognized beneficial effects, ironically, contrast sharply with its emerging role as a culprit in the pathogenesis of cancers. Here, we present an overview of the normal biology of the heat-shock response and highlight its implications in oncogenic processes, including the proteotoxic stress phenotype of cancer; the function of this stress response in helping cancer survive and adapt to proteotoxic stress; and perturbation of proteome homeostasis in cancer as a potential therapeutic avenue. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.22999" xmlns="http://purl.org/rss/1.0/"><title>Human myxomatous mitral valve prolapse: Role of bone morphogenetic protein 4 in valvular interstitial cell activation</title><link>http://dx.doi.org/10.1002%2Fjcp.22999</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Human myxomatous mitral valve prolapse: Role of bone morphogenetic protein 4 in valvular interstitial cell activation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rachana Sainger</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Juan B. Grau</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Emanuela Branchetti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paolo Poggio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William F. Seefried</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Benjamin C. Field</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael A. Acker</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert C. Gorman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joseph H. Gorman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Clark W. Hargrove</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joseph E. Bavaria</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giovanni Ferrari</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:32.564974-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.22999</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.22999</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.22999</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Myxomatous Mitral valve prolapse (MVP) is the most common cardiac valvular abnormality in industrialized countries and a leading cause of mitral valve surgery for isolated mitral regurgitation. The key role of valvular interstitial cells (VICs) during mitral valve development and homeostasis has been recently suggested, however little is known about the molecular pathways leading to MVP. We aim to characterize Bone Morphogenetic Protein 4 (BMP4) as a cellular regulator of mitral valvular interstitial cell activation towards a pathologic synthetic phenotype and to analyze the cellular phenotypic changes and extracellular matrix (ECM) reorganization associated with the development of myxomatous mitral valve prolapse. Microarray analysis showed significant up regulation of BMP4-mediated signaling molecules in myxomatous MVP when compared to controls. Histological analysis and cellular characterization suggest that during myxomatous MVP development, healthy quiescent mitral VICs undergo a phenotypic activation via up regulation of BMP4-mediated pathway. <em>In vitro</em> hBMP4 treatment of isolated human mitral VICs mimics the cellular activation and ECM remodeling as seen in MVP tissues. The present study characterizes the cell biology of mitral VICs in physiological and pathological conditions and provides insights into the molecular and cellular mechanisms mediated by BMP4 during MVP. The ability to test and control the plasticity of VICs using different molecules may help in developing new diagnostic and therapeutic strategies for myxomatous MVP. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Myxomatous Mitral valve prolapse (MVP) is the most common cardiac valvular abnormality in industrialized countries and a leading cause of mitral valve surgery for isolated mitral regurgitation. The key role of valvular interstitial cells (VICs) during mitral valve development and homeostasis has been recently suggested, however little is known about the molecular pathways leading to MVP. We aim to characterize Bone Morphogenetic Protein 4 (BMP4) as a cellular regulator of mitral valvular interstitial cell activation towards a pathologic synthetic phenotype and to analyze the cellular phenotypic changes and extracellular matrix (ECM) reorganization associated with the development of myxomatous mitral valve prolapse. Microarray analysis showed significant up regulation of BMP4-mediated signaling molecules in myxomatous MVP when compared to controls. Histological analysis and cellular characterization suggest that during myxomatous MVP development, healthy quiescent mitral VICs undergo a phenotypic activation via up regulation of BMP4-mediated pathway. In vitro hBMP4 treatment of isolated human mitral VICs mimics the cellular activation and ECM remodeling as seen in MVP tissues. The present study characterizes the cell biology of mitral VICs in physiological and pathological conditions and provides insights into the molecular and cellular mechanisms mediated by BMP4 during MVP. The ability to test and control the plasticity of VICs using different molecules may help in developing new diagnostic and therapeutic strategies for myxomatous MVP. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24016" xmlns="http://purl.org/rss/1.0/"><title>New insights in endometrial carcinogenesis</title><link>http://dx.doi.org/10.1002%2Fjcp.24016</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">New insights in endometrial carcinogenesis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuseppina D'Andrilli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessandro Bovicelli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marco G Paggi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Antonio Giordano</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:29.926816-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24016</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24016</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24016</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Endometrial carcinoma is the most common cancer of the female genital tract in Europe and in the United States. Despite advances in defining the biology of endometrial carcinomas, there has been poor progress in determining markers that distinguish preinvasive endometrial proliferations.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The aim of this review is to highlight the most recent studies regarding the molecular markers involved in endometrial adenocarcinoma pathogenesis and carcinogenesis. We focus on studies that describe markers with potential to progress from endometrial hyperplasia to invasive disease. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Endometrial carcinoma is the most common cancer of the female genital tract in Europe and in the United States. Despite advances in defining the biology of endometrial carcinomas, there has been poor progress in determining markers that distinguish preinvasive endometrial proliferations.The aim of this review is to highlight the most recent studies regarding the molecular markers involved in endometrial adenocarcinoma pathogenesis and carcinogenesis. We focus on studies that describe markers with potential to progress from endometrial hyperplasia to invasive disease. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24012" xmlns="http://purl.org/rss/1.0/"><title>Vitamin C treatment promotes mesenchymal stem cell sheet formation and tissue regeneration by elevating telomerase activity</title><link>http://dx.doi.org/10.1002%2Fjcp.24012</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Vitamin C treatment promotes mesenchymal stem cell sheet formation and tissue regeneration by elevating telomerase activity</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">F. L. Wei</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">C. Y. Qu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">T. L. Song</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">G. Ding</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Z. P. Fan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">D. Y. Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Y. Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">C. M. Zhang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">S. Shi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">S. L. Wang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:25.23343-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24012</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24012</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24012</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Cell sheet engineering has been developed as an alternative approach to improve mesenchymal stem cell-mediated tissue regeneration. In this study, we found that vitamin C (Vc) was capable of inducing telomerase activity in periodontal ligament stem cells (PDLSCs), leading to the up-regulated expression of extracellular matrix type I collagen, fibronectin, and integrin β1, stem cell markers Oct4, Sox2, and Nanog as well as osteogenic markers RUNX2, ALP, OCN. Under Vc treatment, PDLSCs can form cell sheet structures because of increased cell matrix production. Interestingly, PDLSC sheets demonstrated a significant improvement in tissue regeneration compared with untreated control dissociated PDLSCs and offered an effective treatment for periodontal defects in a swine model. In addition, bone marrow mesenchymal stem cell sheets and umbilical cord mesenchymal stem cell sheets were also well constructed using this method. The development of Vc-mediated mesenchymal stem cell sheets may provide an easy and practical approach for cell-based tissue regeneration. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Cell sheet engineering has been developed as an alternative approach to improve mesenchymal stem cell-mediated tissue regeneration. In this study, we found that vitamin C (Vc) was capable of inducing telomerase activity in periodontal ligament stem cells (PDLSCs), leading to the up-regulated expression of extracellular matrix type I collagen, fibronectin, and integrin β1, stem cell markers Oct4, Sox2, and Nanog as well as osteogenic markers RUNX2, ALP, OCN. Under Vc treatment, PDLSCs can form cell sheet structures because of increased cell matrix production. Interestingly, PDLSC sheets demonstrated a significant improvement in tissue regeneration compared with untreated control dissociated PDLSCs and offered an effective treatment for periodontal defects in a swine model. In addition, bone marrow mesenchymal stem cell sheets and umbilical cord mesenchymal stem cell sheets were also well constructed using this method. The development of Vc-mediated mesenchymal stem cell sheets may provide an easy and practical approach for cell-based tissue regeneration. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24014" xmlns="http://purl.org/rss/1.0/"><title>Differential mesengenic potential and expression of stem cell fate modulators in mesenchymal stromal cells from human term placenta and bone marrow</title><link>http://dx.doi.org/10.1002%2Fjcp.24014</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Differential mesengenic potential and expression of stem cell fate modulators in mesenchymal stromal cells from human term placenta and bone marrow</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pamela Jaramillo-Ferrada</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ernst Wolvetang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Justin Cooper-White</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:20.799391-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24014</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24014</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24014</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Placenta has attracted increasing attention over the past decade as a stem cell source for regenerative medicine. In particular, the amniochorionic membrane has been shown to harbour populations of mesenchymal stromal cells (MSCs). In this study, we have characterized <em>ex vivo</em> expanded MSCs from the human amniotic (hAMSCs) and chorionic (hCMSCs) membranes of human full term placentas and adult bone marrow (hBMSCs). Our results show that hAMSCs, hCMSCs and hBMSCs express typical mesenchymal (CD73, CD90, CD105, CD44, CD146, CD166) and pluripotent (Oct-4, Sox2, Nanog, Lin28 and Klf4) markers but not hematopoietic markers (CD45, CD34). <em>Ex vivo</em> expanded hAMSCs were found to be of fetal origin, while hCMSCs cultures contained only maternal cells. Cell proliferation was significantly higher in hCMSCs, compared to hAMSCs and hBMSCs. Integrin profiling revealed marked differences in the expression of α − subunits between the three cell sources. Cadherin receptors were consistently expressed on a subset of progenitors (ranging from 1% to 60%), while N-CAM (CD56) was only expressed in hAMSCs and hCMSCs but not in hBMSCs. When induced to differentiate, hAMSCs and hCMSCs displayed strong chondrogenic and osteogenic differentiation potential but very limited capacity for adipogenic conversion. In contrast, hBMSCs showed strong differentiation potential along the three lineages. These results illustrate how MSCs from different ontological sources display differential expression of cell fate mediators and mesodermal differentiation capacity. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Placenta has attracted increasing attention over the past decade as a stem cell source for regenerative medicine. In particular, the amniochorionic membrane has been shown to harbour populations of mesenchymal stromal cells (MSCs). In this study, we have characterized ex vivo expanded MSCs from the human amniotic (hAMSCs) and chorionic (hCMSCs) membranes of human full term placentas and adult bone marrow (hBMSCs). Our results show that hAMSCs, hCMSCs and hBMSCs express typical mesenchymal (CD73, CD90, CD105, CD44, CD146, CD166) and pluripotent (Oct-4, Sox2, Nanog, Lin28 and Klf4) markers but not hematopoietic markers (CD45, CD34). Ex vivo expanded hAMSCs were found to be of fetal origin, while hCMSCs cultures contained only maternal cells. Cell proliferation was significantly higher in hCMSCs, compared to hAMSCs and hBMSCs. Integrin profiling revealed marked differences in the expression of α − subunits between the three cell sources. Cadherin receptors were consistently expressed on a subset of progenitors (ranging from 1% to 60%), while N-CAM (CD56) was only expressed in hAMSCs and hCMSCs but not in hBMSCs. When induced to differentiate, hAMSCs and hCMSCs displayed strong chondrogenic and osteogenic differentiation potential but very limited capacity for adipogenic conversion. In contrast, hBMSCs showed strong differentiation potential along the three lineages. These results illustrate how MSCs from different ontological sources display differential expression of cell fate mediators and mesodermal differentiation capacity. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24015" xmlns="http://purl.org/rss/1.0/"><title>The protective role of peroxisome proliferator-activated receptor γ coactivator-1α in hyperthyroid cardiac hypertrophy</title><link>http://dx.doi.org/10.1002%2Fjcp.24015</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The protective role of peroxisome proliferator-activated receptor γ coactivator-1α in hyperthyroid cardiac hypertrophy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wei Xu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dongxia Hou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiangrui Jiang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zhiyuan Lu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ting Guo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yuan Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dongjin Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ke Zen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bo Yu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chen-Yu Zhang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:13.124761-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24015</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24015</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24015</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Heart failure is a major cause of death throughout the world. Hyperthyroidism has been shown to induce cardiac hypertrophy, which is a contributing factor to heart failure. However, the mechanism underling effect of thyroid hormone is not completely clear. The present study investigates the role of peroxisome proliferator-activated receptor (PPAR) γ coactivator-1α (PGC-1α) in cardiac hypertrophy induced by Triiodothyronine (T3). We investigated PGC-1α mRNA expression in rat hearts exposed to T3 <em>in vivo</em> and <em>ex vivo</em>. Surprisingly, we found that the extended periods of T3 treatment led to an increase in PGC-1α expression compared to shorter treatment times, which resulted in a reduction of PGC-1α expression. Mechanistic studies showed that suppression of PGC-1α by small interfering RNA in cardiomyocytes amplified the cellular hypertrophic response to T3 stimulation, whereas overexpression of PGC-1α was protective. Furthermore, we presented evidence to show that T3 decreased PGC-1α expression via p38 mitogen-activated protein kinases (MAPK) pathway. Our studies also revealed that overexpression of PGC-1α in cardiomyocytes inhibited basal and T3-induced p38 MAPK phosphorylation. These data indicate for the first time that PGC-1α plays protective role in T3-induced cardiac hypertrophy and that hypertrophic growth induced by T3 involves a regulatory pathway between PGC-1α and p38 MAPK. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Heart failure is a major cause of death throughout the world. Hyperthyroidism has been shown to induce cardiac hypertrophy, which is a contributing factor to heart failure. However, the mechanism underling effect of thyroid hormone is not completely clear. The present study investigates the role of peroxisome proliferator-activated receptor (PPAR) γ coactivator-1α (PGC-1α) in cardiac hypertrophy induced by Triiodothyronine (T3). We investigated PGC-1α mRNA expression in rat hearts exposed to T3 in vivo and ex vivo. Surprisingly, we found that the extended periods of T3 treatment led to an increase in PGC-1α expression compared to shorter treatment times, which resulted in a reduction of PGC-1α expression. Mechanistic studies showed that suppression of PGC-1α by small interfering RNA in cardiomyocytes amplified the cellular hypertrophic response to T3 stimulation, whereas overexpression of PGC-1α was protective. Furthermore, we presented evidence to show that T3 decreased PGC-1α expression via p38 mitogen-activated protein kinases (MAPK) pathway. Our studies also revealed that overexpression of PGC-1α in cardiomyocytes inhibited basal and T3-induced p38 MAPK phosphorylation. These data indicate for the first time that PGC-1α plays protective role in T3-induced cardiac hypertrophy and that hypertrophic growth induced by T3 involves a regulatory pathway between PGC-1α and p38 MAPK. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24013" xmlns="http://purl.org/rss/1.0/"><title>Unsaturated fatty acids induce mesenchymal stem cells to increase secretion of angiogenic mediators</title><link>http://dx.doi.org/10.1002%2Fjcp.24013</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Unsaturated fatty acids induce mesenchymal stem cells to increase secretion of angiogenic mediators</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andria N. Smith</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lara A. Muffley</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Austin N. Bell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Surawej Numhom</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anne M. Hocking</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:03.252513-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24013</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24013</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24013</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24008" xmlns="http://purl.org/rss/1.0/"><title>Crosstalk between adenosine A1 and β1-adrenergic receptors regulates translocation of PKCε in isolated rat cardiomyocytes</title><link>http://dx.doi.org/10.1002%2Fjcp.24008</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Crosstalk between adenosine A1 and β1-adrenergic receptors regulates translocation of PKCε in isolated rat cardiomyocytes</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Satoshi Komatsu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James G. Dobson</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mitsuo Ikebe</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lynne G. Shea</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richard A. Fenton</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:42:01.418271-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24008</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24008</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24008</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Adenosine A<sub>1</sub> receptor (A<sub>1</sub>R)-induced translocation of PKCε to transverse (t) tubular membranes in isolated rat cardiomyocytes is associated with a reduction in β<sub>1</sub>-adrenergic-stimulated contractile function. The PKCε-mediated activation of protein kinase D (PKD) by endothelin-1 is inhibited by β<sub>1</sub>-adrenergic stimulated protein kinase A (PKA) suggesting a similar mechanism of A<sub>1</sub>R signal transduction modulation by adrenergic agonists may exist in the heart. We have investigated the influence of β<sub>1</sub>-adrenergic stimulation on PKCε translocation elicited by A<sub>1</sub>R. Immunofluorescence imaging and Western blotting with PKCε and β-COP antibodies were used to quantify the co-localization of PKCε and t-tubular structures in isolated rat cardiomyocytes. The A<sub>1</sub>R agonist CCPA increased the co-localization of PKCε and t-tubules as detected by imaging. The β<sub>1</sub>-adrenergic receptor agonist isoproterenol (ISO) inhibited this effect of CCPA. Forskolin, a potent activator of PKA, mimicked, and H89, a pharmacological PKA inhibitor, and PKI, a membrane-permeable PKA peptide PKA inhibitor, attenuated the negative effect of ISO on the A<sub>1</sub>R-mediated PKCε translocation. Western blotting with isolated intact hearts revealed an increase in PKCε/β-COP co-localization induced by A<sub>1</sub>R. This increase was attenuated by the A<sub>1</sub>R antagonist DPCPX and ISO. The ISO-induced attenuation was reversed by H89. It is concluded that adrenergic stimulation inhibits A<sub>1</sub>R-induced PKCε translocation to the PKCε anchor site RACK2 constituent of a coatomer containing β-COP and associated with the t-tubular structures of the heart. In that this translocation has been previously associated with the antiadrenergic property of A<sub>1</sub>R, it is apparent that the interactive effects of adenosine and β<sub>1</sub>-adrenergic agonists on function are complex in the heart. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Adenosine A1 receptor (A1R)-induced translocation of PKCε to transverse (t) tubular membranes in isolated rat cardiomyocytes is associated with a reduction in β1-adrenergic-stimulated contractile function. The PKCε-mediated activation of protein kinase D (PKD) by endothelin-1 is inhibited by β1-adrenergic stimulated protein kinase A (PKA) suggesting a similar mechanism of A1R signal transduction modulation by adrenergic agonists may exist in the heart. We have investigated the influence of β1-adrenergic stimulation on PKCε translocation elicited by A1R. Immunofluorescence imaging and Western blotting with PKCε and β-COP antibodies were used to quantify the co-localization of PKCε and t-tubular structures in isolated rat cardiomyocytes. The A1R agonist CCPA increased the co-localization of PKCε and t-tubules as detected by imaging. The β1-adrenergic receptor agonist isoproterenol (ISO) inhibited this effect of CCPA. Forskolin, a potent activator of PKA, mimicked, and H89, a pharmacological PKA inhibitor, and PKI, a membrane-permeable PKA peptide PKA inhibitor, attenuated the negative effect of ISO on the A1R-mediated PKCε translocation. Western blotting with isolated intact hearts revealed an increase in PKCε/β-COP co-localization induced by A1R. This increase was attenuated by the A1R antagonist DPCPX and ISO. The ISO-induced attenuation was reversed by H89. It is concluded that adrenergic stimulation inhibits A1R-induced PKCε translocation to the PKCε anchor site RACK2 constituent of a coatomer containing β-COP and associated with the t-tubular structures of the heart. In that this translocation has been previously associated with the antiadrenergic property of A1R, it is apparent that the interactive effects of adenosine and β1-adrenergic agonists on function are complex in the heart. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24009" xmlns="http://purl.org/rss/1.0/"><title>Alveolar macrophage dynamics in murine lung regeneration</title><link>http://dx.doi.org/10.1002%2Fjcp.24009</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Alveolar macrophage dynamics in murine lung regeneration</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kenji Chamoto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Barry C. Gibney</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maximilian Ackermann</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Grace S. Lee</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Miao Lin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Moritz A. Konerding</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Akira Tsuda</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Steven J. Mentzer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:41:57.75062-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24009</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24009</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24009</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In most mammalian species, the removal of one lung results in dramatic compensatory growth of the remaining lung. To investigate the contribution of alveolar macrophages (AM) to murine post-pneumonectomy lung growth, we studied bronchoalveolar lavage (BAL)-derived AM on 3, 7, 14 and 21 days after left pneumonectomy. BAL demonstrated a 3.0-fold increase in AM (CD45<sup>+</sup>, CD11b<sup>-</sup>, CD11c<sup>+</sup>, F4/80<sup>+</sup>, Gr-1<sup>-</sup>) by 14 days after pneumonectomy. Cell cycle flow cytometry of the BAL-derived cells demonstrated an increase in S + G2 phase cells on days 3 (11.3<span class="underlined ">+</span> 2.7%) and 7 (12.1 <span class="underlined ">+</span> 1.8%) after pneumonectomy. Correspondingly, AM demonstrated increased expression of VEGFR1 and MHC class II between days 3 and 14 after pneumonectomy. To investigate the potential contribution of peripheral blood cells to this AM population, parabiotic mice (wild-type/GFP) underwent left pneumonectomy. Analysis of GFP<sup>+</sup> cells in the post-pneumonectomy lung demonstrated that by day 14, less than 1% of the alveolar macrophage population were derived from the peripheral blood. Finally, AM gene transcription demonstrated a significant shift from decreased transcription of angiogenesis-related genes on day 3 to increased transcription on day 7 after pneumonectomy. The increased number of locally proliferating AM, combined with their growth-related gene transcription, suggests that AM actively participate in compensatory lung growth. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>In most mammalian species, the removal of one lung results in dramatic compensatory growth of the remaining lung. To investigate the contribution of alveolar macrophages (AM) to murine post-pneumonectomy lung growth, we studied bronchoalveolar lavage (BAL)-derived AM on 3, 7, 14 and 21 days after left pneumonectomy. BAL demonstrated a 3.0-fold increase in AM (CD45+, CD11b-, CD11c+, F4/80+, Gr-1-) by 14 days after pneumonectomy. Cell cycle flow cytometry of the BAL-derived cells demonstrated an increase in S + G2 phase cells on days 3 (11.3+ 2.7%) and 7 (12.1 + 1.8%) after pneumonectomy. Correspondingly, AM demonstrated increased expression of VEGFR1 and MHC class II between days 3 and 14 after pneumonectomy. To investigate the potential contribution of peripheral blood cells to this AM population, parabiotic mice (wild-type/GFP) underwent left pneumonectomy. Analysis of GFP+ cells in the post-pneumonectomy lung demonstrated that by day 14, less than 1% of the alveolar macrophage population were derived from the peripheral blood. Finally, AM gene transcription demonstrated a significant shift from decreased transcription of angiogenesis-related genes on day 3 to increased transcription on day 7 after pneumonectomy. The increased number of locally proliferating AM, combined with their growth-related gene transcription, suggests that AM actively participate in compensatory lung growth. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24003" xmlns="http://purl.org/rss/1.0/"><title>Phamaco-metabolomics: an emerging “omics” tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets</title><link>http://dx.doi.org/10.1002%2Fjcp.24003</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Phamaco-metabolomics: an emerging “omics” tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuseppe Corona</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Flavio Rizzolio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Antonio Giordano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuseppe Toffoli</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-21T08:41:53.466457-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24003</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24003</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24003</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In the post-genomics era, metabolomics represents a new “omics” approach that in the last decade has received increased attention in the field of oncology. Metabolomics is based on the holistic study of the metabolic profile that characterizes a specific phenotype in a biological system. The metabolic profile provides a readout of the metabolic state of an individual that cannot be obtained directly from DNA genotyping, gene expression or proteomic profiling analyses. The translational value of metabonomics in the oncology field has been demonstrated by the identification of diagnostic and prognostic biomarkers. The so-called pharmaco-metabolomic approach that is currently emerging aims to identify the individual metabolomic characteristics able to predict drug effectiveness and/or toxicity. This review presents the potential role of phamaco-metabolomics in the future of anticancer pharmacology to achieve customized anticancer treatments and new, targeted therapeutic approaches. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>In the post-genomics era, metabolomics represents a new “omics” approach that in the last decade has received increased attention in the field of oncology. Metabolomics is based on the holistic study of the metabolic profile that characterizes a specific phenotype in a biological system. The metabolic profile provides a readout of the metabolic state of an individual that cannot be obtained directly from DNA genotyping, gene expression or proteomic profiling analyses. The translational value of metabonomics in the oncology field has been demonstrated by the identification of diagnostic and prognostic biomarkers. The so-called pharmaco-metabolomic approach that is currently emerging aims to identify the individual metabolomic characteristics able to predict drug effectiveness and/or toxicity. This review presents the potential role of phamaco-metabolomics in the future of anticancer pharmacology to achieve customized anticancer treatments and new, targeted therapeutic approaches. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24001" xmlns="http://purl.org/rss/1.0/"><title>Extracellular calcium chronically-induced human osteoblasts effects: Specific modulation of osteocalcin and collagen type XV</title><link>http://dx.doi.org/10.1002%2Fjcp.24001</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Extracellular calcium chronically-induced human osteoblasts effects: Specific modulation of osteocalcin and collagen type XV</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elena Gabusi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cristina Manferdini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francesco Grassi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anna Piacentini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luca Cattini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuseppe Filardo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elisabetta Lambertini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roberta Piva</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicoletta Zini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrea Facchini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gina Lisignoli</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-27T07:55:35.277185-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24001</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24001</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24001</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Fluctuation in extracellular calcium (Ca<sup>2+</sup>) concentration occurs during bone remodeling. Free ionised Ca<sup>2+</sup> plays a critical role in regulating osteoblast functions. We analyzed the effects of different concentrations of free ionised Ca<sup>2+</sup> (0.5, 1.3, 2.6 mM) on human osteoblasts and we evaluated osteoblastic phenotype (marker expression and cell morphology) and functions (osteogenic differentiation, cell proliferation and cell signaling). Our data show human osteoblasts that chronically-stimulated with 0.5, 1.3, or 2.6 mM Ca<sup>2+</sup> significantly increase intracellular content of alkaline phosphatase, collagen type I, osteocalcin and bone sialoprotein, whereas collagen type XV was down-modulated and RUNX2 expression was not affected. We also found a Ca<sup>2+</sup> concentration-dependent increase in osteogenic differentiation and cell proliferation, associated to an increase of signaling protein PLCβ1 and p-ERK. Human osteoblast morphology was affected by Ca<sup>2+</sup> as seen by the presence of numerous nucleoli, cells in mitosis, cell junctions and an increased number of vacuoles.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In conclusion, our data show a clear phenotypical and functional effect of extracellular Ca<sup>2+</sup> on human osteoblasts and support the hypothesis of a direct role of this cation in the bone remodeling processes. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Fluctuation in extracellular calcium (Ca2+) concentration occurs during bone remodeling. Free ionised Ca2+ plays a critical role in regulating osteoblast functions. We analyzed the effects of different concentrations of free ionised Ca2+ (0.5, 1.3, 2.6 mM) on human osteoblasts and we evaluated osteoblastic phenotype (marker expression and cell morphology) and functions (osteogenic differentiation, cell proliferation and cell signaling). Our data show human osteoblasts that chronically-stimulated with 0.5, 1.3, or 2.6 mM Ca2+ significantly increase intracellular content of alkaline phosphatase, collagen type I, osteocalcin and bone sialoprotein, whereas collagen type XV was down-modulated and RUNX2 expression was not affected. We also found a Ca2+ concentration-dependent increase in osteogenic differentiation and cell proliferation, associated to an increase of signaling protein PLCβ1 and p-ERK. Human osteoblast morphology was affected by Ca2+ as seen by the presence of numerous nucleoli, cells in mitosis, cell junctions and an increased number of vacuoles.In conclusion, our data show a clear phenotypical and functional effect of extracellular Ca2+ on human osteoblasts and support the hypothesis of a direct role of this cation in the bone remodeling processes. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24002" xmlns="http://purl.org/rss/1.0/"><title>Challenges and opportunities of metabolomics</title><link>http://dx.doi.org/10.1002%2Fjcp.24002</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Challenges and opportunities of metabolomics</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Caroline H. Johnson</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Frank J. Gonzalez</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-27T07:55:34.321032-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24002</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24002</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24002</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Mini-Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The metabolome is a data-rich source of information concerning all the low-molecular-weight metabolites in a biofluid, which can indicate early biological changes to the host due to perturbations in metabolic pathways. Major changes can be seen after minor stimuli, which make it a valuable target for analysis. Due to the diverse and sensitive nature of the metabolome, studies must be designed in a manner to maintain consistency, reduce variation between subjects, and optimize information recovery. Technological advancements in experimental design, mouse models and instrumentation have aided in this effort. Metabolomics has the ultimate potential to be valuable in a clinical setting where it could be used for early diagnosis of a disease and as a predictor of treatment response and survival. During drug treatment, the metabolic status of an individual could be monitored and used to indicate possible toxic effects. Metabolomics therefore has great potential for improving diagnosis, treatment and aftercare of disease. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The metabolome is a data-rich source of information concerning all the low-molecular-weight metabolites in a biofluid, which can indicate early biological changes to the host due to perturbations in metabolic pathways. Major changes can be seen after minor stimuli, which make it a valuable target for analysis. Due to the diverse and sensitive nature of the metabolome, studies must be designed in a manner to maintain consistency, reduce variation between subjects, and optimize information recovery. Technological advancements in experimental design, mouse models and instrumentation have aided in this effort. Metabolomics has the ultimate potential to be valuable in a clinical setting where it could be used for early diagnosis of a disease and as a predictor of treatment response and survival. During drug treatment, the metabolic status of an individual could be monitored and used to indicate possible toxic effects. Metabolomics therefore has great potential for improving diagnosis, treatment and aftercare of disease. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24004" xmlns="http://purl.org/rss/1.0/"><title>Epigenetics of µ-opioid receptors: Intersection with HIV-1 infection of the central nervous system</title><link>http://dx.doi.org/10.1002%2Fjcp.24004</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Epigenetics of µ-opioid receptors: Intersection with HIV-1 infection of the central nervous system</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Patrick M. Regan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rajnish S. Dave</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Prasun K. Datta</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kamel Khalili</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-27T07:55:32.059038-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24004</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24004</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24004</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The abuse of intravenous drugs, such as heroin, has become a major public health concern due to the increased risk of HIV-1 infection. Opioids such as heroin were originally identified and subsequently abused for their analgesic effects. However, many investigations have found additional effects of opioids, including regulation of the immune system. As such, chronic opioid abuse has been shown to promote HIV-1 pathogenesis and facilitate HIV-1-associated neurocognitive dysfunction. Clinical opioids, such as morphine and methadone, as well as illicit opioids, such as heroin, exert their effects primarily through interactions with the µ-opioid receptor (MOR). However, the mechanisms by which opioids enhance neurocognitive dysfunction through MOR-mediated signaling pathways are not completely understood. New findings in the regulation of MOR expression, particularly epigenetic and transcriptional regulation as well as alternative splicing, sheds new insights into possible mechanisms of HIV-1 and opiate synergy. In this review, we identify mechanisms regulating MOR expression and propose novel mechanisms by which opioids and HIV-1 may modulate this regulation. Additionally, we suggest that differential regulation of newly identified MOR isoforms by opioids and HIV-1 has functional consequence in enhancing HIV-1 neurocognitive dysfunction. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The abuse of intravenous drugs, such as heroin, has become a major public health concern due to the increased risk of HIV-1 infection. Opioids such as heroin were originally identified and subsequently abused for their analgesic effects. However, many investigations have found additional effects of opioids, including regulation of the immune system. As such, chronic opioid abuse has been shown to promote HIV-1 pathogenesis and facilitate HIV-1-associated neurocognitive dysfunction. Clinical opioids, such as morphine and methadone, as well as illicit opioids, such as heroin, exert their effects primarily through interactions with the µ-opioid receptor (MOR). However, the mechanisms by which opioids enhance neurocognitive dysfunction through MOR-mediated signaling pathways are not completely understood. New findings in the regulation of MOR expression, particularly epigenetic and transcriptional regulation as well as alternative splicing, sheds new insights into possible mechanisms of HIV-1 and opiate synergy. In this review, we identify mechanisms regulating MOR expression and propose novel mechanisms by which opioids and HIV-1 may modulate this regulation. Additionally, we suggest that differential regulation of newly identified MOR isoforms by opioids and HIV-1 has functional consequence in enhancing HIV-1 neurocognitive dysfunction. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24005" xmlns="http://purl.org/rss/1.0/"><title>Ox-LDL-induced TGF-β1 production in human alveolar epithelial cells: involvement of the Ras/ERK/ PLTP pathway</title><link>http://dx.doi.org/10.1002%2Fjcp.24005</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Ox-LDL-induced TGF-β1 production in human alveolar epithelial cells: involvement of the Ras/ERK/ PLTP pathway</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ling-Li Guo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ya-Juan Chen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tao Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yong-Chun Shen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cheng-Na Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Li Zhao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Qiu-Nan Zuo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ting Yang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jing An</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiao-Hong Zhang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dan Xu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fu-Qiang Wen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-27T07:55:30.584831-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24005</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24005</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24005</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Oxidized-low density lipoprotein (Ox-LDL) has been shown to play an important role in impaired surfactant metabolism and transforming growth factor-β1 (TGF-β1) is a critical mediator in the pathogenesis of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). In this study, we investigated whether Ox-LDL can induce TGF-β1 protein production, and if so, how it achieves this induction in human alveolar epithelial cells (A549). We show here that Ox-LDL not only caused a dose- and time-dependent up-regulation of TGF-β1 production, but also increased Smad3 phosphorylation, Ras/extracellular signal-regulated kinase(ERK) activity and phospholipid transfer protein (PLTP) expression in A549 cells. The inhibition of Ras/ERK activity with specific inhibitors significantly suppressed Ox-LDL-induced TGF-β1 production, Smad3 phosphorylation and PLTP expression. Furthermore, treatment of cells with PLTP siRNA suppressed both TGF-β1 release and Smad3 activation induced by Ox-LDL, but not the activation of Ras/ERK cascade. Taken together, we provide evidences that induction of TGF-β1 production and Smad3 phosphorylation by Ox-LDL is mediated by Ras/ERK/ PLTP pathway in human alveolar epithelial cells. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Oxidized-low density lipoprotein (Ox-LDL) has been shown to play an important role in impaired surfactant metabolism and transforming growth factor-β1 (TGF-β1) is a critical mediator in the pathogenesis of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). In this study, we investigated whether Ox-LDL can induce TGF-β1 protein production, and if so, how it achieves this induction in human alveolar epithelial cells (A549). We show here that Ox-LDL not only caused a dose- and time-dependent up-regulation of TGF-β1 production, but also increased Smad3 phosphorylation, Ras/extracellular signal-regulated kinase(ERK) activity and phospholipid transfer protein (PLTP) expression in A549 cells. The inhibition of Ras/ERK activity with specific inhibitors significantly suppressed Ox-LDL-induced TGF-β1 production, Smad3 phosphorylation and PLTP expression. Furthermore, treatment of cells with PLTP siRNA suppressed both TGF-β1 release and Smad3 activation induced by Ox-LDL, but not the activation of Ras/ERK cascade. Taken together, we provide evidences that induction of TGF-β1 production and Smad3 phosphorylation by Ox-LDL is mediated by Ras/ERK/ PLTP pathway in human alveolar epithelial cells. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24006" xmlns="http://purl.org/rss/1.0/"><title>MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells</title><link>http://dx.doi.org/10.1002%2Fjcp.24006</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Guangdong Yang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yanxi Pei</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Qiuhui Cao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rui Wang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-27T07:55:29.290688-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24006</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24006</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24006</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Cystathionine gamma-lyase (CSE) is the major H<sub>2</sub>S-generating enzyme in vascular smooth muscle cells (SMCs). CSE/H<sub>2</sub>S system contributes to the maintenance of SMC phenotype, and transcript factor specificity protein-1 (SP1) is a critical regulator of <em>CSE</em> expression during SMC differentiation. The involvements of microRNA-21 (miR-21) in cardiovascular pathophysiology have been known, however miR-21 regulation of CSE and SP1 as well as SMC phenotype are uncertain. Using quantitative real-time PCR, we demonstrated that the expression of miR-21 was upregulated in dedifferentiated human aorta SMCs (HASMCs) and injured mouse carotid arteries. To determine the potential roles of miR-21 in SP1-mediated <em>CSE</em> gene expression and SMC phenotypic change, we showed that miR-21 expression was upregulated by miR-21 precursor. Interestingly, miR-21 overexpression significantly repressed the protein expressions of both CSE and SP1, inhibited H<sub>2</sub>S production, stimulated SMC proliferation, and reduced SMC differentiation marker gene expression, respectively. The mRNA expression of <em>CSE</em> but not <em>SP1</em> was inhibited by miR-21 precursor. Blockage of SP1 binding by mithramycin or inhibition of CSE activity by DL-propargylglycine did not change miR-21 expression. We further demonstrated that miR-21 repressed SP1 protein expression by directly targeting at <em>SP1</em> 3' untranslational regions, which in turn downregulated <em>CSE</em> mRNA expression and stimulated SMC proliferation. Take together, these results suggest that miR-21 participates in CSE/H<sub>2</sub>S-mediated-SMC differentiation by targeting <em>SP1</em>. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Cystathionine gamma-lyase (CSE) is the major H2S-generating enzyme in vascular smooth muscle cells (SMCs). CSE/H2S system contributes to the maintenance of SMC phenotype, and transcript factor specificity protein-1 (SP1) is a critical regulator of CSE expression during SMC differentiation. The involvements of microRNA-21 (miR-21) in cardiovascular pathophysiology have been known, however miR-21 regulation of CSE and SP1 as well as SMC phenotype are uncertain. Using quantitative real-time PCR, we demonstrated that the expression of miR-21 was upregulated in dedifferentiated human aorta SMCs (HASMCs) and injured mouse carotid arteries. To determine the potential roles of miR-21 in SP1-mediated CSE gene expression and SMC phenotypic change, we showed that miR-21 expression was upregulated by miR-21 precursor. Interestingly, miR-21 overexpression significantly repressed the protein expressions of both CSE and SP1, inhibited H2S production, stimulated SMC proliferation, and reduced SMC differentiation marker gene expression, respectively. The mRNA expression of CSE but not SP1 was inhibited by miR-21 precursor. Blockage of SP1 binding by mithramycin or inhibition of CSE activity by DL-propargylglycine did not change miR-21 expression. We further demonstrated that miR-21 repressed SP1 protein expression by directly targeting at SP1 3' untranslational regions, which in turn downregulated CSE mRNA expression and stimulated SMC proliferation. Take together, these results suggest that miR-21 participates in CSE/H2S-mediated-SMC differentiation by targeting SP1. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23065" xmlns="http://purl.org/rss/1.0/"><title>JCV agnoprotein-induced reduction in CXCL5/LIX secretion by oligodendrocytes is associated with activation of apoptotic signaling in neurons</title><link>http://dx.doi.org/10.1002%2Fjcp.23065</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">JCV agnoprotein-induced reduction in CXCL5/LIX secretion by oligodendrocytes is associated with activation of apoptotic signaling in neurons</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nana Merabova</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rafal Kaminski</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Barbara Krynska</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shohreh Amini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kamel Khalili</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Armine Darbinyan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-27T07:55:28.330899-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23065</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23065</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23065</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>An indispensable role for oligodendrocytes in the protection of axon function and promotion of neuronal survival is strongly supported by the finding of progressive neuron/axon degeneration in human neurological diseases that affect oligodendrocytes. Imaging and pathological studies of the CNS have shown the presence of neuroaxonal injury in progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the CNS, resulting from destruction of oligodendrocytes upon productive replication of the pathogenic neurotropic polyomavirus JC. Here, we examined the extracellular factors involved in communication between oligodendrocytes and neurons. Culturing cortical neurons with conditioned medium (CM) from rat CG4 oligodendrocytic cells that express the JCV agnoprotein showed that CXCL5/LIX, which is a chemokine closely related to the human CXCL5/ENA78 and CXCL6/GCP-2 chemokines, is essential for neuronal cell survival. We found that in CM from agnoprotein-producing CG-4 cells level of CXC5/LIX is decreased compared to control cells. We also demonstrated that a reduced expression of CXCL5/LIX by CG4 GFP-Agno cells triggered a cascade of signaling events in cortical neurons. Analysis of mitogen-activated protein kinases (MAPK) and glycogen synthase kinase (GSK3) pathways showed that they are involved in mechanisms of neuronal apoptosis in response to the depletion of CXCL5/LIX signaling. These data suggest that agnoprotein-induced dysregulation of chemokine production by oligodendrocytes may contribute to neuronal/axonal injury in the pathogenesis of PML lesions. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>An indispensable role for oligodendrocytes in the protection of axon function and promotion of neuronal survival is strongly supported by the finding of progressive neuron/axon degeneration in human neurological diseases that affect oligodendrocytes. Imaging and pathological studies of the CNS have shown the presence of neuroaxonal injury in progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the CNS, resulting from destruction of oligodendrocytes upon productive replication of the pathogenic neurotropic polyomavirus JC. Here, we examined the extracellular factors involved in communication between oligodendrocytes and neurons. Culturing cortical neurons with conditioned medium (CM) from rat CG4 oligodendrocytic cells that express the JCV agnoprotein showed that CXCL5/LIX, which is a chemokine closely related to the human CXCL5/ENA78 and CXCL6/GCP-2 chemokines, is essential for neuronal cell survival. We found that in CM from agnoprotein-producing CG-4 cells level of CXC5/LIX is decreased compared to control cells. We also demonstrated that a reduced expression of CXCL5/LIX by CG4 GFP-Agno cells triggered a cascade of signaling events in cortical neurons. Analysis of mitogen-activated protein kinases (MAPK) and glycogen synthase kinase (GSK3) pathways showed that they are involved in mechanisms of neuronal apoptosis in response to the depletion of CXCL5/LIX signaling. These data suggest that agnoprotein-induced dysregulation of chemokine production by oligodendrocytes may contribute to neuronal/axonal injury in the pathogenesis of PML lesions. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.24000" xmlns="http://purl.org/rss/1.0/"><title>CASK interacts with PMCA4b and JAM-A on the mouse sperm flagellum to regulate Ca2+ homeostasis and motility</title><link>http://dx.doi.org/10.1002%2Fjcp.24000</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">CASK interacts with PMCA4b and JAM-A on the mouse sperm flagellum to regulate Ca2+ homeostasis and motility</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rolands G. Aravindan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Victor P. Fomin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ulhas P. Naik</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mark J. Modelski</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Meghna U. Naik</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Deni S. Galileo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Randall L. Duncan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Patricia A. Martin-DeLeon</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-21T09:32:32.542842-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.24000</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.24000</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.24000</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Deletion of the highly conserved gene for the major Ca<sup>2+</sup> efflux pump, <em>Plasma membrane calcium/calmodulin-dependent ATPase 4b (Pmca4b),</em> in the mouse leads to loss of progressive and hyperactivated sperm motility and infertility. Here we first demonstrate that compared to wild-type (WT), <em>Junctional adhesion molecule-A</em> (<em>Jam-A</em>) null sperm, previously shown to have motility defects and an abnormal mitochondrial phenotype reminiscent of that seen in <em>Pmca4b</em> nulls, exhibit reduced (P &lt; 0.001) ATP levels, significantly (P &lt; 0.001) greater cytosolic Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>c</sub>) and ∼10-fold higher mitochondrial sequestration, indicating Ca<sup>2+</sup> overload. Investigating the mechanism involved, we used co-immunoprecipitation studies to show that CASK (Ca<sup>2+</sup>/calmodulin-dependent serine kinase), identified for the first time on the sperm flagellum where it co-localizes with both PMCA4b and JAM-A on the proximal principal piece, acts as a common interacting partner of both. Importantly, CASK binds alternatively and non-synergistically with each of these molecules via its single PDZ (PDS-95/Dlg/ZO-1) domain to either inhibit or promote efflux. In the absence of CASK-JAM-A interaction in <em>Jam-A</em> null sperm, CASK-PMCA4b interaction is increased, resulting in inhibition of PMCA4b's enzymatic activity, consequent Ca<sup>2+</sup> accumulation, and a ∼6-fold over-expression of constitutively ATP-utilizing CASK, compared to WT. Thus, CASK negatively regulates PMCA4b by directly binding to it and JAM-A positively regulates it indirectly through CASK. The decreased motility is likely due to the collateral net deficit in ATP observed in nulls. Our data indicate that Ca<sup>2+</sup> homeostasis in sperm is maintained by the relative ratios of CASK-PMCA4b and CASK-JAM-A interactions. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Deletion of the highly conserved gene for the major Ca2+ efflux pump, Plasma membrane calcium/calmodulin-dependent ATPase 4b (Pmca4b), in the mouse leads to loss of progressive and hyperactivated sperm motility and infertility. Here we first demonstrate that compared to wild-type (WT), Junctional adhesion molecule-A (Jam-A) null sperm, previously shown to have motility defects and an abnormal mitochondrial phenotype reminiscent of that seen in Pmca4b nulls, exhibit reduced (P &lt; 0.001) ATP levels, significantly (P &lt; 0.001) greater cytosolic Ca2+ concentration ([Ca2+]c) and ∼10-fold higher mitochondrial sequestration, indicating Ca2+ overload. Investigating the mechanism involved, we used co-immunoprecipitation studies to show that CASK (Ca2+/calmodulin-dependent serine kinase), identified for the first time on the sperm flagellum where it co-localizes with both PMCA4b and JAM-A on the proximal principal piece, acts as a common interacting partner of both. Importantly, CASK binds alternatively and non-synergistically with each of these molecules via its single PDZ (PDS-95/Dlg/ZO-1) domain to either inhibit or promote efflux. In the absence of CASK-JAM-A interaction in Jam-A null sperm, CASK-PMCA4b interaction is increased, resulting in inhibition of PMCA4b's enzymatic activity, consequent Ca2+ accumulation, and a ∼6-fold over-expression of constitutively ATP-utilizing CASK, compared to WT. Thus, CASK negatively regulates PMCA4b by directly binding to it and JAM-A positively regulates it indirectly through CASK. The decreased motility is likely due to the collateral net deficit in ATP observed in nulls. Our data indicate that Ca2+ homeostasis in sperm is maintained by the relative ratios of CASK-PMCA4b and CASK-JAM-A interactions. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23061" xmlns="http://purl.org/rss/1.0/"><title>Angiopoietin-1 but not angiopoietin-2 induces IL-8 synthesis and release by human neutrophils</title><link>http://dx.doi.org/10.1002%2Fjcp.23061</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Angiopoietin-1 but not angiopoietin-2 induces IL-8 synthesis and release by human neutrophils</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paul-Eduard Neagoe</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elizabeth Dumas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fadi Hajjar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Martin G. Sirois</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-20T08:08:29.17934-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23061</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23061</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23061</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We previously reported Tie2 receptor expression on human neutrophils, which promotes chemotactic activities upon activation by both angiopoietins (Ang1 and Ang2). Moreover, we observed that neutrophil pretreatment with Ang1 or Ang2 enhances IL-8 chemotactic effect. Therefore, we assessed the capacity of Ang1 and/or Ang2 to modulate neutrophil IL-8 synthesis and release. Neutrophils isolated from healthy donors were stimulated in a time- (1-6 hours) and concentration- (10<sup>−10</sup>-10<sup>−8</sup> M) dependent manner with both angiopoietins. IL-8 mRNA production was measured by RT-qPCR, whereas its protein synthesis and release from neutrophils was assessed by ELISA. Ang1 (10<sup>−8</sup> M) induced a significant and maximal increase of IL-8 mRNA (4.7-fold) within 1 hour, and promoted maximal IL-8 protein synthesis (3.6-fold) and release (5.5-fold) within 2 hours as compared to control PBS-treated neutrophils. Treatment with Ang2 alone did not modulate IL-8 synthesis or release, and its combination to Ang1 did not affect Ang1 activity. Neutrophil pretreatment with a protein synthesis inhibitor (CHX) increased IL-8 mRNA synthesis by 18-fold, and reduced Ang1-mediated IL-8 protein synthesis and release by 96 and 92% respectively. Pretreatment with a transcription inhibitor (ActD) reduced IL-8 mRNA synthesis by 54% and IL-8 protein synthesis and release by 52 and 79% respectively. Using specific kinase inhibitors, we observed that Ang1-driven IL-8 mRNA and protein synthesis is p42/44 MAPK-dependent and -independent from p38 MAPK and PI3K activity. Our study is the first to report the capacity of Ang1 (as opposed to Ang2) to promote neutrophil IL-8 synthesis and release through the activation of p42/44 MAPK pathway. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>We previously reported Tie2 receptor expression on human neutrophils, which promotes chemotactic activities upon activation by both angiopoietins (Ang1 and Ang2). Moreover, we observed that neutrophil pretreatment with Ang1 or Ang2 enhances IL-8 chemotactic effect. Therefore, we assessed the capacity of Ang1 and/or Ang2 to modulate neutrophil IL-8 synthesis and release. Neutrophils isolated from healthy donors were stimulated in a time- (1-6 hours) and concentration- (10−10-10−8 M) dependent manner with both angiopoietins. IL-8 mRNA production was measured by RT-qPCR, whereas its protein synthesis and release from neutrophils was assessed by ELISA. Ang1 (10−8 M) induced a significant and maximal increase of IL-8 mRNA (4.7-fold) within 1 hour, and promoted maximal IL-8 protein synthesis (3.6-fold) and release (5.5-fold) within 2 hours as compared to control PBS-treated neutrophils. Treatment with Ang2 alone did not modulate IL-8 synthesis or release, and its combination to Ang1 did not affect Ang1 activity. Neutrophil pretreatment with a protein synthesis inhibitor (CHX) increased IL-8 mRNA synthesis by 18-fold, and reduced Ang1-mediated IL-8 protein synthesis and release by 96 and 92% respectively. Pretreatment with a transcription inhibitor (ActD) reduced IL-8 mRNA synthesis by 54% and IL-8 protein synthesis and release by 52 and 79% respectively. Using specific kinase inhibitors, we observed that Ang1-driven IL-8 mRNA and protein synthesis is p42/44 MAPK-dependent and -independent from p38 MAPK and PI3K activity. Our study is the first to report the capacity of Ang1 (as opposed to Ang2) to promote neutrophil IL-8 synthesis and release through the activation of p42/44 MAPK pathway. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23062" xmlns="http://purl.org/rss/1.0/"><title>Inhibition of long term potention by CuZn superoxide dismutase injection in rat dentate gyrus : Involvement of muscarinic M1 receptor</title><link>http://dx.doi.org/10.1002%2Fjcp.23062</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Inhibition of long term potention by CuZn superoxide dismutase injection in rat dentate gyrus : Involvement of muscarinic M1 receptor</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">A Viggiano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">R Serù</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">S Damiano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">B De Luca</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">M Santillo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">P Mondola</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-20T08:08:27.6232-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23062</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23062</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23062</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Long term potentiation and long term depression represent important processes that modulate synaptic transmission that carries out a key role in neural mechanisms of memory.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Many studies give strong evidences on a role of the reactive oxygen species in the induction of LTP in CA1 region of hippocampal slices that was inhibited by adding the scavenger enzyme superoxide dismutase (SOD1).</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Previous data showed that SOD1 is secreted by many cellular lines, including neuroblastoma SK-N-BE cells through microvesicles by an ATP dependent mechanism; moreover, it has been shown that SOD1 interacts with human neuroblastoma cell membranes increasing intracellular calcium levels via a phospholipase C-protein kinase C pathway activation.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The aim of this study was to investigate the effect of intracerebral injection of SOD1 or the inactive form of enzyme (ApoSOD) on the modulation of synaptic trasmission in dentate gyrus of the hippocampus in urethane anaesthetized rats. The results of the present research showed that intracerebral injection of SOD1 and Apo SOD in thedentate gyrus of the rat hippocampal formation inhibits LTP induced by high frequency stimulation of the perforant path. This result cannot be only explained by the dismutation of oxygen radical induced by SOD1 since also Apo SOD, that lacks the enzymatic activity, carries out the same inhibitory effect on LTP induction. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Long term potentiation and long term depression represent important processes that modulate synaptic transmission that carries out a key role in neural mechanisms of memory.Many studies give strong evidences on a role of the reactive oxygen species in the induction of LTP in CA1 region of hippocampal slices that was inhibited by adding the scavenger enzyme superoxide dismutase (SOD1).Previous data showed that SOD1 is secreted by many cellular lines, including neuroblastoma SK-N-BE cells through microvesicles by an ATP dependent mechanism; moreover, it has been shown that SOD1 interacts with human neuroblastoma cell membranes increasing intracellular calcium levels via a phospholipase C-protein kinase C pathway activation.The aim of this study was to investigate the effect of intracerebral injection of SOD1 or the inactive form of enzyme (ApoSOD) on the modulation of synaptic trasmission in dentate gyrus of the hippocampus in urethane anaesthetized rats. The results of the present research showed that intracerebral injection of SOD1 and Apo SOD in thedentate gyrus of the rat hippocampal formation inhibits LTP induced by high frequency stimulation of the perforant path. This result cannot be only explained by the dismutation of oxygen radical induced by SOD1 since also Apo SOD, that lacks the enzymatic activity, carries out the same inhibitory effect on LTP induction. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23063" xmlns="http://purl.org/rss/1.0/"><title>Proteasome modulator 9 is linked to microvascular pathology of T2D</title><link>http://dx.doi.org/10.1002%2Fjcp.23063</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Proteasome modulator 9 is linked to microvascular pathology of T2D</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Claudia Gragnoli</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-20T08:08:25.6866-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23063</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23063</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23063</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The locus 12q24 is linked to type 2 diabetes (T2D) and to changes in retinal vascular caliber in Caucasians. Proteasome Modulator 9 gene (<em>PSMD9)</em> lies in the 12q24 locus and is implicated diabetes onset and in degradation of intracellular proteins in antigenic peptides in the immune response to antigen presentation by MHC class I cells. Within <em>PSMD9</em>, we reported a linkage to T2D and to MODY3 in Italian families. We recently demonstrated a linkage of the <em>PSMD9</em> T2D risk SNPs with T2D-nephropathy, T2D-neuropathy, retinopathy, hypercholesterolemia, and macrovascular pathology.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We aimed at studying the presence of the linkage signal of the <em>PSMD9</em> T2D risk <em>SNPs IVS3</em> <em>+</em> <em>nt460</em>, <em>IVS3</em> <em>+</em> <em>nt437</em>, <em>E197G</em> to microvascular pathology associated to T2D Italian siblings/families.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We screened 200 T2D siblings/families for the <em>PSMD9</em> above-mentioned variants and performed a parametric and non-parametric linkage study by Merlin software.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Our results show significant LOD score in linkage with microvascular pathology for the <em>PSMD9</em> SNPs studied using the non-parametric and parametric linkage analysis. The strongest signal is present under the recessive model. Our statistical power relies on the presence of T2D affected siblings, which represent an ideal dataset to identify linkage with a recessive disease model. Our simulation analysis confirms that the results are not due to random chance.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In summary, the <em>PSMD9 IVS3</em> <em>+</em> <em>nt460</em>, <em>IVS3</em> <em>+</em> <em>nt437, E197G SNPs</em> are linked via the recessive model to microvascular pathology of T2D in Italians. A possible role of PSMD9 in microvascular pathology may be related to a causative pathogenetic role in inflammation as part of an autoimmune process. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>The locus 12q24 is linked to type 2 diabetes (T2D) and to changes in retinal vascular caliber in Caucasians. Proteasome Modulator 9 gene (PSMD9) lies in the 12q24 locus and is implicated diabetes onset and in degradation of intracellular proteins in antigenic peptides in the immune response to antigen presentation by MHC class I cells. Within PSMD9, we reported a linkage to T2D and to MODY3 in Italian families. We recently demonstrated a linkage of the PSMD9 T2D risk SNPs with T2D-nephropathy, T2D-neuropathy, retinopathy, hypercholesterolemia, and macrovascular pathology.We aimed at studying the presence of the linkage signal of the PSMD9 T2D risk SNPs IVS3 + nt460, IVS3 + nt437, E197G to microvascular pathology associated to T2D Italian siblings/families.We screened 200 T2D siblings/families for the PSMD9 above-mentioned variants and performed a parametric and non-parametric linkage study by Merlin software.Our results show significant LOD score in linkage with microvascular pathology for the PSMD9 SNPs studied using the non-parametric and parametric linkage analysis. The strongest signal is present under the recessive model. Our statistical power relies on the presence of T2D affected siblings, which represent an ideal dataset to identify linkage with a recessive disease model. Our simulation analysis confirms that the results are not due to random chance.In summary, the PSMD9 IVS3 + nt460, IVS3 + nt437, E197G SNPs are linked via the recessive model to microvascular pathology of T2D in Italians. A possible role of PSMD9 in microvascular pathology may be related to a causative pathogenetic role in inflammation as part of an autoimmune process. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23058" xmlns="http://purl.org/rss/1.0/"><title>Gender related alterations of β-adrenoceptor mechanisms in heart failure due to arteriovenous fistula</title><link>http://dx.doi.org/10.1002%2Fjcp.23058</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Gender related alterations of β-adrenoceptor mechanisms in heart failure due to arteriovenous fistula</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Melissa R. Dent</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paramjit S. Tappia</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Naranjan S. Dhalla</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-20T08:08:24.301514-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23058</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23058</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23058</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>This study was undertaken to determine gender related changes in different components of β-adrenoceptor (β-AR) system in response to arteriovenous fistula (AV-shunt), which is known to produce heart failure due to volume overload. AV-shunt was induced in male and female rats for 16 wks by the needle technique; ovariectomized (OVX) rats treated with or without estrogen were also used. Although AV-shunt for 16 wks produced cardiac hypertrophy in both sexes, male animals showed cardiac dysfunction whereas cardiac performance was maintained in females. Both β<sub>1</sub>-AR and β<sub>2</sub>-AR protein content and mRNA levels were decreased in male and increased in female hearts post-AV-shunt. The basal adenylyl cyclase (AC) activity was lower in the female heart; however, AC protein content and the increase in epinephrine (EPi)-stimulated AC activity were greater in the female AV-shunt group as compared to males. While AC V/VI and β-arrestin 2 mRNA levels were decreased in males, mRNA level for GRK2 was increased in females post-AV-shunt. In contrast to intact females, AV-shunt OVX animals showed depressed cardiac function, decreased β<sub>1</sub>-AR, β<sub>2</sub>-AR and AC protein content, as well as reduced EPi-stimulated AC activity. Treatment of OVX rats with 17-β estradiol attenuated the AV-shunt induced changes in β-AR and AC protein content as well as cardiac dysfunction. These results reveal that β-AR signal transduction system in response to AV-shunt is downregulated in males and upregulated in females. Furthermore, estrogen appears to play an important role in the upregulation of β-AR mechanisms and the maintenance of cardiac function in AV-shunt females. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>This study was undertaken to determine gender related changes in different components of β-adrenoceptor (β-AR) system in response to arteriovenous fistula (AV-shunt), which is known to produce heart failure due to volume overload. AV-shunt was induced in male and female rats for 16 wks by the needle technique; ovariectomized (OVX) rats treated with or without estrogen were also used. Although AV-shunt for 16 wks produced cardiac hypertrophy in both sexes, male animals showed cardiac dysfunction whereas cardiac performance was maintained in females. Both β1-AR and β2-AR protein content and mRNA levels were decreased in male and increased in female hearts post-AV-shunt. The basal adenylyl cyclase (AC) activity was lower in the female heart; however, AC protein content and the increase in epinephrine (EPi)-stimulated AC activity were greater in the female AV-shunt group as compared to males. While AC V/VI and β-arrestin 2 mRNA levels were decreased in males, mRNA level for GRK2 was increased in females post-AV-shunt. In contrast to intact females, AV-shunt OVX animals showed depressed cardiac function, decreased β1-AR, β2-AR and AC protein content, as well as reduced EPi-stimulated AC activity. Treatment of OVX rats with 17-β estradiol attenuated the AV-shunt induced changes in β-AR and AC protein content as well as cardiac dysfunction. These results reveal that β-AR signal transduction system in response to AV-shunt is downregulated in males and upregulated in females. Furthermore, estrogen appears to play an important role in the upregulation of β-AR mechanisms and the maintenance of cardiac function in AV-shunt females. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23059" xmlns="http://purl.org/rss/1.0/"><title>Monocytes differentiation upon treatment with a peptide corresponding to the C-terminus of activated T cell-expressed Tirc7 protein</title><link>http://dx.doi.org/10.1002%2Fjcp.23059</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Monocytes differentiation upon treatment with a peptide corresponding to the C-terminus of activated T cell-expressed Tirc7 protein</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Caroline C. Mouline</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Guillaume E. Beranger</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Heidy Schmid-Antomarchi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Danielle Quincey</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Momier</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Florian Boukhechba</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Georges F. Carle</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nathalie Rochet</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jean-Claude Scimeca</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-20T08:08:23.252269-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23059</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23059</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23059</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Atp6v0a3</em> gene encodes for two alternative products, Tirc7 and a3 proteins, which are differentially expressed in activated T cells and resorbing osteoclasts respectively. Tirc7 plays a central role in T cell activation, while a3 protein is critical for osteoclast-mediated bone matrix resorption. Based on the large body of evidences documenting the relationships between T cells and osteoclasts, we hypothesized that the extracellular C-terminus of Tirc7 protein could directly interact with osteoclast precursor cells. To address this issue, we performed the molecular cloning of a mouse Atp6v0a3 cDNA segment encoding the last 40 amino acids of Tirc7 protein, and we used this peptide as a ligand added to mouse osteoclast precursor cells. We evidenced that Tirc7-Cter peptide induced the differentiation of RAW264.7 cells into osteoclast-like cells, stimulated an autocrine/paracrine regulatory loop potentially involved in osteoclastic differentiation control, and strongly up-regulated F4/80 protein expression within multinucleated osteoclast-like cells. Using a mouse bone marrow-derived CD11b<sup>+</sup> cell line, or total bone marrow primary cells, we observed that similarly to Rankl, Tirc7-Cter peptide induced the formation of TRACP-positive large multinucleated cells. At last, using mouse primary monocytes purified from total bone marrow, we determined that Tirc7-Cter peptide induced the appearance of small multinucleated cells (3-4 nuclei), devoid of resorbing activity, and which displayed modulations of dendritic cell marker genes expression. In conclusion, we report for the first time on biological effects mediated by a peptide corresponding to the C-terminus of Tirc7 protein, which interfere with monocytic differentiation pathways. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Atp6v0a3 gene encodes for two alternative products, Tirc7 and a3 proteins, which are differentially expressed in activated T cells and resorbing osteoclasts respectively. Tirc7 plays a central role in T cell activation, while a3 protein is critical for osteoclast-mediated bone matrix resorption. Based on the large body of evidences documenting the relationships between T cells and osteoclasts, we hypothesized that the extracellular C-terminus of Tirc7 protein could directly interact with osteoclast precursor cells. To address this issue, we performed the molecular cloning of a mouse Atp6v0a3 cDNA segment encoding the last 40 amino acids of Tirc7 protein, and we used this peptide as a ligand added to mouse osteoclast precursor cells. We evidenced that Tirc7-Cter peptide induced the differentiation of RAW264.7 cells into osteoclast-like cells, stimulated an autocrine/paracrine regulatory loop potentially involved in osteoclastic differentiation control, and strongly up-regulated F4/80 protein expression within multinucleated osteoclast-like cells. Using a mouse bone marrow-derived CD11b+ cell line, or total bone marrow primary cells, we observed that similarly to Rankl, Tirc7-Cter peptide induced the formation of TRACP-positive large multinucleated cells. At last, using mouse primary monocytes purified from total bone marrow, we determined that Tirc7-Cter peptide induced the appearance of small multinucleated cells (3-4 nuclei), devoid of resorbing activity, and which displayed modulations of dendritic cell marker genes expression. In conclusion, we report for the first time on biological effects mediated by a peptide corresponding to the C-terminus of Tirc7 protein, which interfere with monocytic differentiation pathways. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23052" xmlns="http://purl.org/rss/1.0/"><title>AMP-activated protein kinase mediates erythropoietin-induced activation of endothelial nitric oxide synthase</title><link>http://dx.doi.org/10.1002%2Fjcp.23052</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">AMP-activated protein kinase mediates erythropoietin-induced activation of endothelial nitric oxide synthase</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kuo-Hui Su</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yuan-Bin Yu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hsin-Han Hou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jin-Feng Zhao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yu Ru Kou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Li-Ching Cheng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Song-Kun Shyue</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tzong-Shyuan Lee</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-20T08:08:21.786505-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23052</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23052</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23052</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We investigated whether AMP-activated protein kinase (AMPK), a multi-functional regulator of energy homeostasis, participates in the regulation of erythropoietin (EPO)-mediated activation of endothelial nitric oxide synthase (eNOS) in endothelial cells (ECs) and mice. In ECs, treatment with EPO increased the phosphorylation of AMPK, acetyl-CoA carboxylase (ACC) and eNOS, as revealed by western blot analysis. Inhibition of AMPK activation by compound C or dominant-negative AMPK mutant abrogated the EPO-induced increase in the phosphorylation of AMPK, ACC and eNOS, as well as nitric oxide (NO) production. Additionally, suppression of AMPK activation abolished EPO-induced EC proliferation, migration and tube formation. Immunoprecipitation analysis demonstrated that AMPK mediated the EPO-induced increase in the phosphorylation of β common receptor (βCR) and the formation of a βCR–AMPK–eNOS complex. In mice, inhibition of AMPK activation by compound C markedly decreased EPO-elicited angiogenesis in Matrigel plugs. Furthermore, the phosphorylation of AMPK and eNOS was significantly higher in aortas from EPO transgenic mice than wild-type mice. Moreover, treatment with EPO neutralizing antibody greatly reduced the exercise training-induced increase in phosphorylation of AMPK and eNOS in aortas of wild-type mice. Taken together, EPO may trigger AMPK-dependent signaling, which leads to enhanced phosphorylation of βCR and eNOS, increased βCR–AMPK–eNOS complex formation, NO production and, ultimately, angiogenesis. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>We investigated whether AMP-activated protein kinase (AMPK), a multi-functional regulator of energy homeostasis, participates in the regulation of erythropoietin (EPO)-mediated activation of endothelial nitric oxide synthase (eNOS) in endothelial cells (ECs) and mice. In ECs, treatment with EPO increased the phosphorylation of AMPK, acetyl-CoA carboxylase (ACC) and eNOS, as revealed by western blot analysis. Inhibition of AMPK activation by compound C or dominant-negative AMPK mutant abrogated the EPO-induced increase in the phosphorylation of AMPK, ACC and eNOS, as well as nitric oxide (NO) production. Additionally, suppression of AMPK activation abolished EPO-induced EC proliferation, migration and tube formation. Immunoprecipitation analysis demonstrated that AMPK mediated the EPO-induced increase in the phosphorylation of β common receptor (βCR) and the formation of a βCR–AMPK–eNOS complex. In mice, inhibition of AMPK activation by compound C markedly decreased EPO-elicited angiogenesis in Matrigel plugs. Furthermore, the phosphorylation of AMPK and eNOS was significantly higher in aortas from EPO transgenic mice than wild-type mice. Moreover, treatment with EPO neutralizing antibody greatly reduced the exercise training-induced increase in phosphorylation of AMPK and eNOS in aortas of wild-type mice. Taken together, EPO may trigger AMPK-dependent signaling, which leads to enhanced phosphorylation of βCR and eNOS, increased βCR–AMPK–eNOS complex formation, NO production and, ultimately, angiogenesis. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23053" xmlns="http://purl.org/rss/1.0/"><title>Ganoderma lucidum polysaccharides prevent platelet-derived growth factor-stimulated smooth muscle cell proliferation in vitro and neointimal hyperplasia in the endothelial-denuded artery in vivo</title><link>http://dx.doi.org/10.1002%2Fjcp.23053</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Ganoderma lucidum polysaccharides prevent platelet-derived growth factor-stimulated smooth muscle cell proliferation in vitro and neointimal hyperplasia in the endothelial-denuded artery in vivo</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shu-Huei Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chan-Jung Liang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yu-Wen Weng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yung-Hsiang Chen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hsien-Yeh Hsu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hsiung-Fei Chien</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jaw-Shiun Tsai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ying-Chin Tseng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chi-Yuan Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yuh-Lien Chen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-20T08:08:20.97334-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23053</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23053</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23053</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Ganoderma lucidum</em> is used in traditional Chinese medicine to prevent or treat a variety of diseases, including cardiovascular disorders. We previously demonstrated that a glucan-containing extract of Reishi polysaccharides (EORP) has the potent anti-inflammatory action of reducing ICAM-1 expression in lipopolysaccharide (LPS)-treated human aortic endothelial cells (HASMCs) and LPS-treated mice. In the present study, we examined whether EORP inhibited platelet-derived growth factor-BB (PDGF)-stimulated HASMC proliferation and the mechanism involved. EORP dose-dependently reduced cell numbers and DNA synthesis of PDGF-treated HASMCs <em>in vitro</em>. EORP also arrested cell cycle progression in the G0/G1 phase, and this was associated with decreased expression of cyclin D1, cyclin E, CDK2, CDK4, and p21<sup>Cip1</sup> and upregulation of the cyclin-dependent kinase inhibitor p27<sup>Kip1</sup>. The antiproliferative effect of EORP was partly mediated by downregulation of PDGF-induced JNK phosphorylation. In <em>in vivo</em> studies, the femoral artery of C57BL/6 mice was endothelial-denuded and the mice were fed a diet containing 100 mg/Kg/day of EORP. On day 14, both cell proliferation (proliferating cell nuclear antigen-positive cells) in the neointima and the neointima/media area ratio (0.67 ± 0.03 versus 1.46 ± 0.30) were significantly reduced. Our data show that EORP interferes with the mitogenic activation of JNK, preventing entry of HASMCs into the cell cycle <em>in vitro</em> and reducing cell proliferation in the neointima and decreasing the neointimal area <em>in vivo</em>. Thus, EORP may represent a safe and effective novel approach to the prevention and treatment of vascular proliferative diseases. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Ganoderma lucidum is used in traditional Chinese medicine to prevent or treat a variety of diseases, including cardiovascular disorders. We previously demonstrated that a glucan-containing extract of Reishi polysaccharides (EORP) has the potent anti-inflammatory action of reducing ICAM-1 expression in lipopolysaccharide (LPS)-treated human aortic endothelial cells (HASMCs) and LPS-treated mice. In the present study, we examined whether EORP inhibited platelet-derived growth factor-BB (PDGF)-stimulated HASMC proliferation and the mechanism involved. EORP dose-dependently reduced cell numbers and DNA synthesis of PDGF-treated HASMCs in vitro. EORP also arrested cell cycle progression in the G0/G1 phase, and this was associated with decreased expression of cyclin D1, cyclin E, CDK2, CDK4, and p21Cip1 and upregulation of the cyclin-dependent kinase inhibitor p27Kip1. The antiproliferative effect of EORP was partly mediated by downregulation of PDGF-induced JNK phosphorylation. In in vivo studies, the femoral artery of C57BL/6 mice was endothelial-denuded and the mice were fed a diet containing 100 mg/Kg/day of EORP. On day 14, both cell proliferation (proliferating cell nuclear antigen-positive cells) in the neointima and the neointima/media area ratio (0.67 ± 0.03 versus 1.46 ± 0.30) were significantly reduced. Our data show that EORP interferes with the mitogenic activation of JNK, preventing entry of HASMCs into the cell cycle in vitro and reducing cell proliferation in the neointima and decreasing the neointimal area in vivo. Thus, EORP may represent a safe and effective novel approach to the prevention and treatment of vascular proliferative diseases. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23051" xmlns="http://purl.org/rss/1.0/"><title>Emerging role of angiogenin in stress response and cell survival under adverse conditions</title><link>http://dx.doi.org/10.1002%2Fjcp.23051</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Emerging role of angiogenin in stress response and cell survival under adverse conditions</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shuping Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Guo-Fu Hu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-20T08:08:19.365442-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23051</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23051</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23051</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Mini-Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Angiogenin (ANG), also known as ribonuclease (RNASE) 5, is a member of the vertebrate-specific, secreted RNASE superfamily. ANG was originally identified as a tumor angiogenic factor, but its biological activity has been extended from inducing angiogenesis to stimulating cell proliferation and more recently, to promoting cell survival. Under growth conditions, ANG is translocated to nucleus where it accumulates in nucleolus and stimulates ribosomal RNA (rRNA) transcription, thus facilitating cell growth and proliferation. Under stress conditions, ANG is accumulated in cytoplasmic compartments and modulates the production of tiRNA, a novel class of small RNA that is derived from tRNA and is induced by stress. tiRNA suppress global protein translation by inhibiting both cap-dependent and -independent translation including that mediated by weak IRESes. However, strong IRES-mediated translation, a mechanism often used by genes involved in pro-survival and anti-apoptosis, is not affected. Thus, ANG-mediated tiRNA reprogram protein translation, save anabolic energy, and promote cell survival. This recently uncovered function of ANG presents a novel mechanism of action in regulating cell growth and survival. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Angiogenin (ANG), also known as ribonuclease (RNASE) 5, is a member of the vertebrate-specific, secreted RNASE superfamily. ANG was originally identified as a tumor angiogenic factor, but its biological activity has been extended from inducing angiogenesis to stimulating cell proliferation and more recently, to promoting cell survival. Under growth conditions, ANG is translocated to nucleus where it accumulates in nucleolus and stimulates ribosomal RNA (rRNA) transcription, thus facilitating cell growth and proliferation. Under stress conditions, ANG is accumulated in cytoplasmic compartments and modulates the production of tiRNA, a novel class of small RNA that is derived from tRNA and is induced by stress. tiRNA suppress global protein translation by inhibiting both cap-dependent and -independent translation including that mediated by weak IRESes. However, strong IRES-mediated translation, a mechanism often used by genes involved in pro-survival and anti-apoptosis, is not affected. Thus, ANG-mediated tiRNA reprogram protein translation, save anabolic energy, and promote cell survival. This recently uncovered function of ANG presents a novel mechanism of action in regulating cell growth and survival. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23045" xmlns="http://purl.org/rss/1.0/"><title>Regulation of asthmatic airway relaxation by estrogen and heat shock protein 90</title><link>http://dx.doi.org/10.1002%2Fjcp.23045</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Regulation of asthmatic airway relaxation by estrogen and heat shock protein 90</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">S. Intapad</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">C. Dimitropoulou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">C. Snead</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">P. Piyachaturawat</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">J.D. Catravas</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-20T08:08:18.298724-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23045</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23045</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23045</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We tested the hypothesis that asthmatic mouse airways exhibit impaired relaxation to NO donors. Mouse tracheal rings were incubated overnight in serum from asthmatic human subjects or from non-asthmatic controls. The next day, cumulative concentration-response curves (CCRC) to sodium nitroprusside (SNP) and nitroglycerine (NTG) were obtained. Both SNP and NTG relaxed the pre-constricted normal tracheal rings. Tracheal rings exposed to serum from asthmatic patients exhibited a more than a 3-fold increase in the EC50 of SNP and NTG. Pre-incubation of tracheal rings with heat shock protein 90 inhibitors decreased the relaxation of both normal and asthmatic tracheal rings to SNP and NTG. Pre-incubation with estradiol did not affect normal tracheal ring relaxation but exhibited an increase in asthmatic tracheal ring relaxation, which was abolished by an estrogen receptor (ER) antagonist. ER subtype-selective agonists, but not GPR30 agonists, mimicked the action of estradiol on tracheal ring relaxation. Co-incubation of rings with radicicol and estradiol produced an ER-dependent increase in the relaxation response to SNP of both normal and asthmatic ASM. Estrogen-induced relaxation of ASM was abolished by overnight incubation with radicicol and this was associated with reduced expression of ERβ. These data suggest that asthmatic ASM is considerably less responsive to NO-donors and that both estrogen and hsp90 play important roles in ASM relaxation. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>We tested the hypothesis that asthmatic mouse airways exhibit impaired relaxation to NO donors. Mouse tracheal rings were incubated overnight in serum from asthmatic human subjects or from non-asthmatic controls. The next day, cumulative concentration-response curves (CCRC) to sodium nitroprusside (SNP) and nitroglycerine (NTG) were obtained. Both SNP and NTG relaxed the pre-constricted normal tracheal rings. Tracheal rings exposed to serum from asthmatic patients exhibited a more than a 3-fold increase in the EC50 of SNP and NTG. Pre-incubation of tracheal rings with heat shock protein 90 inhibitors decreased the relaxation of both normal and asthmatic tracheal rings to SNP and NTG. Pre-incubation with estradiol did not affect normal tracheal ring relaxation but exhibited an increase in asthmatic tracheal ring relaxation, which was abolished by an estrogen receptor (ER) antagonist. ER subtype-selective agonists, but not GPR30 agonists, mimicked the action of estradiol on tracheal ring relaxation. Co-incubation of rings with radicicol and estradiol produced an ER-dependent increase in the relaxation response to SNP of both normal and asthmatic ASM. Estrogen-induced relaxation of ASM was abolished by overnight incubation with radicicol and this was associated with reduced expression of ERβ. These data suggest that asthmatic ASM is considerably less responsive to NO-donors and that both estrogen and hsp90 play important roles in ASM relaxation. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23046" xmlns="http://purl.org/rss/1.0/"><title>The phosphoinositide 3'-kinase p110δ modulates contractile protein production and IL-6 release in human airway smooth muscle</title><link>http://dx.doi.org/10.1002%2Fjcp.23046</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The phosphoinositide 3'-kinase p110δ modulates contractile protein production and IL-6 release in human airway smooth muscle</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Qi Ge</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lyn M Moir</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas Trian</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kyoko Niimi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maree Poniris</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Peter R Shepherd</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Judith L. Black</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Brian G. Oliver</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Janette K. Burgess</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-20T08:08:16.791951-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23046</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23046</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23046</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Transforming growth factor (TGF) β1 increases pro-inflammatory cytokines and contractile protein expression by human airway smooth muscle (ASM) cells, which could augment airway inflammation and hyperresponsiveness. Phosphoinositide 3' kinase (PI3K) is one of the signaling pathways implicated in TGFβ1 stimulation, and may be altered in asthmatic airways. This study compared the expression of PI3K isoforms by ASM cells from donors with asthma (A), chronic obstructive pulmonary disease (COPD) or neither disease (NA), and investigated the role of PI3K isoforms in the production of TGFβ1 induced pro-inflammatory cytokine and contractile proteins in ASM cells. Results: A cells expressed higher basal levels of p110δ mRNA compared to NA and COPD cells; however COPD cells produced more p110δ protein. TGFβ1 increased 110d mRNA expression to the same extent in the three groups. Neither the p110δ inhibitor IC87114 (1, 10, 30 μM), the p110β inhibitor TGX221 (0.1, 1, 10 μM) nor the PI3K pan inhibitor LY294002 (3, 10 μM) had any effect on basal IL-6, calponin or smooth muscle α-actin (α-SMA) expression. However, TGFβ1 increased calponin and α-SMA expression was inhibited by IC87114 and LY294002 in all three groups. IC87114, TGX221 and LY294002 reduced TGFβ1 induced IL-6 release in a dose related manner in all groups of ASM cells. Conclusion: PI3K p110δ is important for TGFβ1 induced production of the contractile proteins calponin and α-SMA and the proinflammatory cytokine IL-6 in ASM cells, and may therefore be relevant as a potential therapeutic target to treat both inflammation and airway remodeling. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Transforming growth factor (TGF) β1 increases pro-inflammatory cytokines and contractile protein expression by human airway smooth muscle (ASM) cells, which could augment airway inflammation and hyperresponsiveness. Phosphoinositide 3' kinase (PI3K) is one of the signaling pathways implicated in TGFβ1 stimulation, and may be altered in asthmatic airways. This study compared the expression of PI3K isoforms by ASM cells from donors with asthma (A), chronic obstructive pulmonary disease (COPD) or neither disease (NA), and investigated the role of PI3K isoforms in the production of TGFβ1 induced pro-inflammatory cytokine and contractile proteins in ASM cells. Results: A cells expressed higher basal levels of p110δ mRNA compared to NA and COPD cells; however COPD cells produced more p110δ protein. TGFβ1 increased 110d mRNA expression to the same extent in the three groups. Neither the p110δ inhibitor IC87114 (1, 10, 30 μM), the p110β inhibitor TGX221 (0.1, 1, 10 μM) nor the PI3K pan inhibitor LY294002 (3, 10 μM) had any effect on basal IL-6, calponin or smooth muscle α-actin (α-SMA) expression. However, TGFβ1 increased calponin and α-SMA expression was inhibited by IC87114 and LY294002 in all three groups. IC87114, TGX221 and LY294002 reduced TGFβ1 induced IL-6 release in a dose related manner in all groups of ASM cells. Conclusion: PI3K p110δ is important for TGFβ1 induced production of the contractile proteins calponin and α-SMA and the proinflammatory cytokine IL-6 in ASM cells, and may therefore be relevant as a potential therapeutic target to treat both inflammation and airway remodeling. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23047" xmlns="http://purl.org/rss/1.0/"><title>Branch chain amino acid, insulin and hepatic tumor cell proliferation</title><link>http://dx.doi.org/10.1002%2Fjcp.23047</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Branch chain amino acid, insulin and hepatic tumor cell proliferation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Viroj Wiwanitkit</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-20T08:08:15.580399-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23047</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23047</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23047</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Letter to the Editor</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23044" xmlns="http://purl.org/rss/1.0/"><title>Endoplasmic reticulum-specific BH3-only protein BNIP1 induces mitochondrial fragmentation in a Bcl-2- and Drp1-dependent manner</title><link>http://dx.doi.org/10.1002%2Fjcp.23044</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Endoplasmic reticulum-specific BH3-only protein BNIP1 induces mitochondrial fragmentation in a Bcl-2- and Drp1-dependent manner</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Seung-Wook Ryu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kyungsun Choi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sunchang Kim</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chulhee Choi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-20T08:08:14.311977-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23044</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23044</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23044</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Bcl-2/adenovirus E1B 19-kDa interacting protein 1 (BNIP1), which is predominantly localized to the endoplasmic reticulum (ER), is a pro-apoptotic Bcl-2 homology domain 3 (BH3)-only protein. Here, we show that the expression of BNIP1 induced not only a highly interconnected ER network but also mitochondrial fragmentation in a BH3 domain-dependent manner. Functional analysis demonstrated that BNIP1 expression increased dynamin-related protein 1 (Drp1) expression followed by the mitochondrial translocation of Drp1 and subsequent mitochondrial fission. Both BNIP1-induced mitochondrial fission and the translocation of Drp1 were abrogated by Bcl-2 overexpression. These results collectively indicate that ER-specific BNIP1 plays an important role in mitochondrial dynamics by modulating the mitochondrial fission protein Drp1 in a BH3 domain-dependent fashion. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Bcl-2/adenovirus E1B 19-kDa interacting protein 1 (BNIP1), which is predominantly localized to the endoplasmic reticulum (ER), is a pro-apoptotic Bcl-2 homology domain 3 (BH3)-only protein. Here, we show that the expression of BNIP1 induced not only a highly interconnected ER network but also mitochondrial fragmentation in a BH3 domain-dependent manner. Functional analysis demonstrated that BNIP1 expression increased dynamin-related protein 1 (Drp1) expression followed by the mitochondrial translocation of Drp1 and subsequent mitochondrial fission. Both BNIP1-induced mitochondrial fission and the translocation of Drp1 were abrogated by Bcl-2 overexpression. These results collectively indicate that ER-specific BNIP1 plays an important role in mitochondrial dynamics by modulating the mitochondrial fission protein Drp1 in a BH3 domain-dependent fashion. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23054" xmlns="http://purl.org/rss/1.0/"><title>Identification of proteins that associate with integrin α2 by proteomic analysis in human fibrosarcoma HT-1080 cells</title><link>http://dx.doi.org/10.1002%2Fjcp.23054</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Identification of proteins that associate with integrin α2 by proteomic analysis in human fibrosarcoma HT-1080 cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takayuki Uematsu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chieko Konishi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daisuke Hoshino</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiao Han</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">TaizoTomari</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nagayasu Egawa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yoshikazu Takada</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Toshiaki Isobe</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Motoharu Seiki</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Naohiko Koshikawa</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-11T09:06:12.212693-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23054</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23054</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23054</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Integrins are adhesion receptors for components of the extracellular matrix (ECMs) that regulate multiple cellular functions, such as migration, invasion, proliferation and survival by mediating bidirectional signal transmission. Even though many proteins have been reported to associate with integrins both on and in cells, systemic analyses of the adhesome have not been carried out. In previous studies, we identified proteins associating with a membrane-type protease, MT1-MMP, using nano–flow liquid chromatography/tandem mass spectrometry (nano-LC/MS/MS) of associated proteins prepared by optimized conditions for cell lysis and purification. Since integrins were identified as MT1-MMP-associated proteins, we next applied this method to analyze integrin-associated proteins. In this study, we expressed integrin α2 fused at the C terminus to a FLAG peptide in HT1080 cells. Cells stably expressing the chimeric protein were lysed with 1% Brij-98 and affinity purified using anti-FLAG antibody. Integrin β1 co-purified with integrin α2 confirming the specificity of the purification procedure. Analysis of the purified mixture by nano-LC/MS/MS identified 70 proteins. Nineteen of these were membrane proteins, including adhesion proteins, receptors, transporters, proteinases, and ion channel receptors, and the balance were cytoplasmic. Interestingly, eight of the proteins had previously been shown to associate with MT1-MMP. We believe the present study provides a platform to facilitate the study of the mechanisms of cell adhesion, migration and invasion. (217 words) J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Integrins are adhesion receptors for components of the extracellular matrix (ECMs) that regulate multiple cellular functions, such as migration, invasion, proliferation and survival by mediating bidirectional signal transmission. Even though many proteins have been reported to associate with integrins both on and in cells, systemic analyses of the adhesome have not been carried out. In previous studies, we identified proteins associating with a membrane-type protease, MT1-MMP, using nano–flow liquid chromatography/tandem mass spectrometry (nano-LC/MS/MS) of associated proteins prepared by optimized conditions for cell lysis and purification. Since integrins were identified as MT1-MMP-associated proteins, we next applied this method to analyze integrin-associated proteins. In this study, we expressed integrin α2 fused at the C terminus to a FLAG peptide in HT1080 cells. Cells stably expressing the chimeric protein were lysed with 1% Brij-98 and affinity purified using anti-FLAG antibody. Integrin β1 co-purified with integrin α2 confirming the specificity of the purification procedure. Analysis of the purified mixture by nano-LC/MS/MS identified 70 proteins. Nineteen of these were membrane proteins, including adhesion proteins, receptors, transporters, proteinases, and ion channel receptors, and the balance were cytoplasmic. Interestingly, eight of the proteins had previously been shown to associate with MT1-MMP. We believe the present study provides a platform to facilitate the study of the mechanisms of cell adhesion, migration and invasion. (217 words) J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23040" xmlns="http://purl.org/rss/1.0/"><title>Factor XIIIA transglutaminase expression and secretion by osteoblasts is regulated by extracellular matrix collagen and the MAP kinase signaling pathway</title><link>http://dx.doi.org/10.1002%2Fjcp.23040</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Factor XIIIA transglutaminase expression and secretion by osteoblasts is regulated by extracellular matrix collagen and the MAP kinase signaling pathway</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sarah A. Piercy-Kotb</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Aisha Mousa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hadil F. Al-Jallad</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vamsee D. Myneni</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Florencia Chicatun</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Showan N. Nazhat</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mari T. Kaartinen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-29T07:30:48.761965-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23040</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23040</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23040</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Osteoblast differentiation is regulated by the presence of collagen type I (COL I) extracellular matrix (ECM). We have recently demonstrated that Factor XIIIA (FXIIIA) transglutaminase (TG) is required by osteoblasts for COL I secretion and extracellular deposition, and thus also for osteoblast differentiation. In this study we have further investigated the link between COL I and FXIIIA, and demonstrate that COL I matrix increases FXIIIA levels in osteoblast cultures and that FXIIIA is found as cellular (cFXIIIA) and extacellular matrix (ecmFXIIIA) forms. FXIIIA mRNA, protein expression, cellular localization and secretion were enhanced by ascorbic acid (AA) treatment and blocked by dihydroxyproline (DHP) which inhibits COL I externalization. FXIIIA mRNA was regulated by the MAP kinase pathway. Secretion of ecmFXIIIA, and its enzymatic activity in conditioned medium, were also decreased in osteoblasts treated with the lysyl oxidase inhibitor β-aminopropionitrile, which resulted in a loosely packed COL I matrix. Osteoblasts secrete a latent, inactive dimeric ecmFXIIIA form which is activated upon binding to the matrix. Monodansyl cadaverine labeling of TG substrates in the cultures revealed that incorporation of the label occured at sites where fibronectin co-localized with COL I, indicating that ecmFXIIIA secretion could function to stabilize newly deposited matrix. Our results suggest that FXIIIA is an integral part of the COL I deposition machinery, and also that it is part of the ECM-feedback loop, both of which regulate matrix deposition and osteoblast differentiation. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Osteoblast differentiation is regulated by the presence of collagen type I (COL I) extracellular matrix (ECM). We have recently demonstrated that Factor XIIIA (FXIIIA) transglutaminase (TG) is required by osteoblasts for COL I secretion and extracellular deposition, and thus also for osteoblast differentiation. In this study we have further investigated the link between COL I and FXIIIA, and demonstrate that COL I matrix increases FXIIIA levels in osteoblast cultures and that FXIIIA is found as cellular (cFXIIIA) and extacellular matrix (ecmFXIIIA) forms. FXIIIA mRNA, protein expression, cellular localization and secretion were enhanced by ascorbic acid (AA) treatment and blocked by dihydroxyproline (DHP) which inhibits COL I externalization. FXIIIA mRNA was regulated by the MAP kinase pathway. Secretion of ecmFXIIIA, and its enzymatic activity in conditioned medium, were also decreased in osteoblasts treated with the lysyl oxidase inhibitor β-aminopropionitrile, which resulted in a loosely packed COL I matrix. Osteoblasts secrete a latent, inactive dimeric ecmFXIIIA form which is activated upon binding to the matrix. Monodansyl cadaverine labeling of TG substrates in the cultures revealed that incorporation of the label occured at sites where fibronectin co-localized with COL I, indicating that ecmFXIIIA secretion could function to stabilize newly deposited matrix. Our results suggest that FXIIIA is an integral part of the COL I deposition machinery, and also that it is part of the ECM-feedback loop, both of which regulate matrix deposition and osteoblast differentiation. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23042" xmlns="http://purl.org/rss/1.0/"><title>Early endosomal rerouting of major histocompatibility class I conformers</title><link>http://dx.doi.org/10.1002%2Fjcp.23042</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Early endosomal rerouting of major histocompatibility class I conformers</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gordana Blagojević Zagorac</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hana Mahmutefendić</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maja Ilić Tomaš</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Natalia Kučić</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Philippe Le Bouteiller</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pero Lučin</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-29T07:30:47.029695-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23042</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23042</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23042</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Major histocompatibility class I (MHC-I) molecules are present at the cell surface both as fully conformed trimolecular complexes composed of heavy chain, beta-2-microglobulin and peptide, and various open forms, devoid of peptide and/or beta-2-microglobulin (open MHC-I conformers). Fully conformed MHC-I complexes and open MHC-I conformers can be distinguished by well characterized monoclonal antibody reagents that recognize their conformational difference in the extracellular domain. In the present study we used these tools in order to test whether conformational difference in the extracellular domain determines endocytic and endosomal route of plasma membrane proteins. We analyzed plasma membrane localization, internalization, endosomal trafficking and recycling of human and murine MHC-I proteins on various cell lines. We have shown that fully conformed MHC-I and open MHC-I conformers segregate at the plasma membrane and during endosomal trafficking resulting in the exclusion of open MHC-I conformers from the recycling route. This segregation is associated with their partitioning into the membranes of different compositions. As a result, the open MHC-I conformers internalized with higher rate than fully conformed counterparts. Thus, our data suggest the existence of conformation-based protein sorting mechanism in the endosomal system. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Major histocompatibility class I (MHC-I) molecules are present at the cell surface both as fully conformed trimolecular complexes composed of heavy chain, beta-2-microglobulin and peptide, and various open forms, devoid of peptide and/or beta-2-microglobulin (open MHC-I conformers). Fully conformed MHC-I complexes and open MHC-I conformers can be distinguished by well characterized monoclonal antibody reagents that recognize their conformational difference in the extracellular domain. In the present study we used these tools in order to test whether conformational difference in the extracellular domain determines endocytic and endosomal route of plasma membrane proteins. We analyzed plasma membrane localization, internalization, endosomal trafficking and recycling of human and murine MHC-I proteins on various cell lines. We have shown that fully conformed MHC-I and open MHC-I conformers segregate at the plasma membrane and during endosomal trafficking resulting in the exclusion of open MHC-I conformers from the recycling route. This segregation is associated with their partitioning into the membranes of different compositions. As a result, the open MHC-I conformers internalized with higher rate than fully conformed counterparts. Thus, our data suggest the existence of conformation-based protein sorting mechanism in the endosomal system. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23041" xmlns="http://purl.org/rss/1.0/"><title>Gefitinib resistance in HCC Mahlavu cells: Upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation</title><link>http://dx.doi.org/10.1002%2Fjcp.23041</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Gefitinib resistance in HCC Mahlavu cells: Upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adam S. Bodzin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zhengyu Wei</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Reginald Hurtt</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tina Gu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cataldo Doria</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-29T07:30:45.139095-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23041</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23041</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23041</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Hepatocellular carcinoma (HCC) is the major form of primary liver cancer which accounts for more than half million deaths annually worldwide. While the incidence of HCC is still on the rise, options of treatment are limited and the overall survival rate is poor. The acquisition of cancer drug resistance remains one of the key hurdles to successful treatment. Clearly, a thorough understanding of the underlying mechanisms is needed for new strategies to design novel treatments and/or to improve the current therapies. In the present study, we examined the expression of cancer stem cell (CSC) marker CD133, the activation of insulin like growth factor 1 receptor (IGF-1R) signaling, and the nuclear translocation of IGF-1R in HCC Mahlavu cells under the treatment of gefitinib, a cancer drug that inhibits epidermal growth factor receptor (EGFR) pathway. Our results demonstrated that Mahlavu cells exhibited strong gefitinib resistance and the CD133 expression level was dramatically increased (from 3.88% to 32%) after drug treatment. In addition, the gefitinib treated cells displayed increased levels of phosphorylation in IGF-1R and Akt, indicating the intensified activation of this cancer-associated signaling pathway. Moreover, we reveled that IGF-1R underwent nuclear translocation in gefitinib treated cells using confocal microscopy. The IGF-1R nuclear translocation was enhanced under gefitinib treatment and appeared in a dose dependent manner. Our findings suggest that increased IGF-1R nuclear translocation after gefitinib treatment may contribute to the drug resistance and IGF1-R activation, which might also associate with the upregulation of CD133 expression. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Hepatocellular carcinoma (HCC) is the major form of primary liver cancer which accounts for more than half million deaths annually worldwide. While the incidence of HCC is still on the rise, options of treatment are limited and the overall survival rate is poor. The acquisition of cancer drug resistance remains one of the key hurdles to successful treatment. Clearly, a thorough understanding of the underlying mechanisms is needed for new strategies to design novel treatments and/or to improve the current therapies. In the present study, we examined the expression of cancer stem cell (CSC) marker CD133, the activation of insulin like growth factor 1 receptor (IGF-1R) signaling, and the nuclear translocation of IGF-1R in HCC Mahlavu cells under the treatment of gefitinib, a cancer drug that inhibits epidermal growth factor receptor (EGFR) pathway. Our results demonstrated that Mahlavu cells exhibited strong gefitinib resistance and the CD133 expression level was dramatically increased (from 3.88% to 32%) after drug treatment. In addition, the gefitinib treated cells displayed increased levels of phosphorylation in IGF-1R and Akt, indicating the intensified activation of this cancer-associated signaling pathway. Moreover, we reveled that IGF-1R underwent nuclear translocation in gefitinib treated cells using confocal microscopy. The IGF-1R nuclear translocation was enhanced under gefitinib treatment and appeared in a dose dependent manner. Our findings suggest that increased IGF-1R nuclear translocation after gefitinib treatment may contribute to the drug resistance and IGF1-R activation, which might also associate with the upregulation of CD133 expression. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23043" xmlns="http://purl.org/rss/1.0/"><title>Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways</title><link>http://dx.doi.org/10.1002%2Fjcp.23043</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Min Huan Wu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeng-Fan Lo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chia-Hua Kuo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James A. Lin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yueh-Min Lin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Li-Mien Chen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fuu-Jen Tsai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chang-Hai Tsai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chih-Yang Huang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chih-Hsin Tang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-29T07:30:43.222362-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23043</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23043</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23043</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Tumor malignancy is associated with several cellular properties including proliferation and ability to metastasize. Endothelin-1 (ET-1) the most potent vasoconstrictor plays a crucial role in migration and metastasis of human cancer cells. We found that treatment of human chondrosarcoma (JJ012 cells) with ET-1 increased migration and expression of matrix metalloproteinase (MMP)-13. ET-1-mediated cell migration and MMP-13 expression were reduced by pretreatment with inhibitors of focal adhesion kinase (FAK), phosphatidylinositol 3-kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR), as well as the NF-κB inhibitor and the IκB protease inhibitor. In addition, ET-1 treatment induced phosphorylation of FAK, PI3K, AKT, and mTOR, and resulted in increased NF-κB-luciferase activity that was inhibited by a specific inhibitor of PI3K, Akt, mTOR, and NF-κB cascades. Taken together, these results suggest that ET-1 activated FAK/PI3K/AKT/mTOR, which in turn activated IKKα/β and NF-κB, resulting in increased MMP-13 expression and migration in human chondrosarcoma cells. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Tumor malignancy is associated with several cellular properties including proliferation and ability to metastasize. Endothelin-1 (ET-1) the most potent vasoconstrictor plays a crucial role in migration and metastasis of human cancer cells. We found that treatment of human chondrosarcoma (JJ012 cells) with ET-1 increased migration and expression of matrix metalloproteinase (MMP)-13. ET-1-mediated cell migration and MMP-13 expression were reduced by pretreatment with inhibitors of focal adhesion kinase (FAK), phosphatidylinositol 3-kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR), as well as the NF-κB inhibitor and the IκB protease inhibitor. In addition, ET-1 treatment induced phosphorylation of FAK, PI3K, AKT, and mTOR, and resulted in increased NF-κB-luciferase activity that was inhibited by a specific inhibitor of PI3K, Akt, mTOR, and NF-κB cascades. Taken together, these results suggest that ET-1 activated FAK/PI3K/AKT/mTOR, which in turn activated IKKα/β and NF-κB, resulting in increased MMP-13 expression and migration in human chondrosarcoma cells. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23033" xmlns="http://purl.org/rss/1.0/"><title>A novel human hepatoma cell line, FLC-4, exhibits highly enhanced liver differentiation functions through the 3-dimensional cell shape</title><link>http://dx.doi.org/10.1002%2Fjcp.23033</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A novel human hepatoma cell line, FLC-4, exhibits highly enhanced liver differentiation functions through the 3-dimensional cell shape</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas Laurent</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daiki Murase</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sayaka Tsukioka</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tomokazu Matsuura</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Seishi Nagamori</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hiroaki Oda</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-29T07:30:41.599031-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23033</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23033</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23033</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We characterized 3-dimensional human hepatoma cell lines, functional liver cell (FLC) cell lines, to establish a highly differentiated hepatoma cell line. We investigated the effect of extracellular matrix and cell morphology on liver-specific gene expression in FLC cells. The hepatocyte nuclear factor-4α (HNF-4α) and other liver-specific gene expressions were enhanced in spherical FLC-4 cells on EHS-gel, but other human hepatoma cells such as HepG2 did not show the enhancement. Importantly, the liver-specific gene expression levels in spherical FLC-4 cells cultured on EHS-gel were comparable to those of human liver and were much higher than those of other human hepatoma cell lines. The major matrix components and growth factors in EHS-gel did not affect cell shape and liver functions. To exclude any effect of the extracellular matrix, we made spherical FLC-4 cells by actin filament disruption. The actin-disrupted spherical cells also showed an enhanced liver-specific gene expression. We concluded that 3-dimensional cell shape per se is one of the most important determinants of liver differentiation functions in FLC-4 cells. Cell morphology-dependent induction of liver-specific gene expression was mediated through microtubule organization. In conclusion, differentiation of FLC-4 human hepatoma cell line can be enhanced to a human liver-like level through the three-dimensional cell shape in a microtubule-dependent manner. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</p></div>]]></content:encoded><description>We characterized 3-dimensional human hepatoma cell lines, functional liver cell (FLC) cell lines, to establish a highly differentiated hepatoma cell line. We investigated the effect of extracellular matrix and cell morphology on liver-specific gene expression in FLC cells. The hepatocyte nuclear factor-4α (HNF-4α) and other liver-specific gene expressions were enhanced in spherical FLC-4 cells on EHS-gel, but other human hepatoma cells such as HepG2 did not show the enhancement. Importantly, the liver-specific gene expression levels in spherical FLC-4 cells cultured on EHS-gel were comparable to those of human liver and were much higher than those of other human hepatoma cell lines. The major matrix components and growth factors in EHS-gel did not affect cell shape and liver functions. To exclude any effect of the extracellular matrix, we made spherical FLC-4 cells by actin filament disruption. The actin-disrupted spherical cells also showed an enhanced liver-specific gene expression. We concluded that 3-dimensional cell shape per se is one of the most important determinants of liver differentiation functions in FLC-4 cells. Cell morphology-dependent induction of liver-specific gene expression was mediated through microtubule organization. In conclusion, differentiation of FLC-4 human hepatoma cell line can be enhanced to a human liver-like level through the three-dimensional cell shape in a microtubule-dependent manner. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23039" xmlns="http://purl.org/rss/1.0/"><title>Critical evaluation of the use of cell cultures for inclusion in clinical trials of patients affected by Collagen VI myopathies</title><link>http://dx.doi.org/10.1002%2Fjcp.23039</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Critical evaluation of the use of cell cultures for inclusion in clinical trials of patients affected by Collagen VI myopathies</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">P. Sabatelli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">E. Palma</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">A. Angelin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">S. Squarzoni</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">A. Urciuolo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">C. Pellegrini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">T. Tiepolo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">P. Bonaldo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">F. Gualandi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">L. Merlini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">P. Bernardi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">N.M. Maraldi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-27T07:46:06.81259-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23039</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23039</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23039</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Collagen VI myopathies (Ullrich Congenital Muscular Dystrophy (UCMD), Bethlem Myopathy (BM) and Myosclerosis Myopathy) share a common pathogenesis, i.e. mitochondrial dysfunction due to deregulation of the permeability transition pore (PTP). This effect was first identified in the <em>Col6a1</em><sup><em>-/-</em></sup> mouse model and then in muscle cell cultures from UCMD and BM patients; the normalizing effect of cyclosporin A (CsA) confirmed the pathogenic role of PTP opening. In order to determine whether mitochondrial performance can be used as a criterion for inclusion in clinical trials and as an outcome measure of the patient response to therapy, it is mandatory to establish whether mitochondrial dysfunction is conserved in primary cell cultures from UCMD and BM patients. In this study we report evidence that mitochondrial dysfunction and the consequent increase of apoptotic rate can be detected not only, as previously reported, in muscle, but also in fibroblast cell cultures established from muscle biopsies of collagen VI-related myopathic patients. However, the mitochondrial phenotype is no longer maintained after 9 passages in culture. These data demonstrate that the dire consequences of mitochondrial dysfunction are not limited to myogenic cells, and that this parameter can be used as a suitable diagnostic criterion, provided that the cell culture conditions are carefully established. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Collagen VI myopathies (Ullrich Congenital Muscular Dystrophy (UCMD), Bethlem Myopathy (BM) and Myosclerosis Myopathy) share a common pathogenesis, i.e. mitochondrial dysfunction due to deregulation of the permeability transition pore (PTP). This effect was first identified in the Col6a1-/- mouse model and then in muscle cell cultures from UCMD and BM patients; the normalizing effect of cyclosporin A (CsA) confirmed the pathogenic role of PTP opening. In order to determine whether mitochondrial performance can be used as a criterion for inclusion in clinical trials and as an outcome measure of the patient response to therapy, it is mandatory to establish whether mitochondrial dysfunction is conserved in primary cell cultures from UCMD and BM patients. In this study we report evidence that mitochondrial dysfunction and the consequent increase of apoptotic rate can be detected not only, as previously reported, in muscle, but also in fibroblast cell cultures established from muscle biopsies of collagen VI-related myopathic patients. However, the mitochondrial phenotype is no longer maintained after 9 passages in culture. These data demonstrate that the dire consequences of mitochondrial dysfunction are not limited to myogenic cells, and that this parameter can be used as a suitable diagnostic criterion, provided that the cell culture conditions are carefully established. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23006" xmlns="http://purl.org/rss/1.0/"><title>The differential regulation of Gap43 gene in the neuronal differentiation of P19 cells</title><link>http://dx.doi.org/10.1002%2Fjcp.23006</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The differential regulation of Gap43 gene in the neuronal differentiation of P19 cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ji-cheng Zhao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lang-xi Zhang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ye Zhang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yu-fei Shen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-21T08:28:36.20777-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23006</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23006</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23006</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Growth associated protein 43 (Gap43) is a neuron-specific phosphoprotein, which plays critical role in axon growth and synapses functions during neurogenesis. Here we identified two transcription start sites (TSSs) of the mouse <em>Gap43</em> gene designated as a proximal site at +1, and a distal TSS at -414. RT- qPCR data reveal that the transcripts from +1 increase 10-fold on day-1 post <em>all-trans</em> retinoid acid (RA) treatment, reached a peak value at day-4 and gradually reduced. By contrast, the distal TSS directs a late, remarkably sharp increase of the transcripts from the day-5 on. An intense signal of Gap43 at the neurites and neural network is determined by the efficient transcription of the distal promoter as shown in Northern blot and RT-qPCR assay. In addition, the targeting of p300 in combination with a differential enrichment of Brm to Brg1 change at the distal promoter region of the gene is induced under RA treatment. The over hundreds of GA rich stretches and the GAGAG elements located between the two TSSs may take parts in the differential transcription of the two TSSs of the <em>Gap43</em>. Our findings provide the first evidence on the identification and differential transcription of the two TSSs of the mouse <em>Gap43</em> gene, and the preferential distribution of their protein products in the specific stages of RA induced P19 differentiation. These data suggest the efficient transcription of the distal promoter of <em>Gap43</em> is an important mark for the transition of P19 cells from the progenitor stage into neuronal differentiation. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Growth associated protein 43 (Gap43) is a neuron-specific phosphoprotein, which plays critical role in axon growth and synapses functions during neurogenesis. Here we identified two transcription start sites (TSSs) of the mouse Gap43 gene designated as a proximal site at +1, and a distal TSS at -414. RT- qPCR data reveal that the transcripts from +1 increase 10-fold on day-1 post all-trans retinoid acid (RA) treatment, reached a peak value at day-4 and gradually reduced. By contrast, the distal TSS directs a late, remarkably sharp increase of the transcripts from the day-5 on. An intense signal of Gap43 at the neurites and neural network is determined by the efficient transcription of the distal promoter as shown in Northern blot and RT-qPCR assay. In addition, the targeting of p300 in combination with a differential enrichment of Brm to Brg1 change at the distal promoter region of the gene is induced under RA treatment. The over hundreds of GA rich stretches and the GAGAG elements located between the two TSSs may take parts in the differential transcription of the two TSSs of the Gap43. Our findings provide the first evidence on the identification and differential transcription of the two TSSs of the mouse Gap43 gene, and the preferential distribution of their protein products in the specific stages of RA induced P19 differentiation. These data suggest the efficient transcription of the distal promoter of Gap43 is an important mark for the transition of P19 cells from the progenitor stage into neuronal differentiation. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23037" xmlns="http://purl.org/rss/1.0/"><title>Endurance exercise training increases APPL1 expression and improves insulin signaling in the hepatic tissue of diet-induced obese mice, independently of weight loss</title><link>http://dx.doi.org/10.1002%2Fjcp.23037</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Endurance exercise training increases APPL1 expression and improves insulin signaling in the hepatic tissue of diet-induced obese mice, independently of weight loss</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">R Marinho</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">ER Ropelle</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">DE Cintra</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">CT De Souza</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">ASR Da Silva</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">FC Bertoli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">E Colantonio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">V D'Almeida</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">JR Pauli</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-21T08:28:34.503613-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23037</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23037</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23037</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Hepatic insulin resistance is the major contributor to fasting hyperglycemia in type 2 diabetes. The protein kinase Akt plays a central role in the suppression of gluconeogenesis involving forkhead box O1 (Foxo1) and peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1α), and in the control of glycogen synthesis involving the glycogen synthase kinase beta (GSK3β) in the liver. It has been demonstrated that endosomal adaptor protein APPL1 interacts with Akt and blocks the association of Akt with its endogenous inhibitor, tribbles-related protein 3 (TRB3), improving the action of insulin in the liver. Here, we demonstrated that chronic exercise increased the basal levels and insulin-induced Akt serine phosphorylation in the liver of diet-induced obese mice. Endurance training was able to increase APPL1 expression and the interaction between APPL1 and Akt. Conversely, training reduced both TRB3 expression and TRB3 and Akt association. The positive effects of exercise on insulin action are reinforced by our findings that showed that trained mice presented an increase in Foxo1 phosphorylation and Foxo1/PGC-1α association, which was accompanied by a reduction in gluconeogenic gene expressions (PEPCK and G6Pase). Finally, exercised animals demonstrated increased at basal and insulin-induced GSK3β phosphorylation levels and glycogen content at 24 hours after the last session of exercise. Our findings demonstrate that exercise increases insulin action, at least in part, through the enhancement of APPL1 and the reduction of TRB3 expression in the liver of obese mice, independently of weight loss. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Hepatic insulin resistance is the major contributor to fasting hyperglycemia in type 2 diabetes. The protein kinase Akt plays a central role in the suppression of gluconeogenesis involving forkhead box O1 (Foxo1) and peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1α), and in the control of glycogen synthesis involving the glycogen synthase kinase beta (GSK3β) in the liver. It has been demonstrated that endosomal adaptor protein APPL1 interacts with Akt and blocks the association of Akt with its endogenous inhibitor, tribbles-related protein 3 (TRB3), improving the action of insulin in the liver. Here, we demonstrated that chronic exercise increased the basal levels and insulin-induced Akt serine phosphorylation in the liver of diet-induced obese mice. Endurance training was able to increase APPL1 expression and the interaction between APPL1 and Akt. Conversely, training reduced both TRB3 expression and TRB3 and Akt association. The positive effects of exercise on insulin action are reinforced by our findings that showed that trained mice presented an increase in Foxo1 phosphorylation and Foxo1/PGC-1α association, which was accompanied by a reduction in gluconeogenic gene expressions (PEPCK and G6Pase). Finally, exercised animals demonstrated increased at basal and insulin-induced GSK3β phosphorylation levels and glycogen content at 24 hours after the last session of exercise. Our findings demonstrate that exercise increases insulin action, at least in part, through the enhancement of APPL1 and the reduction of TRB3 expression in the liver of obese mice, independently of weight loss. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23038" xmlns="http://purl.org/rss/1.0/"><title>PI3K: A potential therapeutic target for cancer</title><link>http://dx.doi.org/10.1002%2Fjcp.23038</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">PI3K: A potential therapeutic target for cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yingwei Chen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bao-Can Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yongtao Xiao</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-21T08:28:33.792714-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23038</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23038</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23038</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Mini-Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Phosphatidylinositol 3-kinase (PI3K), one member of lipid kinase family, has been demonstrated to play a key role in regulating cell proliferation, adhesion, survival and motility. Recent <em>studies indicate</em> that PI3K related signaling pathway is one of the most commonly activated pathways in human cancers. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, Inhibitors targeting PI3K or nodes in this pathway, AKT and mTOR, are best studied and have reached clinical trials. In this review, we will focus on recent progress on understanding of PI3Ks signaling pathway and the development of PI3K inhibitors. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</p></div>]]></content:encoded><description>Phosphatidylinositol 3-kinase (PI3K), one member of lipid kinase family, has been demonstrated to play a key role in regulating cell proliferation, adhesion, survival and motility. Recent studies indicate that PI3K related signaling pathway is one of the most commonly activated pathways in human cancers. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, Inhibitors targeting PI3K or nodes in this pathway, AKT and mTOR, are best studied and have reached clinical trials. In this review, we will focus on recent progress on understanding of PI3Ks signaling pathway and the development of PI3K inhibitors. J. Cell. Physiol. © 2011 Wiley Periodicals, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23032" xmlns="http://purl.org/rss/1.0/"><title>Initiation of BMP2 signaling in domains on the plasma membrane</title><link>http://dx.doi.org/10.1002%2Fjcp.23032</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Initiation of BMP2 signaling in domains on the plasma membrane</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeremy Bonor</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elizabeth L. Adams</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Beth Bragdon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Oleksandra Moseychuk</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kirk J. Czymmek</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anja Nohe</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-21T08:28:32.730179-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23032</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23032</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23032</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Bone Morphogenetic Protein 2 (BMP2) is a potent growth factor crucial for cell fate determination. It directs the differentiation of mesenchymal stem cells into osteoblasts, chondrocytes, adipocytes and myocytes. Initiation of BMP2 signaling pathways occurs at the cell surface through type I and type II serine/threonine kinases housed in specific membrane domains such as caveolae enriched in the caveolin-1 beta isoform (CAV1β, caveolae) and clathrin coated pits (CCPs). In order for BMP2 to initiate Smad signaling it must bind to its receptors on the plasma membrane resulting in the phosphorylation of the BMP type Ia receptor (BMPRIa) followed by activation of Smad signaling. The current model suggests that the canonical BMP signaling pathway, Smad, occurs in CCPs. However, several recent studies suggested Smad signaling may occur outside of CCPs. Here we determined; 1) The location of BMP2 binding to receptors localized in caveolae, CCPs or outside of these domains using AFM and confocal microscopy. 2) The location of phosphorylation of BMPRIa on the plasma membrane using membrane fractionation, and 3) The effect of down regulation of caveolae on Smad signaling. Our data indicates that BMP2 binds with highest force to BMP receptors localized in caveolae. BMPRIa is phosphorylated in caveolae and the disruption of caveolae inhibited Smad signaling in the presence of BMP2. This suggests caveolae are necessary for the initiation of Smad signaling. We propose an extension of the current model of BMP2 signaling, in which the initiation of Smad signaling is mediated by BMP receptors in caveolae. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</p></div>]]></content:encoded><description>Bone Morphogenetic Protein 2 (BMP2) is a potent growth factor crucial for cell fate determination. It directs the differentiation of mesenchymal stem cells into osteoblasts, chondrocytes, adipocytes and myocytes. Initiation of BMP2 signaling pathways occurs at the cell surface through type I and type II serine/threonine kinases housed in specific membrane domains such as caveolae enriched in the caveolin-1 beta isoform (CAV1β, caveolae) and clathrin coated pits (CCPs). In order for BMP2 to initiate Smad signaling it must bind to its receptors on the plasma membrane resulting in the phosphorylation of the BMP type Ia receptor (BMPRIa) followed by activation of Smad signaling. The current model suggests that the canonical BMP signaling pathway, Smad, occurs in CCPs. However, several recent studies suggested Smad signaling may occur outside of CCPs. Here we determined; 1) The location of BMP2 binding to receptors localized in caveolae, CCPs or outside of these domains using AFM and confocal microscopy. 2) The location of phosphorylation of BMPRIa on the plasma membrane using membrane fractionation, and 3) The effect of down regulation of caveolae on Smad signaling. Our data indicates that BMP2 binds with highest force to BMP receptors localized in caveolae. BMPRIa is phosphorylated in caveolae and the disruption of caveolae inhibited Smad signaling in the presence of BMP2. This suggests caveolae are necessary for the initiation of Smad signaling. We propose an extension of the current model of BMP2 signaling, in which the initiation of Smad signaling is mediated by BMP receptors in caveolae. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23034" xmlns="http://purl.org/rss/1.0/"><title>The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss</title><link>http://dx.doi.org/10.1002%2Fjcp.23034</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tetyana Shandala</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yeap Shen Ng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Blair Hopwood</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yuen-Ching Yip</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bruce K. Foster</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cory J. Xian</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-21T08:28:31.411974-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23034</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23034</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23034</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Intensive cancer chemotherapy leads to significant bone loss, the underlying mechanism of which remains unclear. The objective of this study was to elucidate mechanisms for effect of the commonly used anti-metabolite methotrexate (MTX) on osteocytes and on general bone homeostasis. The current study in juvenile rats showed that MTX chemotherapy caused a 4.3 fold increase in the number of apoptotic osteocytes in tibial metaphysis, which was accompanied by a 1.8 fold increase in the number of TRAP-positive bone resorbing osteoclasts, and a 35% loss of trabecular bone. This was associated with an increase in transcription of the osteoclastogenic cytokines IL-6 (10 fold) and IL-11 (2 fold). Moreover, the metaphyseal bone of MTX-treated animals exhibited a 37.6% increase in the total number of osteocytes, along with 4.9 fold higher expression of the DMP-1 transcript. In cultured osteocyte-like MLO-Y4 cells, MTX treatment significantly increased Caspase-3-mediated apoptosis, which was accompanied by the formation of plasma membrane-born apoptotic bodies and an increase in IL-6 (24 fold) and IL-11 (29 fold) mRNA expression. Conditioned media derived from MTX-treated MLO-Y4 cells was twice as strong as untreated media in its capacity to induce osteoclast formation in primary bone marrow osteoclast precursors. Thus, our <em>in vivo</em> and <em>in vitro</em> data suggested that MTX-induced apoptosis of osteocytes caused higher recruitment of DMP-1 positive osteocytes and increased osteoclast formation, which could contribute towards the loss of bone homeostasis <em>in vivo</em>. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</p></div>]]></content:encoded><description>Intensive cancer chemotherapy leads to significant bone loss, the underlying mechanism of which remains unclear. The objective of this study was to elucidate mechanisms for effect of the commonly used anti-metabolite methotrexate (MTX) on osteocytes and on general bone homeostasis. The current study in juvenile rats showed that MTX chemotherapy caused a 4.3 fold increase in the number of apoptotic osteocytes in tibial metaphysis, which was accompanied by a 1.8 fold increase in the number of TRAP-positive bone resorbing osteoclasts, and a 35% loss of trabecular bone. This was associated with an increase in transcription of the osteoclastogenic cytokines IL-6 (10 fold) and IL-11 (2 fold). Moreover, the metaphyseal bone of MTX-treated animals exhibited a 37.6% increase in the total number of osteocytes, along with 4.9 fold higher expression of the DMP-1 transcript. In cultured osteocyte-like MLO-Y4 cells, MTX treatment significantly increased Caspase-3-mediated apoptosis, which was accompanied by the formation of plasma membrane-born apoptotic bodies and an increase in IL-6 (24 fold) and IL-11 (29 fold) mRNA expression. Conditioned media derived from MTX-treated MLO-Y4 cells was twice as strong as untreated media in its capacity to induce osteoclast formation in primary bone marrow osteoclast precursors. Thus, our in vivo and in vitro data suggested that MTX-induced apoptosis of osteocytes caused higher recruitment of DMP-1 positive osteocytes and increased osteoclast formation, which could contribute towards the loss of bone homeostasis in vivo. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23035" xmlns="http://purl.org/rss/1.0/"><title>Engineered endothelial progenitor cells that overexpress prostacyclin protect vascular cells</title><link>http://dx.doi.org/10.1002%2Fjcp.23035</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Engineered endothelial progenitor cells that overexpress prostacyclin protect vascular cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Qi Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yutao Xi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Toya Terry</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shui-Ping So</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anita Mohite</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jia Zhang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Geru Wu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiaobing Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jie Cheng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ke-He Ruan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James T. Willerson</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richard A.F. Dixon</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-21T08:28:30.303917-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23035</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23035</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23035</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Prostacyclin (PGI2) is a potent vasodilator and important mediator of vascular homeostasis; however, its clinical use is limited because of its short (&lt;2 minute) half-life. Thus, we hypothesize that the use of engineered endothelial progenitor cells (EPCs) that <em>constitutively secrete high levels of</em> PGI2 may overcome this limitation of PGI2 therapy. A cDNA encoding COX-1-10aa-PGIS, which links human cyclooxygenase-1(COX-1) to prostacyclin synthase (PGIS), was delivered via nucleofection into outgrowth endothelial progenitor cells (EPCs) derived from rat bone marrow mononuclear cells. <em>PGI2-secreting</em> strains (PGI2-EPCs) were established by continuous subculturing of transfected cells under G418 selection. Genomic PCR, RT-PCR, and Western blot analyses confirmed the overexpression of COX-1-10aa-PGIS in PGI2-EPCs. PGI2-EPCs secreted significantly higher levels of <em>PGI2 in vitro</em> than native EPCs (<em>P</em> &lt; 0.05) and showed higher intrinsic angiogenic capability; conditioned medium from PGI2-EPCs promoted better tube formation than conditioned medium from native EPCs (<em>P</em> &lt; 0.05). Cell- and paracrine-mediated in vitro angiogenesis was attenuated when COX-1-10aa-PGIS protein expression was knocked down. <em>Whole-cell patch-clamp studies showed that</em> 4-aminopyridine–<em>sensitive K</em><sup><em>+</em></sup><em>current density was increased significantly in rat smooth muscle cells (rSMCs) cocultured under hypoxia with PGI2-EPCs</em> (7.50 ± 1.59pA/pF, <em>P</em> &lt; 0.05.) compared with <em>rSMCs</em> cocultured with native EPCs (3.99 ± 1.26 pA/pF.)<em>. In conclusion,</em> we <em>successfully created EPC strains that overexpress an active novel enzyme resulting in consistent secretion of PGI2.</em> PGI2-EPCs showed enhanced intrinsic proangiogenic properties and provided favorable paracrine-mediated cellular protections, including promoting in-vitro angiogenesis of native EPCs and hyperpolarization of SMCs under hypoxia. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</p></div>]]></content:encoded><description>Prostacyclin (PGI2) is a potent vasodilator and important mediator of vascular homeostasis; however, its clinical use is limited because of its short (&lt;2 minute) half-life. Thus, we hypothesize that the use of engineered endothelial progenitor cells (EPCs) that constitutively secrete high levels of PGI2 may overcome this limitation of PGI2 therapy. A cDNA encoding COX-1-10aa-PGIS, which links human cyclooxygenase-1(COX-1) to prostacyclin synthase (PGIS), was delivered via nucleofection into outgrowth endothelial progenitor cells (EPCs) derived from rat bone marrow mononuclear cells. PGI2-secreting strains (PGI2-EPCs) were established by continuous subculturing of transfected cells under G418 selection. Genomic PCR, RT-PCR, and Western blot analyses confirmed the overexpression of COX-1-10aa-PGIS in PGI2-EPCs. PGI2-EPCs secreted significantly higher levels of PGI2 in vitro than native EPCs (P &lt; 0.05) and showed higher intrinsic angiogenic capability; conditioned medium from PGI2-EPCs promoted better tube formation than conditioned medium from native EPCs (P &lt; 0.05). Cell- and paracrine-mediated in vitro angiogenesis was attenuated when COX-1-10aa-PGIS protein expression was knocked down. Whole-cell patch-clamp studies showed that 4-aminopyridine–sensitive K+current density was increased significantly in rat smooth muscle cells (rSMCs) cocultured under hypoxia with PGI2-EPCs (7.50 ± 1.59pA/pF, P &lt; 0.05.) compared with rSMCs cocultured with native EPCs (3.99 ± 1.26 pA/pF.). In conclusion, we successfully created EPC strains that overexpress an active novel enzyme resulting in consistent secretion of PGI2. PGI2-EPCs showed enhanced intrinsic proangiogenic properties and provided favorable paracrine-mediated cellular protections, including promoting in-vitro angiogenesis of native EPCs and hyperpolarization of SMCs under hypoxia. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23029" xmlns="http://purl.org/rss/1.0/"><title>Imatinib treatment inhibits IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients</title><link>http://dx.doi.org/10.1002%2Fjcp.23029</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Imatinib treatment inhibits IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roberto Ciarcia</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria Teresa Vitiello</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Massimiliano Galdiero</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carmen Pacilio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Valentina Iovane</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Danila d'Angelo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Pagnini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuseppe Caparrotti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniele Conti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Valentina Tomei</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Salvatore Florio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Antonio Giordano</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-21T08:28:26.936662-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23029</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23029</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23029</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Imatinib (IM) is considered the gold standard for Chronic myeloid leukemia (CML) treatment, although resistance is emerging as a significant problem. The proinflammatory cytokines interleukin-6 (IL-6) and interleukin-8 (IL-8) play an important role in cell proliferation, survival, and resistance to glucocorticoid-mediated cell death. Several transcription factors such as NF-KB and AP-1 are activated in response to physiopathological increases and modulation of intracellular calcium levels. Our previous study demonstrated that lymphocytes from CML patients showed dysregulated calcium homeostasis and oxidative stress. Alteration in ionized calcium concentration in the cytosol has been implicated in the initiation of secretion, contraction, and cell proliferation. In this study we hypothesized that IL-6, IL-8, NF-kB, AP-1 and intracellular calcium may be used as selective and prognostic factors to address the follow-up in CML patients treated with imatinib. Our results demonstrated a significant down-regulation in IL-6 and IL-8 release as well as NF-kB and AP-1 activation in lymphomonocytes from Imatinib-treated patients, compared to samples from untreated patients. In parallel, IM treatment, <em>in vivo</em> and <em>in vitro,</em> were able to modulate the intracellular calcium concentration of peripheral blood mononuclear cells of CML patients by acting at the level of InsP<sub>3</sub> receptor in the endoplasmic reticulum and at the level of the purinergic receptors on plasma membrane. The results of this study show that measurements of NF-kB, AP-1, IL-6, IL-8 and intracellular calcium in CML patients treated with Imatinib may give important information to the haematologist on diagnostic criteria and are highly predictive in patients with newly diagnosed CML. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</p></div>]]></content:encoded><description>Imatinib (IM) is considered the gold standard for Chronic myeloid leukemia (CML) treatment, although resistance is emerging as a significant problem. The proinflammatory cytokines interleukin-6 (IL-6) and interleukin-8 (IL-8) play an important role in cell proliferation, survival, and resistance to glucocorticoid-mediated cell death. Several transcription factors such as NF-KB and AP-1 are activated in response to physiopathological increases and modulation of intracellular calcium levels. Our previous study demonstrated that lymphocytes from CML patients showed dysregulated calcium homeostasis and oxidative stress. Alteration in ionized calcium concentration in the cytosol has been implicated in the initiation of secretion, contraction, and cell proliferation. In this study we hypothesized that IL-6, IL-8, NF-kB, AP-1 and intracellular calcium may be used as selective and prognostic factors to address the follow-up in CML patients treated with imatinib. Our results demonstrated a significant down-regulation in IL-6 and IL-8 release as well as NF-kB and AP-1 activation in lymphomonocytes from Imatinib-treated patients, compared to samples from untreated patients. In parallel, IM treatment, in vivo and in vitro, were able to modulate the intracellular calcium concentration of peripheral blood mononuclear cells of CML patients by acting at the level of InsP3 receptor in the endoplasmic reticulum and at the level of the purinergic receptors on plasma membrane. The results of this study show that measurements of NF-kB, AP-1, IL-6, IL-8 and intracellular calcium in CML patients treated with Imatinib may give important information to the haematologist on diagnostic criteria and are highly predictive in patients with newly diagnosed CML. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23030" xmlns="http://purl.org/rss/1.0/"><title>Tracking the 2009 H1N1 influenza virus in the Italian region Campania</title><link>http://dx.doi.org/10.1002%2Fjcp.23030</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Tracking the 2009 H1N1 influenza virus in the Italian region Campania</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ciro Esposito</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Antimo Di Spirito</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nunzia Cuomo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuseppe Di Nicuolo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giovanni Flaminio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fabiana Altamura</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniele Ambrosino</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Federich Cantalupo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Caterina Costa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francesca Pentimalli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giulio Tarro</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-16T12:56:18.571385-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23030</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23030</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23030</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Mini-Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>A novel swine-origin influenza A (H1N1) virus affecting humans was detected in April 2009 in Mexico, Canada and USA. The S-OIV infection caused a mild to severe febrile respiratory disease throughout the world. Here, we briefly review the main features of influenza A viruses, which caused also other pandemics in the past, and focus in particular on the epidemiology data of the H1N1 influenza in the Italian region Campania, which resulted the most affected by the S-OIV and the one with more lethal cases. In Campania the peak of influenza preceded of about two weeks the incidence peak at the national level. Moreover, the percentage of H1N1-positive patients was much higher in the main town Naples, compared to the other Campania provinces. The age group from 7 months to 17 years was the most affected by the H1N1 infection (43,45%), similarly to what reported at the national level. Here, we discuss the possible reasons of the high H1N1 incidence in Campania and the implications that these findings could have on the future prevention campaigns. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</p></div>]]></content:encoded><description>A novel swine-origin influenza A (H1N1) virus affecting humans was detected in April 2009 in Mexico, Canada and USA. The S-OIV infection caused a mild to severe febrile respiratory disease throughout the world. Here, we briefly review the main features of influenza A viruses, which caused also other pandemics in the past, and focus in particular on the epidemiology data of the H1N1 influenza in the Italian region Campania, which resulted the most affected by the S-OIV and the one with more lethal cases. In Campania the peak of influenza preceded of about two weeks the incidence peak at the national level. Moreover, the percentage of H1N1-positive patients was much higher in the main town Naples, compared to the other Campania provinces. The age group from 7 months to 17 years was the most affected by the H1N1 infection (43,45%), similarly to what reported at the national level. Here, we discuss the possible reasons of the high H1N1 incidence in Campania and the implications that these findings could have on the future prevention campaigns. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fjcp.23021" xmlns="http://purl.org/rss/1.0/"><title>Crosstalk between mitochondrial (dys)function and mitochondrial abundance</title><link>http://dx.doi.org/10.1002%2Fjcp.23021</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Crosstalk between mitochondrial (dys)function and mitochondrial abundance</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sébastien Michel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anaïs Wanet</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Aurélia De Pauw</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Guillaume Rommelaere</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thierry Arnould</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Patricia Renard</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-16T12:56:13.441509-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/jcp.23021</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/jcp.23021</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fjcp.23021</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Mini-Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>A controlled regulation of mitochondrial mass through either the production (biogenesis) or the degradation (mitochondrial quality control) of the organelle represents a crucial step for proper mitochondrial and cell function. Key steps of mitochondrial biogenesis and quality control are overviewed, with an emphasis on the role of mitochondrial chaperones and proteases that keep mitochondria fully functional, provided the mitochondrial activity impairment is not excessive. In this case, the whole organelle is degraded by mitochondrial autophagy or “mitophagy”. Beside the maintenance of adequate mitochondrial abundance and functions for cell homeostasis, mitochondrial biogenesis might be enhanced, through discussed signalling pathways, in response to various physiological stimuli, like contractile activity, exposure to low temperatures, caloric restriction and stem cells differentiation. In addition, mitochondrial dysfunction might also initiate a retrograde response, enabling cell adaptation through increased mitochondrial biogenesis.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Although the examples cited above suggest that the control of mitochondrial mass, through biogenesis or quality control, is beneficial to the cell/organism demands, the data generated from diverse pathologies suggest that modulations in mitochondrial abundance/functions may participate to the pathogenesis. Increased mitochondrial abundance is generally described to characterize mitochondrial myopathies as well as most cancers, and is generally accompanied by qualitative modifications of mitochondria, thereby affecting programmed cells death susceptibility. On the contrary, in ageing, obesity and type 2 diabetes, mitochondrial biogenesis and functions are generally down-regulated. The development of insulin resistance, favoured by an impaired mitochondrial function, tends to reduce the abundance of the organelle, through a vicious circle. J. Cell. Physiol. © 2011 Wiley-Liss, Inc.</p></div>]]></content:encoded><description>A controlled regulation of mitochondrial mass through either the production (biogenesis) or the degradation (mitochondrial quality control) of the organelle represents a crucial step for proper mitochondrial and cell function. Key steps of mitochond
